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Background: Diabetes-related foot ulcers give rise to considerable morbidity, generate a high monetary
cost for health and social care services and precede the majority of diabetes-related lower extremity
amputations. There are many clinical prediction rules in existence to assess risk of foot ulceration but
few have been subject to validation.
Objectives: Our objectives were to produce an evidence-based clinical pathway for risk assessment
and management of the foot in people with diabetes mellitus to estimate cost-effective monitoring
intervals and to perform cost-effectiveness analyses and a value-of-information analysis.
Design: We developed and validated a prognostic model using predictive modelling, calibration and
discrimination techniques. An overview of systematic reviews already completed was followed by a
review of randomised controlled trials of interventions to prevent foot ulceration in diabetes mellitus.
A review of the health economic literature was followed by the construction of an economic model,
an analysis of the transitional probability of moving from one foot risk state to another, an assessment
of cost-effectiveness and a value-of-information analysis.
Interventions: The effects of simple and complex interventions and different monitoring intervals for
the clinical prediction rules were evaluated.
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Main outcome measure: The main outcome was the incidence of foot ulceration. We compared the
new clinical prediction rules in conjunction with the most effective preventative interventions at
different monitoring intervals with a ‘treat-all’ strategy.
Data sources: Data from an electronic health record for 26,154 people with diabetes mellitus in one
Scottish health board were used to estimate the monitoring interval. The Prediction Of Diabetic foot
UlcerationS (PODUS) data set was used to develop and validate the clinical prediction rule.
Review methods: We searched for eligible randomised controlled trials of interventions using search
strategies created for Ovid® (Wolters Kluwer, Alphen aan den Rijn, the Netherlands), MEDLINE,
EMBASE and the Cochrane Central Register of Controlled Trials. Randomised controlled trials in
progress were identified via the International Standard Randomised Controlled Trial Number Registry
and systematic reviews were identified via PROSPERO. Databases were searched from inception to
February 2019.
Results: The clinical prediction rule was found to accurately assess the risk of foot ulceration. Digital
infrared thermometry, complex interventions and therapeutic footwear with offloading devices were
found to be effective in preventing foot ulcers. The risk of developing a foot ulcer did not change over
time for most people. We found that interventions to prevent foot ulceration may be cost-effective
but there is uncertainty about this. Digital infrared thermometry and therapeutic footwear with
offloading devices may be cost-effective when used to treat all people with diabetes mellitus
regardless of their ulcer risk.
Limitations: The threats to the validity of the results in some randomised controlled trials in the
review and the large number of missing data in the electronic health record mean that there is
uncertainty in our estimates.
Conclusions: There is evidence that interventions to prevent foot ulceration are effective but it is not
clear who would benefit most from receiving the interventions. The ulceration risk does not change
over an 8-year period for most people with diabetes mellitus. A change in the monitoring interval from
annually to every 2 years for those at low risk would be acceptable.
Future work recommendations: Improving the completeness of electronic health records and sharing
data would help improve our knowledge about the most clinically effective and cost-effective
approaches to prevent foot ulceration in diabetes mellitus.
Study registration: This study is registered as PROSPERO CRD42016052324.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 62. See the NIHR Journals Library website for further project information.
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Plain English summary
People with diabetes sometimes have problems with their feet that can become serious and makegetting around harder and life less enjoyable. We have developed a test based on a simple score
to find out a person’s risk of getting a foot ulcer. We also wanted to know how often the test needs
to be done.
People who have been tested and learn that they might go on to have foot problems rightly expect
to be given treatment that stops the problem happening in the first place. In this project, we read
many written reports about the best treatments to prevent foot ulcers. We found that some things
can prevent foot ulcers, such as wearing special shoes and insoles, taking the temperature of the skin
of the foot and resting when the temperature rises, and receiving specialist care from diabetes foot
care teams. However, we also looked at the costs of the test and treatments and found that some
treatments are better value for money than others.
By using people’s health data from NHS computers, we discovered that very few people with diabetes
develop a worse risk score for foot ulcers as time goes on, and it seems that being tested every year
is not necessary for everyone. New clinical trials might help to improve foot health for people with
diabetes, but if all of the researchers who have collected data from people in clinical trials shared
their data it would be possible to find out more about who will gain most from these treatments
without spending a lot on new research. It is clear that better input of patients’ health data into
NHS computers will benefit diabetes research in the future.
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Scientific summary
Background
Diabetes-related foot ulcers give rise to considerable morbidity, generate a high monetary cost for health
and social care services and are known to precede the majority of diabetes-related lower extremity
amputations. Identifying those at risk of developing a foot ulcer and providing an effective intervention
to prevent these wounds developing has been a long-time goal of many working in the field.
There are many clinical prediction rules in existence to assess the risk of foot ulceration in diabetes
mellitus, but few have been subject to validation. In the UK, two diabetes clinical guidelines make
recommendations about the management of the foot and risk assessment procedures, and preventative
interventions for those found to be at risk. However, the recommendations in these influential documents
are based predominantly on clinical consensus, and robust evidence that routine monitoring reduces the
number of diabetes-related foot ulcers or lower extremity amputations is scarce.
Current clinical guidelines for the management of the diabetic foot from the National Institute for
Health and Care Excellence recommend that people with diabetes mellitus have a foot examination
involving several elements and a vascular assessment with an ankle–brachial pressure index test
every year. For those judged to be at moderate or high risk, monitoring is escalated to 6-monthly
intervals and up to a maximum frequency of once per week. As peripheral neuropathy, the most
common foot complication of diabetes mellitus, is irreversible, these intensive monitoring intervals
are unlikely to positively influence patient outcomes. The recommendations of the diabetes guideline
from the Scottish Intercollegiate Guidelines Network (synonymous with the Scottish Care Information –
Diabetes Collaboration SCI-Diabetes, a computerised decision support tool) include a foot examination
involving five risk factors and advocate the use of some expensive equipment not readily available
outside specialist care settings. The Scottish Intercollegiate Guidelines Network diabetes guideline states
that monitoring should take place at least annually but concedes that the optimal frequency is unknown,
citing evidence from one cohort study in which low-risk patients had a 99.6% (95% confidence interval
99.5% to 99.7%) chance of being ulcer free at 1.7 years.
Both UK national diabetes guidelines (from the Scottish Intercollegiate Guidelines Network and the
National Institute for Health and Care Excellence) advise that patients in higher-risk categories be referred
to a multidisciplinary foot clinic for specialist care, but there is a lack of evidence to show whether or not
these expensive teams of clinicians and resource-intense arrangements result in fewer lesions.
Objectives
The objective was to undertake an evidence-based evaluation of the clinical effectiveness and cost-
effectiveness of the foot ulcer risk assessments and structured care interventions for people with
diabetes mellitus.
Our research questions were:
l What is the estimated clinical effectiveness and cost-effectiveness of the use of a validated clinical
prediction rule as part of structured care to reduce the incidence of diabetes-related foot ulcers?
l What is the likely clinical effectiveness and cost-effectiveness of alternative strategies including
monitoring intervals?
l Is there potential worth in undertaking further research, particularly a randomised controlled trial
of preventative interventions?
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Our research objectives were to produce an evidence clinical pathway by:
l extending (developing) our existing prognostic model into a clinical prediction rule and conducting
its external validation
l undertaking a survival analysis of the time to ulceration and analysing routinely collected data from
people with diabetes mellitus to calculate the transitional probability of an individual moving from
one risk state to another over time to inform the economic model
l conducting a systematic overview of the evidence of preventative effects of interventions for foot
ulceration in diabetes mellitus that have been evaluated in systematic reviews and randomised
controlled trials.
And then:
l combining the evidence from these three objectives in a cost-effectiveness decision model framework
and analyse alternative clinically effective and cost-effective regimens at different monitoring intervals
l performing a value-of-information analysis.
Methods
The clinical prediction rule
Our previous research developed a predictive model with three risk factors for foot ulceration in
diabetes mellitus (inability to feel a 10-g monofilament, absent pulses and history) using data from
16,385 people with diabetes mellitus worldwide. Four studies, two in the community in the UK and
two in hospitals in mainland Europe and the USA, were used to develop the clinical prediction rule.
The outcome was defined as a binary outcome of foot ulceration within 2 years.
We used the prediction model with the three risk factor predictors and the corresponding coefficients
to show how much the log-odds change when monofilaments, pulses or history change from test
negative to test positive and an individual’s estimate change given baseline risk. A random-effects
meta-analysis of the three intercepts from the Prediction Of Diabetic foot UlcerationS (PODUS)
studies with 2 years of follow-up to produce a single average intercept was used. We used this and
the log-odds coefficients for the three predictors to calculate the probability of ulcer for each possible
predictor combination and to produce a clinical prediction rule scoring scheme. Finally, we calculated
the probability of ulcer for each score using a population average method. The clinical prediction rule’s
internal validity was calculated by examining its discrimination and calibration; its external validity was
then assessed in a fifth data set.
The reviews
We searched for eligible systematic reviews and randomised controlled trials of interventions using
search strategies created for Ovid® (Wolters Kluwer, Alphen aan den Rijn, the Netherlands) MEDLINE,
Ovid EMBASE and the Cochrane Central Register of Controlled Trials. Randomised controlled trials in
progress were identified via the International Standard Randomised Controlled Trial Number Registry.
People of any age with a diagnosis of diabetes mellitus, either type 1 or type 2, who participated in
randomised controlled trials of interventions to prevent foot ulceration in diabetes mellitus were eligible
for inclusion. Eligible interventions could be either simple or complex, that is comprising several interacting
components. We included randomised controlled trials that compared the effects of interventions with
those of standard care or active comparators. The primary outcome was incident (new) and recurrent foot
ulcers reported as binary outcomes (present/absent).
One reviewer screened all titles and abstracts to identify potentially relevant systematic reviews
and randomised controlled trials. A second reviewer screened a 10% random sample of the yield.
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The two reviewers working independently screened the full text of papers, and data were extracted into
review-specific data extraction tools by two reviewers working independently. For the overview we used the
risk of bias in systematic reviews tool to assess the risk of bias, and for randomised controlled trials we used
the items recommended in the Cochrane handbook. [Higgins JPT, Green S. Cochrane Handbook for Systematic
Reviews of Interventions.Version 5.1.0 (updated March 2011). 2018. URL: www.handbook.cochrane.org.]
For the review of randomised controlled trials, we calculated pooled relative risks of effects and 95%
confidence intervals using a frequentist meta-analytical approach with data analysed on an intention-
to-treat basis. Trials were weighted in accordance with the inverse variance method for the dichotomous
primary outcome of the overview: foot ulceration. Heterogeneity was assessed using the I2 statistic.
Economic evaluation
Our economic evaluation was undertaken from the perspective of the UK NHS and Personal Social
Services; that is, the costs relevant to the economic analysis were those incurred by the NHS and
Personal Social Services. Our search returned 15 relevant papers to be reviewed.
We investigated the costs and health outcomes associated with each clinical pathway over a 20-year time
horizon.We created a new conceptual semi-Markov model to visually represent the events that we sought
to capture and how these events relate to costs and quality-adjusted life-year outcomes. To calculate the
monitoring interval for risk assessment, we used data from an electronic health record (Scottish Care
Information – Diabetes Collaboration), which is used in the routine management of NHS patients with
diabetes mellitus in Scotland. Transition probabilities (of moving from one risk category to another) that
are required for the model were then estimated based on a set of parametric survival models.
The project researchers received advice from an independent Study Steering Committee.
Results
The clinical prediction rule
We produced a clinical prediction rule that gives scores from 0 to 4. The study-specific estimates have
a calibration slope of 1 and an intercept of 0, and the model has ideal calibration in the data set in
which it was developed. The discrimination and calibration plots generated by the clinical prediction
rule in the validation data set produced very similar results to those obtained in the internal validation.
The calibration results suggest that calibration is good in low-risk patients, but the clinical prediction
rule can over-estimate risk in high-risk groups.
The reviews
We identified 20 systematic reviews that aimed to evaluate interventions to prevent foot ulceration
in participants with diabetes mellitus. Nine included only randomised controlled trials and 10 included
randomised controlled trials and observational studies. Our separate search for randomised controlled
trials found 22 that met the eligibility criteria.We identified eight separate interventions and evidence of
effectiveness from three. Digital infrared thermometry, complex interventions such as specialist foot
clinics, and therapeutic footwear with offloading devices appear to be effective in preventing foot
ulceration in people with diabetes mellitus.
The pooled effect from trials of digital skin thermometry indicates this to be a potentially promising
preventative intervention that deserves further evaluation in larger trials; however, advising patients
to abstain from all weight-bearing activities when their foot temperature rises by > 4 °C may prove
challenging, and an inability to abstain could diminish any beneficial effects. A benefit from specialist
foot care for those at high risk of ulceration became apparent only in our pooled analysis, and this
effect was not evident in the individual trials. Education by itself appears to be ineffective in reducing
the incidence of foot ulcers, and the small trials of antifungal nail lacquer, elastic stockings and
podiatric care did not show evidence of effect.
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Economic evaluation
Our review of published cost–utility analyses of the prevention of diabetes-related foot ulcer revealed
considerable heterogeneity in the way that the clinical and cost consequences of treatments have been
modelled in the literature, and that risk monitoring frequency has not been considered.
Our cost-effectiveness acceptability curves show considerable uncertainty surrounding which
intervention is most likely to be deemed cost-effective, with no clear strategy producing the greatest
probability at a willingness to pay of £20,000 per quality-adjusted life-year gained. Only in the case of
infrared digital thermometry does the treat-all strategy come out as providing the greatest probability
of cost-effectiveness, although, even for this intervention, the cost-effectiveness acceptability curve
suggests just over 30% probability that this strategy is likely to be the most cost-effective at a
willingness to pay of £20,000 per quality-adjusted life-year.
Our analysis of data from the NHS Fife population who attend foot clinics suggests that patients’
diabetes-related foot ulcer risk does not readily change over time. Despite the significant uncertainty,
our health economic model suggests that preventative diabetes-related foot ulcer interventions have
the potential to be considered cost-effective.
Discussion
For risk assessment programmes to be effective, simple clinical assessment procedures available for
use by health-care staff with varying degrees of skill are needed. The clinical prediction rule developed
and validated by our group is based on only three risk factors, which are cheap, easy to obtain and
accurate in identifying those at risk, especially those at low risk, who constitute the vast majority of
people with diabetes mellitus. Its use in clinical practice could simplify current approaches to risk
assessment, which could reduce the time spent testing, the costs associated with expensive tests
and the time needed to train staff to carry out more complex diagnostic procedures.
To our knowledge, the time interval for foot risk assessments has not been subject to evaluation
before. By using data from the electronic health record of people with diabetes mellitus in one health
board in Scotland, we are able to show that, in the majority of people with diabetes mellitus, foot ulcer
risk status does not change much over time, and a move towards less frequent risk assessment is
indicated for the majority of people. This finding suggests that a move towards less frequent risk
monitoring of patients would be acceptable.
The majority of systematic reviews aiming to identify effective interventions to prevent foot ulceration
did not reach clear, reproducible conclusions about the effect of treatments. As most of the researchers
undertaking these summaries lacked sources of funding, this is possibly unsurprising. The absence of
meta-analyses of data in the systematic reviews may also have contributed to the opacity, and by
pooling data we detected effective interventions for reducing the incidence of foot ulcers.
Trials have shown that the use of digital infrared thermometers can reduce foot ulcers if foot
temperature increase leads to a subsequent reduction in activity; however, assessing the levels of
compliance with advice to rest in the trial populations will be important.
The markedly different effect in the subgroup analyses of data from two trials of footwear and offloading
devices that involved people with no history of ulcers compared with four trials that included only people
with a history of ulceration is interesting. If an agreement to share data among the investigators of trials
of footwear and offloading was reached, comparing outcomes from subgroups of people in trials already
completed or ongoing in an individual patient data meta-analysis could clarify effectiveness without
incurring the high cost of a new trial.
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The failure of individual trials of complex interventions to show beneficial effects until data were
pooled in a meta-analysis supports the opinion of others that trials of specialist foot care in diabetes
mellitus need to recruit very large samples of patients. Education by itself appears to be ineffective in
reducing the incidence of foot ulcers, and the small trials of antifungal nail lacquer, elastic stockings
and podiatric care lacked evidence of effectiveness.
The economic evaluation showed that there is potential for the diabetes-related foot ulcer treatments
identified by the systematic review to be cost-effective but uncertainty in the model parameters and
other elements (e.g. patient acceptability and adherence to interventions) prohibits a strong conclusion.
A better understanding of what constitutes ‘current practice’ in foot care programmes across the UK,
in terms of risk assessment methods (risk factors and how they are assessed), interventions offered
and the level of adherence to clinical guidelines, would be helpful. There is a need for further research
into the effectiveness and acceptability of and adherence to potentially preventative diabetes-related
foot ulcer interventions. Improving the recording of patients’ test results and the number of important
events in the Scottish Care Information – Diabetes Collaboration computerised support tool and in
electronic health records more generally would be of value.
Study registration
This study is registered as PROSPERO CRD42016052324.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 62
See the NIHR Journals Library website for further project information.
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Chapter 1 Background
Diabetes-related foot ulcers give rise to considerable morbidity, generate a high monetary costfor health and care services and are known to precede the majority of diabetes-related lower
extremity amputation (LEA).1,2 Identifying those at risk of developing a foot ulcer and providing an
effective intervention to prevent these wounds developing has been a long-time goal of many working
in the field.
Routinely collected data from Scotland show that the incidence of diabetes-related foot ulceration
(DFU) among people with diabetes mellitus was 4.9% in 2014.3 An estimated prevalence of 2.5% across
the whole of the UK diabetes mellitus population generates an annual economic burden of £300M to
provide community and primary health care for those with the condition.4 The additional cost of LEA
more than doubles this cost to approximately £662M.4 High levels of variation in diabetes-related LEA
between primary care trusts in England have been reported, and one possible explanation for these
differences in patient outcomes might be differences in the delivery of care.5 For those who experience
a DFU, the likelihood of 5-year survival is poor, with mortality estimates of between 25% and 50%
consistently reported over a 20-year period in the UK and in other parts of Europe.6
A reduction in all LEA in Scotland between 2004 and 2008 reached statistical significance only for
those with diabetes mellitus, but the cause of this was unclear.7 Improvements in the recording of
cases of diabetes mellitus may have confounded the data analysis but the effects of large-scale public
health interventions and trends in prescribing may also have contributed. Legislation to ban smoking
in public places was introduced in Scotland in 2006 and led to reductions in the number of admissions
for acute coronary syndrome and the incidence of cerebral infarctions.8 A cohort study using data from
46,864 people with diabetes mellitus and without diabetes mellitus in Spain also found the prescribing
of statins to significantly reduce atherosclerotic cardiovascular disease in those with diabetes mellitus,
but not in the general population.9 Given the direct association between smoking, cardiovascular
disease and LEA, it is possible that amputation rates are influenced more by large-scale public health
interventions and prescribing habits than by interventions focusing on the foot.
Many clinical prediction rules (CPRs) for the assessment of foot ulceration risk in people with diabetes
mellitus are available, but few have been subject to validation.10 In the UK, two clinical guidelines11,12
for diabetes mellitus make recommendations about the management of the foot, and recommend
risk assessment procedures and preventative interventions for those found to be at risk. However, the
recommendations in these influential documents are based predominantly on clinical consensus, and
robust evidence to show that routine monitoring reduces the number of ulcers or LEA is scarce.13
Current clinical guidelines for the management of the diabetic foot from the National Institute for
Health and Care Excellence (NICE) recommend that people with diabetes mellitus undergo an annual
foot examination, involving several elements, and a vascular assessment including measurement of
ankle–brachial pressure index (ABI). For those judged to be at moderate or high risk, monitoring is
escalated to 6-monthly intervals and up to a maximum frequency of once per week.11 As peripheral
neuropathy (the most common foot complication of diabetes mellitus) is irreversible, such frequent
monitoring is unlikely to positively influence patient outcomes. The diabetes guideline from the Scottish
Intercollegiate Guidelines Network (SIGN) [which is synonymous with the Scottish Care Information –
Diabetes Collaboration (SCI-Diabetes), a computerised decision-support tool] recommends a foot
examination assessing five risk factors and advocates the use of some expensive equipment not readily
available outside specialist care settings.12 The SIGN diabetes guideline states that monitoring should
take place at least annually, but concedes that the optimal frequency is unknown, citing evidence from
one cohort study in which low-risk patients had a 99.6% [95% confidence interval (CI) 99.5% to 99.7%]
chance of being ulcer free at 1.7 years after testing.14
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A systematic review (SR) and meta-analysis of individual patient data (IPD) collected worldwide
[Prediction Of Diabetic foot UlcerationS (PODUS)]15 enabled the external validation of a predictive
model involving only three predictors: insensitivity to a 10-g monofilament, absent pedal pulses and
a history of ulceration or LEA. All three predictors are easy and cheap to ascertain and, therefore, likely
to be used in clinical practice. These three predictors also performed well in external validation using an
independent data set; however, the results of the PODUS analyses were expressed as summary odds
ratios (ORs) from a meta-analysis, which do not readily allow clinicians to assess the risk of ulceration
for individual patients. The development of a CPR based on the PODUS analyses was needed and
the development of a simple scoring system to identify patients at higher risk of ulceration is a key
objective of this research. The majority of the 1221 foot ulcers experienced by a group of 16,385
patients occurred 2 years after risk assessment, supporting a recommendation for 2-year monitoring
of those at low risk. What is not clear, however, is how often people who are at moderate or high risk
should be tested.
It is reasonable to expect that, once a person is identified as being at moderate or high risk of foot ulcer,
effective preventative measures will be available. Unfortunately, although both of the UK national
diabetes guidelines advise that patients in the higher-risk categories be referred to a multidisciplinary
foot clinic for specialist care, there is a lack of evidence to show whether or not these expensive teams
of clinicians and resource-intense arrangements result in fewer lesions.16 Furthermore, the nature and
effect of the particular interventions they provide and the best composition of the specialist team are
unclear. Routine risk assessments for bad outcomes without effective preventative interventions might
result only in worried patients; however, an effective CPR might allow diabetic patients at high risk to
be triaged into more effective but more expensive preventative regimens. High-performance monitoring
is more costly; therefore, we need to evaluate the cost-effectiveness of different monitoring frequencies.
It has been suggested that a large, robust randomised controlled trial (RCT) to evaluate the effect of
a CPR used at different monitoring frequencies to underpin a stratified approach is overdue, as is a
thorough concurrent evaluation of the cost-effectiveness of this type of care pathway.17,18 However,
each of the necessary elements of the pathway remains in need of evaluation to ensure the creation of
a truly evidence-based clinical approach. The purpose of this research is to create an evidence-based
clinical pathway to identify those at risk of foot ulceration and provide effective interventions that are
likely to reduce foot ulceration in people with diabetes mellitus.
Given the increased prevalence of diabetes mellitus, such an evidence-based approach could replace
the frequent, detailed foot examinations people with diabetes mellitus currently receive, identify
effective preventative interventions and reduce the large burden of costs on NHS services tasked
with delivering foot care to people with diabetes mellitus.
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
Chapter 2 Overall research objectives
Aim
We aim to undertake an evidence-based evaluation of the clinical effectiveness and cost-effectiveness
of foot ulcer risk assessments and structured care interventions for people with diabetes mellitus.
Research questions
i. What is the estimated clinical effectiveness and cost-effectiveness of a validated CPR as part of
structured care to reduce the incidence of DFU?
ii. What is the likely clinical effectiveness and cost-effectiveness of alternative strategies, including
monitoring intervals?
iii. Is there worth in undertaking further research, particularly a RCT?
Objectives
Our research objectives are to produce an evidence clinical pathway by:
l extending (developing) our existing prognostic model into a CPR and conducting its
external validation
l undertaking a survival analysis of the time to ulceration to inform the economic model
l conducting an overview of SRs to identify the effects and costs of available interventions (simple
interventions such as pressure-relieving insoles and complex interventions such as specialist foot
care teams)
l combining the evidence from research questions (i), (ii) and (iii) in a cost-effectiveness decision
model framework and analysing alternative clinical and cost-effective regimens at different
monitoring intervals
l carrying out a value-of-information analysis.
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Chapter 3 Clinical prediction rule:
PODUS data
Introduction
A CPR is a way of presenting a statistical model that facilitates predictions that inform clinical decision-
making. Statistical models can be unwieldy; they may have many predictors or predictors requiring
transformation from their original scale, which can be off-putting to end-users and increase the scope
for human error. In addition, the type of statistical model that is used for prediction is generally either
a logistic regression model or a Cox proportional hazards model. These two models can be used to
investigate the relationship between predictors and a binary or a categorical outcome (logistic
regression) or the time until a binary outcome occurs (Cox proportional hazards model). Both types
of statistical model require the use of a calculator, or similar, to make a prediction for an individual
patient, as the estimate requires taking an exponential.
This chapter describes how we developed a statistical model for the prediction of DFU, used this
model to create a simple-to-use CPR and validated the CPR in a data set not used in the development
phase. We used the Transparent Reporting of a multivariable prediction model for Individual Prognosis
Or Diagnosis (TRIPOD) statement as a framework for reporting (see Appendix 3, Table 41).19
Clinical prediction rules can be presented simply as a regression equation, a nomogram or a scoring
system; other formats are also possible. Whichever format is chosen, it should be remembered that
the CPR is only as good as its underlying statistical model; therefore, the methodological requirements
for good practice when building and validating a statistical model apply equally to CPRs. In addition,
the presentation of a CPR can affect its acceptability to end-users. Our aim was to produce a CPR
that does not require a calculator and is simple enough to be of very little burden in a busy clinic.
The benefit of a CPR is based not only on ease of use, but also, for example, on whether or not it
provides useful information not otherwise available: will it improve patient outcomes and are there
other ways to predict foot ulcer? The burden and sequelae of DFU to patients and the NHS are
immense, so there is enormous interest in predicting which patients will develop ulceration. Therefore,
it is unsurprising that we are not the first to attempt to make the prediction of ulcer easier for health
professionals working directly with patients. This project, PODUS 2020, is a development of the work
conducted in PODUS 2015, a SR and meta-analysis of IPD,15 in which we used the PODUS data sets to
calculate ORs to quantify the association between risk categories, based on the recommendations of
the International Working Group on Diabetic Foot (IWGDF), NICE and SIGN, and foot ulcer, as these
are the guidelines likely to be used in the UK. The guidelines did not produce ORs that were significantly
different from those obtained using insensitivity to monofilament only. Our final PODUS 2020 prediction
model is simpler than current guidelines as it has only three predictors; it also includes insensitivity
to monofilament. We knew, therefore, that we could use the PODUS data to develop and validate a
simpler CPR that could perform at least as well as existing guidelines.
Methods
Source of data
The data for PODUS 2020 came from a previous research project, PODUS 2015 (see Appendix 3), published
in the National Institute for Health Research (NIHR) Health Technology Assessment journal.15 PODUS 2015
obtained eight studies and had access to another two identified from an IPD SR. Eight studies contributed
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data to PODUS 2015.20–27 Access to a ninth study28 was available via a Safe Haven facility; a 10th study29
was not directly available but the PODUS 2015 team could request results of analyses from the data set.
After the publication of PODUS 2015, we re-ran the searches to identify new studies and found only
one that met the inclusion criteria. Unfortunately, the authors of that study did not respond to requests
to share their data.30 The search strategy to find studies was last run in June 2017 for MEDLINE and in
August 2017 for EMBASE, and was published as appendix 3 of the PODUS 2015 Health Technology
Assessment journal publication.
Inclusion criteria for development and validation studies
Studies could be included in PODUS 2015 if patients had diabetes mellitus, predictors had been assessed at
recruitment, foot ulcer status was assessed at follow-up and the study had recruited at least 100 patients.
In addition, for a study to be included in PODUS 2020 development data sets, we required that it collected
data on insensitivity to a 10-g monofilament, presence/absence of pedal pulses, history of ulceration or
amputation, and the time period in which the ulcer occurs. As we planned to conduct a one-step meta-
analysis at the development stage, we needed to merge all of the development data sets, and so required
them to be stored on the same server. These criteria reduced the number of eligible development studies
to four.20,21,24,25 Four studies did not provide data on sensitivity to monofilaments and/or the presence or
absence of a pedal pulse,22,23,26,27 and the access arrangements for the Leese et al.28 and Boyko et al.29 data
sets meant that they could not be stored on the same server as those of the other studies. The Boyko et al.29
data set had been used for validation in PODUS 2015, but included a very small proportion of women
(< 2%).We therefore decided to use the Leese et al.28 data set for validation of the CPR.
We had no date restriction on studies. Recruitment dates ranged from 1 May 1995 to 10 November
2007 in the development data sets, and the final follow-up date was 5 December 2008. In the Leese
et al.28 validation data set, recruitment dates ranged from 28 January 2001 to 8 December 2006 and
the final follow-up date was 2007.
Critical appraisal of contributing studies
We used the Prediction model Risk Of Bias ASsessment Tool (PROBAST) tool to critically appraise the
four validation studies and the external validation study.31 This was not used for PODUS 2015 because
PODUS 2015 predated the publication of the PROBAST tool.
Participants
The four studies for development in PODUS 2020 comprised two studies set in the community in the
UK and two hospital-based studies: one in mainland Europe and one in the USA. All studies recruited a
consecutive sample. The Leese et al.28 data set used for validation is from another community-set study
in the UK. The inclusion criteria for the data to be collected from each patient were as described in
Inclusion criteria for development and validation studies; however, we also stipulated for both PODUS 2015
and PODUS 2020 that patients had to be aged ≥ 18 years and ulcer free at the time of recruitment.
This meant that we had to remove from the analysis data set a small proportion of patients in some
studies who had an ulcer at the time of recruitment. All studies were observational, and patients received
the standard care in that setting.
Outcome
In PODUS 2020 we defined a binary outcome of presence or absence of foot ulceration within 2 years.
Ulceration status was assessed by podiatrists (persons who diagnose and treat foot ailments; also known
as chiropodists) or self-report questionnaires.We chose 2 years as the time interval as it is sufficient for
an at-risk patient to develop an ulcer, it is clinically meaningful and it allowed us to use the largest study20
(> 6000 patients) that had defined the outcome as development of an ulcer by 2 years. The other three
development data sets21,24,25 included either date of ulceration or time to ulceration, and, therefore,
the data could be recoded to match the largest data set. However, we note that the planned length of
follow-up in the Crawford et al.21 data set was only 1 year, and this was accounted for in our analyses.
Assessment of outcome was, where possible, blinded to test results in three of the four development
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studies, but not in the Monteiro-Soares and Dinis-Ribeiro24 and Leese et al.28 validation study. It is,
of course, not possible to blind podiatrists to previous amputations. As time to ulceration is also of
interest, we conducted a survival analyses with the three studies with time-to-event data and present
the results in Appendix 3.
Selection of predictors in PODUS 2020
In PODUS 2015, six predictors were selected from a potential candidate list of 22: age, sex, body mass
index, smoking, height, weight, alcohol intake, glycated haemoglobin (HbA1c), insulin regime, duration of
diabetes mellitus, eye problems, kidney problems, insensitivity to a 10-g monofilament, absence of pedal
pulses, tuning fork, biothesiometer, ankle reflexes, ABI, peak plantar pressure, prior ulcer, prior amputation
and foot deformity. Predictors were chosen for clinical plausibility, availability in at least three studies
and lack of clinical heterogeneity. Statistical criteria such as small p-values were not used. Six variables
were chosen for inclusion in the primary model in PODUS 2015: age, sex, duration of diabetes mellitus,
insensitivity to a 10-g monofilament, absence of pedal pulses and prior ulcer or amputation. The analysis
was a two-step meta-analysis. In each data set we fitted a logistic regression model with the six predictors,
which gave us adjusted estimates for each predictor. We conducted a meta-analysis for each predictor
using the generic inverse method.32 We had used a two-step method so that we could include, in the
second stage, aggregate data (i.e. log-odds ratios and their variances) derived from the Leese et al.28
data set with > 3000 patients. The Leese et al.28 data set was housed on a different server and so could
not be used in a one-step meta-analysis, although this is the preference of some methodologists.33
We tested these six predictors in the 10th, externally held data set,29 which had 1489 people and 229
ulcer outcomes.We considered the PODUS 2015 results to be replicated in the external data set if the
predictor achieved statistical significance, if its effect was in the same direction as the PODUS 2015
estimate and if its CIs overlapped. The predictors that survived this process were insensitivity to a 10-g
monofilament, absence of pedal pulses and prior ulcer or amputation.
For the CPR, we decided not to use the three predictors that were not replicated in the Boyko et al.29
data set: age, sex and duration of diabetes mellitus. Age and duration of diabetes mellitus are credible
predictors of any diabetic complication, including foot ulcer. They are also continuous, which means
that, in theory, they could be used to generate more precise risk estimates than categorical predictors;
however, their inclusion in the CPR would require a calculator, or similar, to estimate risk. CPRs are
a form of clinical decision support system that tend not to be used unless they are integrated into
the existing workflow.34 The project did not have access to resources to support a website, or similar,
that would calculate risk for health professionals or embed the CPR into NHS information technology
systems. However, we could use three binary predictors that were replicated to produce a simple
CPR that can be paper based and does not require any calculation from the users to implement.
Practicalities as well as the lack of replication in the Boyko et al.29 data set were reasons to drop age
and duration of diabetes mellitus from our CPR model; however, we understand that some individuals
will be interested in the six predictor model, and the results from this model are in Appendix 3 and make
direct comparisons with the three-predictor model. We also investigated possible reasons why age and
duration of diabetes mellitus did not reach statistical significance or were not replicated predictors in the
Boyko et al.29 data set. For simplicity, we also chose not to use the category sex as a predictor. Discussion
with potential users of the CPR showed that they were very much in favour of a simpler model.
Definition of the PODUS 2020 predictors
We decided to use the three replicated predictors only (i.e. monofilaments, pulses and history) in the
CPR. These three binary predictors were measured at the initial assessment of each patient in each
study. In detail, the predictors are:
l Insensitivity to a 10-g monofilament at any site on either foot was defined as test positive. This test is
carried out by podiatrists. The podiatrist touches the sole of the patient’s foot with a monofilament
and the patient states whether or not he or she felt it.
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l In general, there are two pulses tested in each foot: the dorsalis pedis and the posterior tibial
pulses. We defined absence of either pulse on either foot as test positive, although it is known that
the dorsalis pedis pulse is missing in some healthy individuals.35
l History of ulceration or amputation was ascertained either at initial assessment or from patient
records. Patients were considered test positive for history if they had experienced either ulcer
or amputation.
As predictors were measured before outcome in three of the four development studies, the measurement
of predictors was blind to outcome. However, assessment of predictors blind to other predictors generally
did not occur and would not always be possible; for example, toe amputation would be apparent to any
podiatrist assessing monofilaments or pulses.
As in PODUS 2015, we chose to use patient rather than foot as the unit of analysis. The three binary
predictors are defined as above, as this was the only way to have a consistent definition in all four
development data sets; for example, Crawford et al.21 recorded the presence or absence of each of
the four foot pulses, whereas Abbott et al.20 recorded the number of foot pulses per person (0–4).
The outcome was binary and was defined as the occurrence or not of ulcer by 2 years.
In the PODUS 2015 publication, there is an extensive examination of differences and similarities
between the studies as sources of heterogeneity.15 We repeat some of those analyses here to provide
a description of the contributing data sets, with emphasis on the predictors chosen for PODUS 2020.
Sample size considerations
Sample size calculations are generally not carried out for meta-analyses conducted as part of a SR,
as the aim is to use not an acceptable minimum but all of the available data. Post hoc sample size
calculations are problematic and not recommended by statisticians, and so we did not conduct any.36
The development data sets have a total of 8255 people with 430 ulcer outcomes, giving 143 events
per variable. This is well above the often-cited rule of thumb of 10 events per variable.37
Statistical models can often give overly optimistic results if the data from which they were derived
come from small data sets, if data-driven methods are used to select variables or if too many variables
are used. A way of compensating for optimistic results is to use a shrinkage factor:38 a number < 1 by
which the coefficients are multiplied. All of the shrinkage factors that we calculated during the model
development phase were > 0.9999, which would have resulted in negligible changes, so we did not
use shrinkage factors. Shrinkage factors are affected by sample size and complexity of model but our
model is simple and our sample size (events) is large relative to the number of included predictors.
The external validation data set had 3324 patients and 128 ulcer outcomes, meeting the
recommendation of at least 100 events and 100 non-events to investigate model performance.39
Missing data
To account for missing data, we would have considered multiple imputation if we thought that data
were likely to be missing at random (MAR).40 However, the proportion of missing data was very small
(0–3% in the development data sets and < 2% in the largest data set of > 6000 patients) and so the
results of any imputation exercise would not have made any notable difference to our results; therefore,
we analysed the data using complete cases only, that is, patients for whom data on monofilaments,
pulses, history and ulcer outcomes at 2 years were available.
One reason why outcome information at 2 years might be missing is death of the patient before 2 years.
However, death was not consistently recorded across the data sets; for example, in the development
studies, the largest study had recorded only one death in 2 years and another did not record deaths at
all. The other two development studies were more systematic about including death data. Overall, the
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proportion of patients recorded as having died was 2%. If a patient had died, but had all information on
predictors and outcome, that person was included in our analyses.
Some patients had missing data on previous amputation or ulcer history. However, the clinical context in
which these data were collected means that it is very important to record when ulcers and amputations
have occurred; therefore, the data were not MAR and are far more likely to be missing if the patients did
not have previous ulcers and did not have amputations. Patients who were missing ulcer or amputation
history were, therefore, recoded as test negative for these two items. The numbers of patients whose
data were recoded are given in each study’s flow chart (Figures 1–4).
Patients recruited
(n = 6603)
Patients missing
monof ilaments
(n = 125)
Patients with
monofilament 
test results
(n = 6478)
Patients with
pulses
(n = 6478 recorded)
Patients with both
amputation and
ulcer history
(n = 6417)
Patients with either
amputation or
ulcer history
(n = 38)
Patients with neither
amputation nor
ulcer history
(n = 23)
Patients with ulcer
outcome data
(n = 6478)
FIGURE 1 Flow of patients in the Abbott et al.20 data set. All patients had 2-year ulcer outcome recorded. Not all
patients are shown at each stage.
Patients recruited
(n = 1193)
Patients missing
 monof ilament
(n = 13)
Patients with
monofilament 
test results
(n = 1180) Patients with
ulcer outcome data
(n = 1180)
Patients with time to ulcer/
end of follow-up
(n = 1175)
Patients missing time to ulcer/
end of follow-up
(n = 5)
Patients with
pulses recorded
(n = 1180)
Patients with both ulcer
and amputation history
(n = 1180)
FIGURE 2 Flow of patients in the Crawford et al.21 data set. Not all patients are shown at each stage.
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Length of follow-up in the Crawford et al.21 data set
The PODUS 2020 outcome variable is ulcer occurrence by 2 years, and we knew that the Crawford et al.21
study had prespecified the follow-up period to be 12 months. We received ethics approval from the
Scotland A Research Ethics Committee (reference 16/SS/0213: Integrated Research Approval System
project ID 97542), Caldicott approval from NHS Tayside (reference IGTCAL3842) and NHS Tayside
approval (reference 2017DM03, NHS Research Scotland reference NRS17/9754) for permission to
contact the participants in the study by Crawford et al.21 to ask if they would consent to include longer-
term data in PODUS 2020, some of which were stored on paper records. Despite all these efforts,
follow-up data were obtained from only 42% of the original sample (see Appendix 3, Figure 33). Efforts
were hampered by the non-retention of patient records for more than 8 years post death, patients being
uncontactable and patients who did not consent. The PODUS 2020 Steering Committee discussed this
issue and recommended that the data should not be used for the current project.
Patients recruited
(n = 248)
Patients missing
monof ilaments
(n = 3)
Patients with
monofilament 
test results
(n = 245) Patients with
ulcer outcome data
(n = 245)
Patients with time to ulcer/
end of follow-up
(n = 242)
Patients missing time to ulcer/
end of follow-up
(n = 3)
Patients with
pulses recorded
(n = 245)
Patients with both ulcer
and amputation history
and one with amputation
history only
(n = 244)
FIGURE 3 Flow of patients in the Pham et al.25 study. Not all patients are shown at each stage.
Patients recruited
(n = 3412)
Patients missing
monof ilaments
(n = 2)
Patients with
monofilament 
test results
(n = 3410) Patients with
ulcer outcome data
(n = 3336)
Patients with time to ulcer/
end of follow-up
(n = 3324)
Patients missing time to ulcer/
end of follow-up
(n = 12)
Patients with
pulses recorded
(n = 3336)
Patients with history
(n = 3336)
Patients with ulcer history
(n = 3336)
Patients with amputation history
(n = 3221)
FIGURE 4 Flow of patients in the Leese et al.28 study. Not all patients are shown at each stage.
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Analysis
Statistical analysis methods: choice of model
Given a binary outcome, the obvious method of analysis is logistic regression. Although other methods
are available, we chose to base the CPR on a logistic regression model because this model is simple to
implement and acceptable to the medical community, and the methods for assessing its performance are
well developed. The selection of predictors was described in Definition of the PODUS 2020 predictors.
We did not consider adding any interaction terms as these often do not improve the predictive ability
of the model19 and would have made the CPR more complex.
As the data came from four studies, we used logistic regression with a separate intercept for each study
to allow for clustering of participants within studies and to allow for between-study variation in baseline
risk. This was especially important because of the inclusion of the Crawford et al.21 study, which had a
follow-up duration of only 1 year, compared with 2 years in the other three studies. Although ORs of
included predictors were similar in studies with 1- and 2-year’ follow-up, the baseline risk was not
comparable, as it was higher in those studies with 2-year’ follow-up because of the longer time period.
For defining the intercept for our final CPR based on this logistic regression model, we chose a weighted
average of the intercept estimates from the three studies with 2-year follow-up. This weighted average was
obtained by using a random-effects meta-analysis of the three intercepts, and fitting using the DerSimonian
and Laird method, which allows for both within-study variability (i.e. variance of intercept estimates) and
between-study heterogeneity (i.e. genuine differences in baseline risk across studies beyond chance) (see
Appendix 3, Figure 42). Therefore, the intercept in our final CPR model was not based on the Crawford et al.21
study (because of its 1-year follow-up), but predictor effects were based on the four developmental studies.
Statistical analysis methods: transformation of the logistic regression model into a clinical
prediction rule
We adapted the method described by Steyerberg41 to generate a CPR from our logistic regression
analyses. In brief, Steyerberg’s method is (1) multiply and round regression coefficients, (2) search
scores for continuous predictors, (3) estimate the multiplication factor for the scores and (4) estimate
the intercept and present a score chart. We omitted the second step because we had no continuous
predictors and the third because our multiplication factor was 1. Steyerberg’s method could be applied
to many different kinds of statistical model. We made a further modification to allow for the effect of
the non-linear logit function used in logistic regression.
The outcome variable in binary logistic regression is the natural logarithm of the odds, or log-odds,
of the binary event occurring:
log-odds = intercept + β1x1 + β2x2 + . . ., (1)
where βs are log-odds ratios and the xs are the predictors. The intercept is the log-odds of the outcome
occurring when all the predictors are zero. The probability of the outcome occurring can be calculated
from the log-odds. For each unit change in x, the log-odds will increase by the corresponding β (a fixed
amount), but the effect on the probability of outcome is not fixed because of the non-linear nature of
the log-odds; for example, if the log-odds is 1.3, the corresponding probability is 78.6%. If the log-odds
increases by 0.5 to 1.8, the probability becomes 85.8%, an increase in probability of 7.2%. If the log-odds
is 2.3 and it is increased again by 0.5 to 2.8, the probability changes from 90.9% to 94.3%, an increase
in probability of 3.4%, less than half the change before. The same change in log-odds does not mean
the same change in probability given different values of initial log-odds; therefore, when considering
the transformation of the logistic regression model into a simpler CPR, we also took account of the
probabilities that would result from the scoring system as well as the size of the coefficients. This
process was greatly simplified by having only three binary predictors. The number of possible predictor
combinations is only eight, and it is not onerous to calculate the probability of ulcer for each combination.
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To be explicit, our method was as follows:
1. Fit the logistic regression model with the three risk factor predictors (monofilament, pulses and
history) and study. This gives coefficients showing the extent to which the log-odds change for
patients who have a test-positive result for monofilaments, pulses or history in comparison with
lower-risk test-negative patients. There are also individual estimates for the intercept for each study.
The intercept is the baseline risk of ulcer on the log-odds scale. We used SAS® PROC LOGISTIC
(SAS Institute Inc., Cary, NC, USA; SAS and all other SAS Institute Inc. product or service names are
registered trademarks or trademarks of SAS Institute Inc. in the US and other countries. ® indicates
USA registration) with maximum likelihood estimation.
2. Conduct a random-effects meta-analysis of the three intercepts from the studies with 2-year
follow-up to get a single average intercept.
3. Use this average intercept and the log-odds coefficients for the three predictors to calculate the
probability of ulcer for each possible predictor combination; as there are three binary predictors,
there are eight combinations.
4. Multiply and round the coefficients of the predictors to get a CPR scoring scheme, bearing in mind
that we wanted predictor combinations with similar probabilities of ulcer to have the same score.
5. Repeat step 1 and step 2 using only the CPR score instead of monofilaments, pulses and history.
6. Calculate the probability of ulcer for each score using a population average method.
In the case of a patient who has already contributed to one of the four development data sets, the
most accurate estimate of baseline risk will be the appropriate study-specific intercept. A common
way to estimate baseline risk for patients not recruited to the development data sets is simply to use
the average intercept; however, our preference is to use the population average intercept method
described by Pavlou et al.42 to get estimates of ulcer risk that are applicable to patients in new studies.
Validation of the clinical prediction rule
We assessed the internal validity of the CPR by examining its discrimination and calibration.
Discrimination addresses how well the model’s predicted risks discriminate between those who will
and those who will not develop an ulcer, and the calibration of how well the estimated risk matches
the actual risk of ulceration. We used receiver operating characteristic (ROC) plots and the area under
the ROC curve as a statistic of discrimination; the latter is also known as a c-statistic. We assessed
calibration with calibration plots, estimation of the calibration slope, and calibration in the large.
We assessed the external validity of the CPR in the Leese et al.28 data set again by examining the
discrimination and calibration in the same way. For the validity analyses, we used the probability of
ulcer as estimated by the CPR score and compared it with actual ulcer outcome at 2 years.
Other methods of assessing model performance in terms of clinical benefit are available, such as net
benefit and decision curves, but we also noted that the performance of the CPR would be addressed
using a health economic model.
Using discrimination and calibration statistics in both the development data sets and the Leese et al.28
validation data set aids comparison of the internal and external validity of the CPR. Exploratory analyses
of all the data sets and investigation of heterogeneity was part of PODUS 2015. Hence we knew that
the Leese et al.28 data set was broadly similar to the other data sets. In fact, there was an overlap of
patients recruited to the Crawford et al.21 and Leese et al.28 data sets, and so we had to remove some
patients from the Leese data set to avoid duplication of data. Relevant tables are in Results.
We have also included a net benefit graph to assess potential clinical impact.43 All analyses were conducted
with SAS 9.4 [URL: www.sas.com (accessed 19 February 2019)] and R 3.4.2 [URL: https://cran.r-project.org/
(accessed 19 February 2019)]. The pROC,44 meta32 and rms45 packages in R statistical software (The R
Foundation for Statistical Computing, Vienna, Austria) were used.
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Results
Description of the individual studies
The quality of the cohort studies used to create the PODUS CPR is detailed in Table 1.31
The flow of patients in the Abbott et al.20 data set is shown in Figure 1. The 38 patients with a history
of amputation or ulcer and the 23 patients with a history of neither were coded accordingly. Thus, the
number of complete cases was 6417 (97%) when recoded ulcer and amputation history was excluded
and 6478 (98%) when it was included. One death was recorded in the study, but this patient was also
missing pulses and so could not have been included in the development data set.
The number of complete cases in the Crawford et al.21 data set was 1175 (98.5%), as 18 patients were
dropped from the analysis because information on monofilament sensitivity was absent and a further
five were dropped because no follow-up time was provided and so ulcer occurrence by 2 years could
not be calculated. There were 59 deaths in total in the Crawford et al.21 data set.
All of the variables required by the CPR were fully recorded in the Monteiro-Soares and Dinis-Ribeiro24
(n = 360) study and so we did not create a flow diagram. As the study setting was secondary care, these
data are likely to be accurate. Some other data were missing in the Monteiro-Soares and Dinis-Ribeiro24
study, for example 189 (53%) patients were missing vibration perception threshold (VPT) data, but these
were not required for the CPR. Deaths were not recorded.
In the Pham et al.25 study, the number of complete cases was 242 (97.6%). Three patients were missing
a monofilament measurement and three had no time to ulcer/end of follow-up. One patient with
a negative amputation history but no ulcer history was coded as negative for history. There were
13 deaths in the Pham et al.25 study.
The total number of patients in the development data sets was 8404 and the total number who
contributed to the analyses was 8255, an overall rate of complete data of 98%.
Among the Leese et al.28 data set, 295 patients were removed from the analysis as they were included
in the Crawford et al.21 data set. The Crawford et al.21 and Leese et al.28 studies recruited in a similar
time period in overlapping geographical areas; however, we used the Scottish NHS patient identifier,
the Community Health Index number46 (URL: www.ndc.scot.nhs.uk/Dictionary-A-Z/Definitions/index.
asp?ID=128%26Title=CHI%20Number), to remove Crawford et al.21 patients from the Leese et al.28
data set. This reduced the size of the Leese et al.28 data set from 3707 to 3412 patients.
TABLE 1 The risk-of-bias results for the PODUS studies
First author
and year of
publication
Risk of bias Applicability Overall
Participants Predictors Outcome Participants Predictors Outcome
Risk of
bias Applicability
Abbott 200220 + + + + + + + +
Crawford 201121 + + + + + + + +
Monteiro-Soares
201024
+ + + + + + + +
Pham 200025 + + + + + + + +
Leese 201128 + + – + + + – +
+, yes; –, no.
DOI: 10.3310/hta24620 Health Technology Assessment 2020 Vol. 24 No. 62
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
13
The percentage of complete cases in the Leese et al.28 data set was 97.4%; again, we considered this
high enough not to require multiple imputation. During the follow-up period, 95 patients died.
We calculated summary statistics for all the predictors considered for the primary analysis of PODUS 2015,
while noting that there is an extensive description of all the data sets in the PODUS 2015 publication.15
Summary statistics for age, duration of diabetes mellitus, sex, length of follow-up, sensitivity to
monofilaments, absent pulses, history of amputation or ulceration and the results of outcomes (ulcer)
are in Tables 2–9.
Although the Leese et al.28 study recorded patients’ test dates, in the case of occurrence only the year
was recorded. Therefore, for this data set, we recorded an ulcer as having occurred within 2 years if
one was recorded within 2 years of the year that the patient was first seen. This is not a precise way of
coding ulcer outcome by 2 years, but it allowed us to use the data set. Ulcer outcomes were recorded
from 2001 to 2007; the median year of occurrence was 2005.
TABLE 2 Summary statistics for age for each development study, all of the development data sets and the Leese et al.28
validation data set
First author and year of
publication Recorded (n) Missing (n)
Age (years)
Mean SD Median Minimum Maximum
Abbott 200220 6572 31 61.3 13.2 63 18 95
Crawford 201121 1193 0 70.5 10 72 22 94
Monteiro-Soares 201024 360 0 64.3 10.4 65 22 90
Pham 200025 247 1 58.3 12.5 58 20 83
All development data sets 8372 32 62.7 13.1 64 18 95
Leese 201128 3412 0 65.1 13.1 67 19 101
SD, standard deviation.
TABLE 3 Summary statistics for known duration of diabetes mellitus (years) for each development study, all of the
development data sets and the Leese et al.28 validation data set
First author and year of
publication Recorded (n) Missing (n)
Duration of diabetes (years)
Mean SD Median Minimum Maximum
Abbott 200220 6570 33 8.2 8.2 5 0 60
Crawford 201121 1191 2 8.8 8.4 6 0 63
Monteiro-Soares 201024 360 0 15.8 10.4 15 1 45
Pham 200025 247 1 13.9 10.8 12 0 54
All development data sets 8368 36 8.8 8.6 6 0 63
Leese 201128 3402 10 6.8 7.8 4 0 58
SD, standard deviation.
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TABLE 4 Summary statistics for sex for each development study, all of the development data sets and the Leese et al.28
validation data set
First author and year of
publication
Missing Men Women
Total (N)n % n % n %
Abbott 200220 1 0.02 3515 35.2 3087 46.8 6603
Crawford 201128 0 0 611 51.2 582 48.8 1193
Monteiro-Soares 201024 0 0 164 45.6 196 54.4 360
Pham 200025 0 0 124 50.0 124 50.0 248
All development data sets 1 0.0 4414 52.5 3989 47.5 8404
Leese 201128 0 0 1931 56.6 1481 43.4 3412
TABLE 5 Summary statistics for length of follow-up (months) for each development study and all of the development
data sets
First author and year of
publication
Recorded
(n)
Missing
(n) Mean SD Median Minimum Maximum
Abbott 200220 6603 0 24 0 24 24 24
Crawford 201128 1188 5 11.2 2.8 12 0 29
Monteiro-Soares 201024 360 0 30.8 22.2 25 3 86
Pham 200025 244 4 24.4 11.2 24 0 40
All development data sets 8395 9 22.5 7 24 0 86
SD, standard deviation.
Either time to ulcer or, if no ulcer occurred, time to when patient was last followed up and known to be ulcer free.
Note that these numbers may not match the flow charts as this table includes patients with missing data on other
predictors. Leese et al.28 is not included as the date of ulcer was recorded only as a year.
TABLE 6 Summary statistics for sensitivity/insensitivity to 1-g monofilament testing for each development study, all of
the development data sets and the Leese et al.28 validation data set
First author and year of
publication
Missing Sensitive Insensitive
Total (N)n % n % n %
Abbott 200220 125 1.89 5200 78.8 1278 19.4 6603
Crawford 201128 13 1.09 914 76.6 266 22.3 1193
Monteiro-Soares 201024 0 0 194 53.9 166 46.1 360
Pham 200025 3 1.21 60 24.2 185 74.6 248
All development data sets 141 1.68 6368 75.8 1895 22.5 8404
Leese 201128 2 0.06 2703 79.2 707 20.7 3412
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TABLE 7 Summary statistics for pulses testing for each development study, all of the development data sets and the
Leese et al.28 validation data set
First author and year of
publication
Missing Present Absent
Total (N)n % n % n %
Abbott 200220 3 0.05 4643 70.4 1957 29.7 6603
Crawford 201128 0 0 969 81.2 224 18.8 1193
Monteiro-Soares 201024 0 0 287 79.7 73 20.3 360
Pham 200025 2 0.81 210 85.4 36 14.6 248
All development data sets 5 0.06 6109 72.7 2290 27.2 8404
Leese 201128 76 2.23 2858 83.8 478 14.0 3412
‘Present’ indicates all four pulses are present and ‘absent’ indicates that at least one is absent. Note that these numbers
may not match the flow charts as this table includes patients with missing data on other predictors.
TABLE 8 Summary statistics for history of amputation or ulceration for each development study, all of the development
data sets and the Leese et al.28 validation data set
First author and year of
publication
No history History
Total (N)n % n %
Abbott 200220 6291 95.3 312 4.7 6603
Crawford 201128 1107 92.8 86 7.2 1193
Monteiro-Soares 201024 223 61.9 137 38.1 360
Pham 200025 71 28.6 177 71.4 248
All development data sets 7692 91.5 712 8.5 8404
Leese 201128 3216 94.3 196 5.7 3412
Note that missing results were coded as test-negative. Note that these numbers may not match the flow charts as this
table includes patients with missing data on other predictors.
TABLE 9 Summary statistics for results for ulcer outcome by 2 years for each development study, all of the development
data sets and the Leese et al.28 validation data set
First author and year of
publication
Missing No ulcer Ulcer
Total (N)n % n % n %
Abbott 200220 0 0 6312 95.6 291 4.4 6603
Crawford 201128 5 0.42 1165 97.7 23 1.9 1193
Monteiro-Soares 201024 0 0 308 85.6 52 14.4 360
Pham 200025 4 1.61 175 70.6 69 27.8 248
All development data sets 9 0.11 7960 94.7 435 5.2 8404
Leese 201128 0 0 3279 96.1 133 3.9 3412
Note that these numbers may not match the flow charts as this table includes patients with missing data on
other predictors.
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From the coding detailed above, the total number of patients from the development data sets used
in the logistic regression model underlying the CPR was 8255 (98%), of whom 430 had ulcer-positive
outcomes and 7825 had ulcer-negative outcomes at 2 years. In the Leese et al.28 validation data set
3324 patients had suitable data, of whom 128 had an ulcer by 2 years and 3196 did not. We did not
compute unadjusted ORs for the predictor and outcome, as this work had already been done as part
of PODUS 2015.15
Development and testing of the clinical prediction rule: initial logistic
regression model and random-effects meta-analysis
As outlined in Statistical analysis methods: transformation of the logistic regression model into a clinical
prediction rule, the results of steps 1 and 2 of building the CPR are presented here.
On the log-odds scale, the initial logistic regression model with original predictors (coded 0 if
test negative and 1 if test positive) was:
log-odds of ulcer by 2 years = –3:81 + (1:11 × mono) + (0:70 × + pulse) + (1:95 × history). (2)
The intercept of –3.81 was taken from a random-effects meta-analysis of the intercepts of the three
studies with 2-year follow-up data.
Calculating probability of ulcer for each predictor combination
We used Equation 2 to carry out step 3 of the CPR building by first calculating the log-odds of ulcer for
each prediction combination and then converting that log-odds to a probability.
Generating a scoring scheme
Part of step 4 was examining ulcer risk probabilities (Table 10). This showed that some different
predictor combinations had similar risk. For example, we wanted the (0,0,1) predictor combination with
a probability of 0.134 to have the same score as the (1,1,0) combination with a probability of 0.118.
TABLE 10 Probability of ulcer for each of the eight predictor combinations
Monofilament
sensitive
Pulses
present
No history of
ulcer or amputation
Probability of
ulcer at 2 years
0 0 0 0.022
0 1 0 0.043
1 0 0 0.062
1 1 0 0.118
0 0 1 0.134
0 1 1 0.238
1 0 1 0.318
1 1 1 0.484
Monofilament is coded 0 if the patient is sensitive to a 10-g monofilament and 1 otherwise. Pulses are coded 0 if all
four pulses are present and 1 otherwise. Patients with no known history of ulcer or amputation are coded 0 and 1
otherwise. The probability of ulcer is calculated using Equation 2.
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Using the probabilities and the method of multiplying and rounding the predictor coefficients described
by Steyerberg,41 the CPR scoring method is:
l score 1 if patient is insensitive to monofilaments
l score 1 if patient is missing any pulse
l score 2 if patient has a history of ulcer or amputation.
This results in a CPR that gives scores from 0 to 4. We calculated this score for each patient and
refitted the logistic regression model using CPR score as the only predictor.
Refitting the logistic regression model with clinical prediction rule score as the only predictor
The resulting logistic regression model from steps 4 and 5 in Statistical analysis methods: transformation
of the logistic regression model into a clinical prediction rule using CPR score is:
log-odds of ulcer at 2 years = –3:73 + (0:944 × score). (3)
The intercept again was taken from a random-effects meta-analysis of the intercepts of the three
studies with 2-year follow-up data. We did not use this formula to calculate the probability of an ulcer,
but, if we had decided to, the corresponding formula for probability would be:
Probability of ulcer at 2 years =
1
1 + e−(−3:73 +0:944 ×score)
. (4)
Using Equation 4 would be perfectly acceptable, but we could calculate population-averaged probabilities
of ulcer, which should be generalisable to new studies. The formula for doing so is complex, and not
something that can be done easily without statistical software.42 We therefore calculated the probabilities
for our end-users, as one of our aims is that our CPR be easy to use. This is the sixth and final step outlined
in Statistical analysis methods: transformation of the logistic regression model into a clinical prediction rule.
Internal validity of the clinical prediction rule
The calibration of the CPR is shown in Figure 5 (using the study-specific estimates) and in Figure 6
(using the population average estimates). The study-specific estimates, by definition, have a calibration
slope of 1 and an intercept of 0, showing that the model has ideal calibration in the data set in which
it was developed. The changes in slope and intercept for the population average estimates show that
the CPR has been slightly recalibrated. We show these graphs for comparison with the calibration plot
obtained with the Leese et al.28 validation data set and because external calibration is a better guide of
how a model will perform than internal calibration.
Discrimination of the CPR shown in Table 11 was assessed by calculating the area under the ROC curve
(Figure 7). The c-statistic for the CPR is 0.796 (95% CI 0.772 to 0.820) and for the three-predictor model
(monofilaments, pulses and history) is 0.802 (95% CI 0.778 to 0.825).
External validity of the clinical prediction rule
The discrimination and calibration plots generated by the CPR in the Leese et al.28 data set show very
similar results to those of the internal validation (Figures 8–10). Again, the calibration statistics suggest
that the probability of ulcer at 2 years is underestimated by the CPR.
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FIGURE 5 Calibration plot for the CPR using study-specific estimates from the development data sets.
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FIGURE 6 Calibration plot for the CPR using population average estimates from the development studies.
TABLE 11 Population-based probability of ulcer at 2 years for each CPR score, calculated using Pavlou’s method for
population average estimates in the development data sets
CPR score Patients (n)
Probability of
ulcer at 2 years 95% CI
0 4646 0.024 0.014 to 0.03
1 2406 0.060 0.035 to 0.09
2 676 0.140 0.085 to 0.21
3 358 0.292 0.192 to 0.41
4 169 0.511 0.379 to 0.641
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We also compared the performance of the CPR with that of the original three-predictor model and
found very little loss of accuracy with the CPR (Table 12). Appendix 3 gives a further comparison of the
three-predictor and score models, using the development data sets.
The c-statistic for the CPR is 0.829 (95% CI 0.790 to 0.868). The c-statistic for the three-predictor
model is 0.834 (95% CI 0.794 to 0.873).
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FIGURE 7 The ROC curves for the CPR and three-predictor model for the prediction of ulcer at 2 years derived from
the development data sets.
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FIGURE 8 The external validation ROC plot from the Leese et al.28 data set.
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FIGURE 9 The external validation calibration plot from the Leese et al.28 data set for the CPR.
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FIGURE 10 The external validation calibration plot from the Leese et al.28 data set for the three-predictor model.
TABLE 12 External data calibration statistics for the three-predictor and CPR models
Model Intercept (95% CI) Slope (95% CI)
Three predictors 0.046 (–0.336 to 0.428) 1.133 (0.990 to 1.276)
CPR score –0.059 (–0.431 to 0.314) 1.139 (0.994 to 1.283)
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At a risk threshold of 6%, the net benefit is 0 for treat none and < 0 for treat all, but 0.015 for using
the CPR (Figure 11). This can be interpreted as follows: if we choose to treat patients with CPR scores
of ≥ 1, then, for every 1000 individuals, 15 additional cases of ulcer at 2 years would be correctly
identified for treatment by the CPR, without increasing the number treated unnecessarily. At a risk
threshold of 14%, the number of additional cases of ulcer at 2 years identified for treatment would be
10 per 1000 individuals.
Table 13 shows the PODUS CPR that is designed to predict the risk of ulceration within 2 years of
patients with diabetes mellitus who do not currently have a foot ulcer.
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FIGURE 11 Net benefit plot for use of the CPR to identify patients who would benefit from an intervention to prevent
foot ulcer, generated from the Leese et al.28 validation data set.
TABLE 13 Printable display version of the PODUS CPR
PODUS CPR Score
Test with 10-g monofilament
Insensitive at any site – score 1 point
Sensitive at all sites – score 0 points
Check pedal pulses
Any pulse missing – score 1 point
Four pulses present – score 0 points
Has there been an ulcer or amputation previously?
Any ulcer or amputation – score 2 points
No ulcer or amputation – score 0 points
Total score out of 4
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Discussion
The CPR is simple and can be used without a calculator. The elements of the scoring system comprise
neurological damage, as assessed by sensitivity to a 10-g monofilament; vascular damage, as assessed
by the presence or absence of pedal pulses; and propensity to ulcerate, as assessed by history. This will
give the CPR face validity for end-users. Monofilament sensitivity and the presence of pulses are quick,
simple and cheap to measure. History of ulcer or amputation should be noted in the patient’s records
or identifiable from the patient’s presentation.
An important component in the development of complications in diabetes mellitus is self-care by patients.
We have very few data on this in the PODUS data sets, and so the statistical model underlying our CPR
is incomplete. This may be why the CPR underestimates risk as some of the risk of ulcer development
will depend on the level of diabetic control achieved by the patient; however, how self-care should be
measured is the subject of ongoing research.47
The performance of the CPR in the Leese et al.28 validation data set suggests that simplifying the three-
predictor model into the CPR resulted in little loss of discrimination and calibration. The calibration
graphs indicate that both the CPR and the three-predictor model are least accurate for high-risk
patients: those with a history of ulceration or amputation and at least one other risk factor. However,
the treatment pathway for these patients is the same, so the use of neither the CPR nor the three-
predictor model would result in a change in their care.
Ideally, the CPR will be validated in a new, prospective study. A new study’s results would be applicable
to patients living with diabetes mellitus today. Although we made every reasonable effort to gather all of
the data that were available, the data sets are not very recent and the factors driving the development
of foot ulcer may have changed.
A small number of patients developed ulcers despite exhibiting no neurological or vascular damage
(< 5% of all ulcers), but amputation is rarely necessary in such cases. The proportion of patients with
this predictor combination was 1.96% in the development data sets and 0.93% in the validation data set.
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Chapter 4 Systematic review of
preventative interventions for foot
ulceration in diabetes mellitus: an overview
Introduction
Accurate prediction models are useful for informing treatment decisions, but their value is ultimately
dependent on the availability of effective interventions to modify an individual’s probability of
developing a condition without causing further harm.41,48 The effect of interventions is most reliably
assessed in RCTs, as this is the only method of clinical evaluation that controls for known and unknown
confounding factors. We were aware of important SRs of RCTs published from 1998 onwards that had
identified RCTs that evaluated interventions to prevent foot ulceration in diabetes mellitus.16,18,49–51
The existence of these SRs with similar objectives to our own introduced the possibility that the most
efficient way to obtain numerical summaries of data (evidence) could be from an overview of SRs.
Overviews are used to summarise the effect of multiple interventions for a single condition.52 They
share some of the characteristics of SRs: a planned methodological approach, a defined question, a
search strategy, methods of data extraction and assessment of review quality. We sought to obtain
estimates of effect for preventative interventions for foot ulceration in diabetes mellitus from SRs of
RCTs sufficient to populate an economic model.53,54 The protocol for the overview was registered with
PROSPERO (CRD42016052324).
Overview question
How effective are preventative strategies for foot ulceration?
Aim
The aim was to produce an overview of the effects of interventions to prevent foot ulceration in
diabetes mellitus.
Objectives
The objectives were to identify SRs of RCTs and to obtain data about their effect on the incidence of
foot ulcers to calculate measures of effect from individual RCTs, or pool estimates from several trials
with which to populate an economic model.
Method
Searches
We searched for SRs using electronic search strategies created for Ovid® (Wolters Kluwer, Alphen aan den
Rijn, the Netherlands) MEDLINE, Ovid EMBASE and the Cochrane Library without language restrictions
from inception until February 2019 (see Appendix 4). Our approach to searching was informed by a search
string created by staff at the Centre for Reviews and Dissemination at the University of York to identify
SRs. SRs in progress were identified via PROSPERO [URL: www.crd.york.ac.uk/prospero/ (last accessed
1 May 2020)].
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Eligibility criteria
We assessed the scope of each review to ensure that it matched our objectives.
Participants
The participants were people of any age with a diagnosis of diabetes mellitus, either type 1 or type 2.
Intervention(s)
Simple interventions (e.g. pressure-distributing insoles or bespoke footwear or education packages in
relation to foot care or other aspects of self-management aimed at patients or health-care professionals)
or complex interventions (e.g. care from a specialist multidisciplinary team in which several interacting
interventions were evident) were considered for inclusion in the review. SRs of wound treatments,
including trials that evaluated dressings for foot ulcers, were excluded.
Comparator(s)
We included SRs that reported standard care or active comparators, including simple and complex
interventions.
Outcomes
Primary outcomes
Incident (new) and recurrent foot ulcers were reported as binary outcomes (present or absent). These
were defined in various ways, including as ‘a full thickness skin defect that requires more than 14 days
to heal’55 or using a classification system:56
l absolute numbers of incident ulcers
l absolute numbers of recurrent ulcers.
Secondary outcomes
l Amputation [minor, intrinsic to the foot (i.e. below the ankle), or major, involving the foot and leg].
l Mortality.
l Gangrene.
l Infection.
l Adverse events.
l Harms.
l Time to ulceration.
l Quality of life (QoL) [assessed using the EuroQol-5 Dimensions (EQ-5D), Short Form questionnaire-12
items (SF-12), or Short Form questionnaire-36 items (SF-36)].
l Timing of screening.
l Self-care.
l Hospital admissions.
l Psychological (knowledge/behaviour).
Study design
We sought to obtain evidence of the effectiveness of interventions from SRs of RCTs. Where we
identified SRs that included randomised and non-randomised studies, we included the review but
extracted data only from the RCTs.
Review selection and data extraction
One reviewer screened all titles and abstracts to identify potentially relevant SRs. A second reviewer
screened a 10% random sample of the yield. Two reviewers (DN and AA) working independently
screened the full texts of titles considered potentially relevant to determine whether or not the
objectives of each review matched our own with regard to the population, interventions, comparisons,
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outcomes and study design. Disagreements were resolved by discussion with a third reviewer (FC).
Data were extracted into a review-specific data extraction tool (see Appendix 5, Data extraction
and quality assessment: systematic review of randomised controlled trials) by two reviewers working
independently (DN and FC). Separate data extraction and quality assessment tools were designed and
piloted for the SRs. The following data were extracted:
l review author and funder details
l review objectives
l eligibility criteria for trials to be included in the review
l populations (including risk of ulceration), interventions, comparisons, outcomes and method of
synthesis (e.g. narrative synthesis or meta-analysis).
Risk-of-bias (quality) assessment
We undertook an assessment of the quality of reporting using the risk of bias in systematic reviews
(ROBIS) tool.57 This tool assesses bias in four domains that correspond to the main processes for
conducting SRs: determination of study eligibility criteria, identification and selection of studies,
data collection and study appraisal, and synthesis methods and findings (Tables 14 and 15).
We distinguished between SRs that included study designs other than RCTs and those that included
RCTs alone, and we tabulated the two groups separately. This is because the ROBIS tool contains an
assessment of the appropriateness of the synthesis relating to the nature and similarity in the research
questions, study designs and outcomes across included studies (ROBIS domain 4; item 4.3), and we
anticipated that the syntheses of data in reviews that included both RCTs and observational studies
might be based on all included study designs (randomised and observational) and, if reviewers failed
to separate the data from different types of study designs, might not reflect the findings from the
RCT data alone.
Plan for data analysis
From each included SR we extracted absolute numbers for the primary and secondary outcomes and
measures of effect with associated 95% CIs as reported in the reviews. We also noted the reviews’
overall conclusions about the effects of preventative interventions.
TABLE 14 Risk of bias of SRs including RCTs alone
Review (first author and
year of publication)
Domain
Study eligibility
criteria
Study identification
and selection
Data collection
and study appraisal
Synthesis
methods
and findings
Adiewere 201858 Unclear Unclear Unclear High
Arad 201159 Unclear High Low High
Binning 201960 Low Low High Low
Dorresteijn 201251 Low Low Low Low
He 201361 Low High Unclear High
Hoogeveen 201516 Low Low Low Low
Kaltenthaler 199862 Unclear High Unclear Low
Mason 199918 Unclear High Low Low
O’Meara 200049 Low Low Low Low
Spencer 200050 Low Low Low Low
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Results
Our search, conducted up to February 2019, retrieved 7020 references. The level of agreement between
the two reviewers (DN and AA) for selecting records by title and abstract was 58%, and disagreements
were resolved by discussion with a third reviewer (FC). The flow diagram in Appendix 4, Figure 51, shows
the number of articles at each stage of the process. We scrutinised 136 articles in a full-paper check,
subsequently excluding 118 (see Appendix 3, Table 41). We added two reviews that were identified from
searching the reference lists of the 18 reviews identified from the search of databases.
In total, we identified 20 SRs that aimed to evaluate interventions to prevent foot ulceration in diabetes
mellitus. Ten included only RCTs, and 10 included RCTs and observational studies; among the latter,
one SR was an updated version of another.64,65 All reviews were published between 1998 and 2019.
Tables 16 and 17 detail the scope of the reviews and Tables 18 and 19 detail the results of the overview.
Interventions
Education alone
Researchers from Glasgow, UK, and Amsterdam, the Netherlands, conducted a SR to assess the effect
of motivational interviewing on adherence to interventions to prevent diabetic foot ulceration.60 A search
of 11 databases for articles published until 2018 found one RCT79 that met our eligibility criteria. The
reviewers used a 21-item checklist designed to identify bias in and quality of studies of the foot in diabetes
mellitus. Only one of the included trials measured foot ulceration as an outcome. Other outcomes included
behaviour and knowledge of foot care practices. A narrative synthesis found insufficient evidence about
the value of motivational interviewing (or similar behavioural interventions) in preventing DFU.
Our assessment of bias in this review found weaknesses in the data collection, which involved only
one reviewer.
Researchers from Utrech, the Netherlands, reported a SR that assessed the effect of educational
interventions on the prevention of diabetic foot ulcerations, which was published in the Cochrane
Library.51 A search of five databases from inception until 2012 identified two RCTs that met our
eligibility criteria (n = 231 people with diabetes mellitus who either had a history of foot ulceration or
were at high risk of foot ulceration). A variety of outcomes were measured in the included trials: foot
TABLE 15 Risk of bias of SRs including studies of different design
Review (first author and
year of publication)
Domain
Study eligibility
criteria
Study identification
and selection
Data collection
and study appraisal
Synthesis
methods
and findings
Buckley 201363 Low High Unclear Low
Bus 201664 and Bus 200865 Low Low Low High
Healy 201466 Low High Low Unclear
Heuch 201667 Low High Low Low
Maciejewski 200468 Unclear High Low Low
Mayfield 200069 High High Unclear Unclear
Paton 201170 Low Unclear Low High
Ahmad Sharoni 201671 Low High Low Unclear
van Netten 201672 Low Low Low High
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TABLE 16 Summary of scope of the review: SR of RCTs alone
SR (first author and year of
publication)/country/funder Aim Search strategy Definition of ulcer
RCTs and total
number of patients
Adiewere 201858
UK
The Independent Diabetes
Trust
To examine the effectiveness of
patient education in preventing or
reducing the incidence or recurrence
of foot ulcers in adults with diabetes
Six databases: MEDLINE, EMBASE, CINAHL, PsycINFO,
the Cochrane Library and Evidence-based Nursing.
Searched from inception until September 2017
Nursing portal, National Library for Health, Excerpta
Medica (Excepta Medica BV, Amsterdam, the
Netherlands) and Google Scholar (Google Inc.,
Mountain View, CA, USA), bibliographies of relevant
textbooks
Search strategy reported: not reported
Excluded studies reported: no
Not reported Six RCTs; 1525
Arad 201159
USA
NR
To evaluate trials of interventions to
prevent DFU and not methods that
simply predict the likelihood of future
ulcers or treat pre-existing foot ulcers
Six databases: MEDLINE, PubMed, Clinical Trials
section of the Cochrane Library, ClinicalTrials.gov,
WHO’s International Clinical Trials Registry Platform
Number registry and Google databases. Searched
from 1 January 1960 to 30 April 2010
Search strategy reported: not reported/unclear
Excluded studies reported: no
Not reported Eight RCTs; 3520
Binning 201960
UK
NR
To determine whether or not
motivational interviewing is an
effective intervention to improve
adherence behaviours for the
prevention of DFU
Eleven databases: MEDLINE, CINAHL, ProQuest®
(ProQuest LLC, Ann Arbor, MI, USA), Nursing &
Allied Health Database, PsycINFO, CENTRAL, AMED,
EMBASE, Web of Science™ (Clarivate Analytics,
Philadelphia, PA, USA) core collections and
Science Direct® (Elsevier, Amsterdam, the
Netherlands)
Search strategy reported: yes
Excluded studies reported: no
Foot ulceration One RCT; 131
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TABLE 16 Summary of scope of the review: SR of RCTs alone (continued )
SR (first author and year of
publication)/country/funder Aim Search strategy Definition of ulcer
RCTs and total
number of patients
Dorresteijn 201251
The Netherlands
NR
To assess the effects of patient
education on the prevention of DFU
Five databases: Cochrane Wounds – 3 September
2014; CENTRAL up to 2012 issue 7; MEDLINE,
EMBASE, and CINAHL up to July 2012; Ovid
MEDLINE 2009 to July week 3 2012; Ovid MEDLINE
In-Process & Other Non-Indexed Citations, 31 July
2012; Ovid EMBASE (2009 to 2012 week 30) and
CINAHL [via EBSCOhost (EBSCO Information
Services, Ipswich, MA, USA)] 2009 to 26 July 2012
Search strategy reported: yes
Excluded studies reported: yes
Foot ulcers are open sores Two RCTs; 225
He 201361
China
NR
To assess the effectiveness of
intensive vs. routine education on
diabetes mellitus for preventing DFU
Five databases: CENTRAL up to 2013 issue 1;
PubMed and EMBASE (1978–2013); VIP
(1989–2013); and Wang Fang Data (1980–2013)
Search strategy reported: insufficient
Excluded studies reported: no
Not reported Two RCTs; 231
Hoogeveen 201516
The Netherlands
NR
To determine the effectiveness of
complex interventions against single
interventions for the prevention of
DFU. A complex intervention is
defined as an integrated care
approach, combining two or more
prevention strategies on at least two
different levels of care: the patient,
the health-care provider and/or the
structure of health care
Nine databases: Cochrane Wounds up to 22 May
2015; CENTRAL, the DARE, the HTA database,
the NHS EED via the Cochrane Library up to 2015,
issue 4; MEDLINE and MEDLINE In-Process & Other
Non-Indexed Citations from 1946 to 21 May 2015;
EMBASE from 1974 to 21 May 2015; and CINAHL
from 1982 to 22 May 2015
Search strategy reported: yes
Excluded studies reported: yes
SR did not report, but this
differed for each study
Three RCTs; 2458
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SR (first author and year of
publication)/country/funder Aim Search strategy Definition of ulcer
RCTs and total
number of patients
Kaltenthaler 199862
UK
NR
To critically review evidence on the
effectiveness of interventions for
treating and preventing DFU
Eight databases: CINAHL, the Cochrane Library,
EMBASE, HealthSTAR, MEDLINE, PharmacoEconomics
& Outcomes News, NHS EED and DataStar (Absolute
Technology Ltd, Southampton, UK). Searched from
1986 to 1996
Search strategy reported: no
Excluded studies reported: no
Wagner Classification
System divides DFUs into
grades of severity 0–573
Two RCTs; 464
Mason 199918
UK
NHS Executive and British
Diabetic Association
To identify effective interventions for
the management of the diabetic foot
Eight databases: Cochrane Trials Register, MEDLINE,
EMBASE, CINAHL, HealthSTAR, PsychLIT, Science
Citation Index, and Social Science Citation Index.
Searched from 1983 ‘onwards’
Search strategy reported: no
Excluded studies reported: no
At risk or damaged foot in
diabetes defined not DFUs in
particular74
Three RCTs; 2465
O’Meara 200049
UK
National Institute for Health
Research, UK
To examine the clinical effectiveness
and cost-effectiveness of
interventions for the prevention and
treatment of DFU; to identify
significant gaps in the research
evidence; to outline the type of
research needed to provide relevant
information to the NHS
Nineteen databases: MEDLINE from 1966 up to end
of 1998; and Science Citation Index (Clarivate
Analytics, Philadelphia, PA, USA), BIOSIS, British
Diabetic Association Database, CINAHL, CISCOM,
Cochrane Database of Systematic Reviews, Cochrane
Wounds, Current Research in Britain, DARE,
Dissertation Abstracts International, Department of
Health and Social Security data, EconLit, EMBASE,
Index to Scientific & Technical Proceedings, NHS EED
(NHS Centre for Reviews and Dissemination), Royal
College of Nursing Database, System for Information
on Grey Literature in Europe (SIGLE – BLAISE-LINE)
and National Research Register up to the end of 1998
Search strategy reported: yes
Excluded studies reported: yes
Author defined diabetic foot,
using Wagner’s system75 for
the classification of diabetic
feet, but did not define DFU
Four RCTs; 2625
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TABLE 16 Summary of scope of the review: SR of RCTs alone (continued )
SR (first author and year of
publication)/country/funder Aim Search strategy Definition of ulcer
RCTs and total
number of patients
Spencer 200050
UK
No external sources of
support
To assess the effectiveness of
pressure-relieving interventions in the
prevention and treatment of DFU
Nineteen databases: in the paper reported only
Cochrane Wounds Group methods used in search
strategy. This uses the Cochrane Wounds and
CENTRAL – both dates not reported; MEDLINE from
1946 onwards; EMBASE from 1974 onwards;
EBSCOhost from 1982 onwards; CINAHL trial
registries; ClinicalTrials.gov; the WHO’s International
Clinical Trial Registry platform; and the European
Union Clinical Trials Register (all dates not reported)
Search strategy reported: insufficient
Excluded studies reported: yes
Not reported One RCT; 69
AMED, Allied and Complementary Medicine Database; BIOSIS, Bioscience Information Service; CINAHL, Cumulative Index to Nursing and Allied Health Literature; CISCOM,
Centralised Information Service for Complementary Medicine; DARE, Database of Abstracts of Reviews of Effects; NHS EED, NHS Economic Evaluation Database; NR, not reported;
VIP, Vendor Information Pages; WHO, World Health Organization.
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TABLE 17 Summary of scope of the review: SR of studies including different designs
SR (first author and
year of publication)/
country/funder Aim Search strategy Definition of ulcer
RCTs and total
number of patients
Buckley 201363
Ireland
Health Research Board
Ireland
To determine the effect of contact with
a podiatrist on the occurrence of LEAs
in people with diabetes
Four databases: PubMed from 1966 to 25 September
2011; CINAHL from 1981 to 25 September 2011;
EMBASE from 1974 to 25 September 2011; and the
Cochrane databases from 1991 to 25 September 2011
Search strategy reported: yes
Excluded studies reported: yes
Not reported One RCT; 91
Bus 201664 and Bus 200865
The Netherlands
NR
To assess the effectiveness of footwear
and offloading interventions to prevent
or heal foot ulcers or to reduce
mechanical pressure
Eight databases: PubMed, EMBASE, CINAHL, Cochrane
Database of Systematic Reviews, CENTRAL, NHS Economic
Evaluation Database, and Health Technology Assessment
Database. Searched from May 2006 to July 2014
Search strategy reported: yes
Excluded studies reported: yes
Not reported Seven RCTs; 1476
Healy 201466
UK
NR
To examine the quality and
effectiveness of footwear to prevent
DFU or to reduce biomechanical risk
factors for ulceration
Three databases: CINAHL, MEDLINE and Cochrane
Register of Controlled Trials. Searched up to
December 2012
Search strategy reported: insufficient
Excluded studies reported: no
Not reported Two RCTs; 469
Heuch 201667
Australia
NR
To identify, critically appraise and
synthesise the best available evidence
on methods of offloading to prevent
the development, and reduce the risk,
of primary foot ulceration in adults
with diabetes
Thirteen databases: PubMed, Cochrane Database of
Systematic Reviews, CINAHL, EMBASE, Scopus, Google
Scholar, Cochrane – Protocols, Research and Trials Register,
ClinicalTrials.gov, NHS Research Register, regard (database of
Economic and Social Research Council), OpenSIGLE, MedNar,
WorldWideScience. Searched up to November 2013
Search strategy reported: yes
Excluded studies reported: yes
Cochrane Wound Group:76
an area of skin loss resulting
from poor blood supply
and/or reduced nerve
function in the lower limb
caused by diabetes mellitus
0 RCTs
Maciejewski 200468 To review the evidence for the
effectiveness of therapeutic footwear in
preventing re-ulceration in people
One database: MEDLINE from 1980 to ‘present’ Not reported Two RCTs; 469
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TABLE 17 Summary of scope of the review: SR of studies including different designs (continued )
SR (first author and
year of publication)/
country/funder Aim Search strategy Definition of ulcer
RCTs and total
number of patients
USA
Department of Veterans
Affairs
with diabetes and to discuss factors
influencing study findings
Search strategy reported: insufficient
Excluded studies reported: no
Mayfield 200069
USA
NR
To evaluate Semmes–Weinstein
monofilament and other threshold testing
in preventing ulcers and amputation
One database: MEDLINE from 1985 to 2000
Search strategy reported: insufficient
Excluded studies reported: no
Not reported One RCT; 2001
Paton 201170
UK
NR
To evaluate the effectiveness of insoles
used for the prevention of ulcer in
neuropathic diabetic foot
Two databases: MEDLINE and CINAHL.
Searched up to 2008
Search strategy reported: insufficient
Excluded studies reported: no
Not reported One RCT; 69
Ahmad Sharoni 201671
Malaysia
NR
To assess the effectiveness of health
education programmes to improve foot
self-care practices and foot problems
among older people with diabetes
Six databases: EBSCOhost medical collections
(MEDLINE, CINAHL, Psychology and Behavioural
Sciences Collection), SAGE, Wiley Online Library (John
Wiley & Sons, Inc., Hoboken, NJ, USA), ScienceDirect,
SpringerLink (Springer Nature Switzerland AG, Cham,
Switzerland), and Web of Science. Searched from
January 2000 to March 2015.
Search strategy reported: yes
Excluded studies reported: no
Not reported One RCT; 172
van Netten 201672
The Netherlands
NR
To determine the effectiveness of
patient education to prevent foot
ulceration in persons with diabetes who
are at risk of foot ulceration and do not
have a current foot ulcer
Eight databases: PubMed, Excerpta Medica database
(EMBASE) via OvidSP (Health First, Rockledge, FL, USA),
CINAHL, Cochrane Database of Systematic Reviews, DARE,
CENTRAL,WHO’s International Clinical Trials Registry
Platform and ClinicalTrials.gov. Searched up to July 2014
Search strategy reported: yes
Excluded studies reported: no
A DFU was defined as a
‘full thickness lesion of the
skin distal to the malleoli
in a person with DM’77
17 RCTs; 3107
CINAHL, Cumulative Index to Nursing and Allied Health Literature; DARE, Database of Abstracts of Reviews of Effect; DM, diabetes mellitus; NHS EED, NHS Economic Evaluation
Database; OpenSIGLE, Open System for Information on Grey Literature in Europe; WHO, World Health Organization.
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TABLE 18 Summary of the results of the overview: SRs of RCTs alone
SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Adiewere 201858 Intervention: patient education
Control: standard care
Risk status: unclear
Patient education
Monami 1995.78 DFU: RR 0.08 (95% CI 0.00 to 1.34).
Knowledge improved; p = 0.001
Gershater 2011.79 Ulcer recurrence: intervention group
(n = 19) 48%, control group (n = 22) 38% (p > 0.05)
Lincoln 2008.80 Recurrent ulcers: foot care behaviour
showed a significant improvement in intervention group
(p = 0.03). No clinical benefits from education
Rönnemaa 1997.81 Foot care knowledge improved in
the intervention group after 12 months. No effects of
education on DFUs or amputation rate. Increase in foot
care knowledge in the intervention group (p = 0.004)
Malone 1989.82 Marked reduction in ulceration incidence
in the intervention group (n= 8) compared with the
control group (n= 28): RR 0.31 (95% CI 0.14 to 0.66).
Amputation: RR 0.33 (95% CI 0.15 to 0.76)
Bloomgarden 1987.83 Education had no significant effects
on ulceration, amputation, callus formation, nail dystrophy
or fungal infection
Meta-analysis
continued
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TABLE 18 Summary of the results of the overview: SRs of RCTs alone (continued )
SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Arad 201159 Interventions:
l Enhanced patient education and caretaker monitoring
l Therapeutic footwear and insoles
l Surgical
l Plantar foot temperature-guided avoidance therapy
Control: no information
Risk status: high risk
Patient education
Litzelman 1993.6 Number of participants not reported;
outcomes unclear
Lincoln 2008.80 No difference in the rate of foot ulcers
McCabe 1998.84 Decrease in major amputations but not in
minor amputations or ulcerations
Therapeutic footwear
Uccioli 1995.85 At 1 year there was a significant difference
(27.7% vs. 58.3%) but the direction of the effect is unclear
Reiber 2002.86 No differences in incidence of foot
ulceration between the two groups
Lavery et al. (unpublished: personal communication to
Arad59). Patients with a history of foot ulceration showed a
reduction of > 90% but patients without a history did not
Plantar foot temperature-guided avoidance therapy
Lavery 2004.87 Patients (n = 85), 7% vs. 2% (the ulceration
rate in the intervention and control groups); p = 0.01
Lavery 2007.88 Ulceration rate was 30% in the intervention
and control groups and 8.5% in the temperature-guided
avoidance therapy group
Armstrong 2007.89 Ulcer rates for two groups unclear
(12.2–4.7% in the temperature group)
Narrative
Binning 201960 Intervention: motivational interviewing
Control: not reported
Risk status: ‘at risk of DFUs’
Gershater 2011.79 Incidence of ulceration as an outcome.
The intervention did not improve ulceration rates
compared with the control group
Narrative
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SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Dorresteijn 201251 Intervention: education aimed at DFUs, diabetes in
general, including foot care education, diabetic foot
programme with patient education on foot care
Control: all types of controls were considered for
inclusion and so this varied between trials
Risk status: varied
Intensive compared with brief educational interventions
Lincoln 2008.80 Ulcer rate at 12 months: 36/87 vs. 35/85.
Amputation at 12 months: 9/87 vs. 9/85
Cisneros 2010.90 Foot ulcers were observed in 22/51
people. The accompanying survival curve in the trial report
showed a trend towards longer event-free survival in
intervention group participants, but this was not
statistically significant (p = 0.362; hazard ratio not
reported)
Numerical summary, data plotted on
a forest plot without summary
statistic
He 201361 Intervention: intensive diabetic education. Unclear
how provided
Control: routine diabetes education
Risk status: not reported
Lincoln 2008.80 Ulceration: RR 1.00 (95% CI 0.70 to 1.44)
Amputation: RR 0.97 (95% CI 0.37 to 2.59)
Cisneros 2010.90 Ulcers: RR 0.53 (95% CI 0.28 to 1.02)
Meta-analysis with summary statistic:
RR, OR, mean differences, 95% CI
Hoogeveen 201516 Intervention: complex integrating care combining two or
more prevention strategies on two or more different
levels of care: patient, health-care provider and/or
structure of health care. Differed for each study. Included
education and footwear
Control: differed for each study but included written foot
care instructions only as a single intervention, with usual
care or alternative complex intervention, which differed
from the experiment on two different levels
Risk status: varied
More intensive and comprehensive complex interventions vs.
usual care
McCabe 1998.84 Ulcers at 2-year follow-up: intervention
group 24/1001 vs. control group 35/1000; RR 0.69 (95% CI
0.41 to 1.14). Amputation: intervention group 7/1001;
control group 23/1000 (RR 0.30, 95% CI 0.13 to 0.71)
Liang 2012.91 Ulcers: intervention group, 0/31; control
group, 7/31. Amputation: intervention group, 0/31; control
group, 2/31
Educationally focused interventions vs. usual care or less
intensive programmes
Litzelman 1993.92 Amputation: intervention group, 1/191;
control group, 4/205
No ulcer data mentioned
Meta-analysis without summary
statistic; with summary statistic risk
ratios and 95% CI
continued
D
O
I:
1
0
.3
3
1
0
/h
ta2
4
6
2
0
H
ealth
T
ech
n
o
lo
gy
A
ssessm
en
t
2
0
2
0
V
o
l.2
4
N
o
.6
2
©
Q
u
een
’s
P
rin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
2
0
.T
h
is
w
o
rk
w
as
pro
d
u
ced
b
y
C
raw
fo
rd
et
al.u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cial
C
are.T
h
is
issu
e
m
ay
b
e
freely
repro
d
u
ced
fo
r
th
e
pu
rpo
ses
o
f
private
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,th
e
fu
ll
repo
rt)
m
ay
b
e
in
clu
d
ed
in
pro
fessio
n
al
jo
u
rn
als
pro
vid
ed
th
at
su
itab
le
ackn
o
w
led
gem
en
t
is
m
ad
e
an
d
th
e
repro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g.
A
pplicatio
n
s
fo
r
co
m
m
ercial
repro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
al
In
stitu
te
fo
r
H
ealth
R
esearch
,
E
valu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lph
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
pto
n
Scien
ce
P
ark,So
u
th
am
pto
n
SO
1
6
7
N
S,U
K
.
3
7
TABLE 18 Summary of the results of the overview: SRs of RCTs alone (continued )
SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Kaltenthaler 199862 Intervention: health education, therapeutic footwear
Control: no education, and patients wore their own shoes
Risk status: not reported
Health education
Litzelman 1993.92 Lower extremity abnormality:
59% reduction in risk in the intervention group
Therapeutic shoes
Uccioli 1995.85 Ulcer relapse rate: 27.7% in the
intervention group vs. 58.3% in the control group
Narrative
Mason 199918 Intervention:
l Patient education – general diabetic care, foot care,
special foot care sessions
l Screening for patients at increased risk of ulceration
l Orthotic device, therapeutic shoes plus custom-
moulded insoles
Control: none or normal education, usual care,
conventional podiatric care, patient’s own shoes
Risk status: not reported
Patient education
Litzelman 1993.92 Significant reduction in serious lesions
(OR 0.41, 95% CI 0.16 to 1.00; p = 0.05). Amputation
rate 1/191 in the intervention group and 4/205 in the
control group
Screening and interventions for patients with raised risk
of ulceration
McCabe 1998.84 Ulcer rate: 24/1001 in the intervention
group vs. 35/1000 in the control group
Proportion of ulcers leading to amputations: intervention
group, 7/24; control group, 23/35
Amputations (major): intervention group, 1/1001; control
group, 6/1001
Footwear in patients with raised risk of ulceration
Uccioli 1995.85 Ulcer relapse rate: intervention
group, 9/33; control group, 21/36
Narrative
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SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
O’Meara 200049 Intervention: orthotics, podiatry, therapeutic shoes with
custom-moulded insoles, standard below-knee elastic
stockings, education, insulin treatment, multifaceted
health-care intervention, simple education and routine
diabetic teaching, screening, prevention programme
Control: traditional podiatrist treatment/routine patient
care – written instructions, ordinary non-therapeutic
shoes, elastic stockings vs. no stockings, usual care,
no special foot care education
Risk status: high risk
Uccioli 1995.85 Ulcer relapse at 1 year: intervention group,
9/33; control group, 21/36 (OR 0.29, 95% CI 0.11 to 0.74)
Ulcer-free time: intervention group mean, 9.1 (SD 3.7)
months, control group mean, 3.7 (SD 3.1) months
Belcaro 1992.93 Number of ulcerated limbs at year 4:
intervention group, 3/148; control group, 10/150 (OR 0.33,
95% CI 0.11 to 1.00). Total number of ulcers: intervention
group, 3/74; control group, 10/75 (OR 0.31, 95% CI 0.10
to 0.98)
Litzelman 1993.92 Serious foot lesions: intervention group,
7/176; control group, 16/175 (OR 0.32, 95% CI 0.19 to
1.00). Amputation rate (foot or limb): intervention group,
1/191; control group, 4/205 (OR 0.32, 95% CI 0.05
to 1.86)
McCabe 1998.84 Incidence of ulceration: intervention
group, 24/1001; control group, 35/1000
Proportion of ulcers leading to amputations: intervention
group, 29%; control group, 66%
Number of amputations: intervention group, 7 (one major
and six minor); control group; 25 (12 major and 13 minor)
Narrative and meta-analysis with
summary statistic ORs
Spencer 200050 Intervention: orthotics, podiatry, total contact casting,
therapeutic shoes, education
Control: not reported
Risk status: varied
Pressure-relieving devices vs. standard care
Uccioli 1995.85 Incidence of ulcer relapse: intervention
group, 9/33; control group, 21/36 (OR 0.29, 95% CI
0.11 to 0.74)
Mean ulcer-free time WMD: 5.40 (95% CI 3.78 to 7.02)
Meta-analysis without pooled
summary statistics
RR, relative risk; SD, standard deviation; WMD, weighted mean difference.
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TABLE 19 Summary of results of overview: SRs of studies including different designs
SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Buckley 201363 Intervention: patient education, podiatry, chiropody
Control: written information or chiropodist
treatment, not specifically recommended
Risk status: varied
Chiropodist visit
Plank 200394
Recurrence rate of ulcers: not reported in SR
Amputation at 1 year: intervention group, 2; control group, 1
Meta-analysis with summary
statistic: RR. Separate forest
plots for RCT/cohort
Bus 201664 and
Bus 200865
Interventions:
l casting
l footwear
l surgical offloading
l other offloading techniques
Control:
l standard care alone
l no intervention
l sham treatment
Risk status: high risk
Footwear and orthoses
Lavery 2012.95 Ulcer recurrence: intervention group, 2.0% (n = 3/149);
control group, 6.7% (n= 10/150) (p = 0.08)
Rizzo 2012.96 Ulcer incidence at 1 year: intervention group, 12.8%;
control group, 38.6% (p < 0.0001). At 3 years: intervention group,
17.6%; control group, 61.0% (p < 0.0001). At 5 years: intervention
group, 23.5%; control group, 72.0% (p = 0.0001)
Scirè 2009:97 Ulcer incidence: intervention group, 1.1% (1/89); control
group, 15.4% (12/78) (p < 0.001)
Uccioli 1995.85 Ulcer recurrence: intervention group, 27.7%; control
group, 58.3%; p = 0.009
Ulbrecht 2014.98 Ulcer recurrence at 16.5 months: intervention group,
9.1%; control group 25.0% (p < 0.007; HR 3.4, 95% CI 1.3 to 8.7). All
lesions at 6 months: in intervention group significantly less than in
control group (p = 0.042). Ulcer recurrence at 6 months: in intervention
group significantly less than in control group (p = 0.003)
Not reported. Reported in
discrete sections
Bus 2013.99 Ulcer recurrence: intervention group, 33 of 85 (38.8%);
control group, 38 of 86 (44.2%) (p = 0.48; OR 0.80, 95% CI 0.44 to
1.47). Ulcer recurrence in 79 adherent patients (i.e. > 80% of steps in
prescribed footwear): intervention group, 9 of 35 (25.7%); control
group, 21 of 44 (47.8%) (p = 0.045; OR 0.38, 95% CI 0.15 to 0.99).
All lesions at 12 months: not significantly different (p = 0.073). Ulcer
recurrence at 12 months: in intervention group significantly less than
in control group (p = 0.0041)
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SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Reiber 2002.86 Recurrent ulcers in 2 years: intervention group 1, 26;
intervention group 2, 31; control group, 38. Number of patients with
an ulcer in 2 years: intervention group 1, 14.9% (18/121), intervention
group 2, 14.3% (17/119), control group, 16.9% (27/160). Relative risk
ratios: intervention group 1 vs. control group 0.88 (95% CI 0.51
to 1.52), intervention group 2 vs. control group 0.85 (95% CI 0.48
to 1.48)
Healy 201466 Intervention: footwear as a method for offloading to
prevent DFU
Control: usual footwear
Risk status: high risk
Reiber 2002.86 Ulceration: intervention group 1.15%; intervention
group 2, 14%; control group 7%
Uccioli 1995.85 Ulcer relapse: intervention group 2, 7.7%; control
group 5, 8.3% (p = 0.009)
(Absolute numbers unclear for both studies)
Narrative
Heuch 201667 Intervention: customised rigid orthotic device
Control: traditional treatment by podiatrist
Risk status: low risk
No RCTs were identified that met the criteria for our overview Narrative reported in
discrete sections
Maciejewski 200468 Intervention: therapeutic footwear, therapeutic shoes
with insoles (cork/polyurethane inserts), slippers
Control: unclear in reporting
Risk status: high risk
Uccioli 1995.85 Re-ulceration: intervention group. 27.7%; control
group, 58.3% (RR 0.47, 95% CI 0.23 to 0.90; OR 0.26)
Reiber 2002:86 No significant difference in re-ulceration between
cork and control groups (RR 0.88, 95% 0.51 to 1.52) or between
polyurethane and control groups (RR 0.85, 95% 0.48 to 1.48)
Narrative reported in
discrete sections
Mayfield 200069 Intervention: screening
Control: unclear in reporting
Risk status: low risk
Klenerman and McCabe 1998.84,100 Ulcers: intervention group 24
vs. control group 35. Minor amputations: intervention group 6 vs.
control group 13. Major amputations: intervention group 6 vs. control
group 12
Narrative reported in
discrete sections
continued
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TABLE 19 Summary of results of overview: SRs of studies including different designs (continued )
SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Paton 201170 Intervention: therapeutic footwear with PPT and
Plastazote®-casted insoles (Zotefoam, Croydon, UK),
magnetic insoles
Control: own footwear or sham
Risk status: high
Uccioli 1995.85 Ulcer relapses: intervention group, 27.7%; control
group, 58.3%. Therapeutic insoles plus shoes not associated with
ulceration: R = –0.315 (95% CI –0.54 to –0.08). Ulcer-free time:
intervention group, 9.1 ± 3.7 months, control group, 3.7 ± 3.1 months
Narrative reported in
discrete sections
Ahmad Sharoni 201671 Intervention: education programmes to improve foot
self-care practices and foot problems
Control: usual care
Risk status: not reported
Lincoln 2008.80 No significant difference was observed between
groups in ulcer or amputation incidence at either 6 or 12 months
Narrative reported in
discrete sections
van Netten 201672 Interventions:
l Patient education
l Self-management
l Therapeutic footwear
l Surgical intervention
l Integrated foot care
Control: usual care
Risk status: ‘at risk’
Foot care programmes
Liang 2012.91 Ulcers: intervention group, 0%; control group, 24.1%
(n = 7) (p = 0.0137). Minor amputation: intervention, group, 0% (n = 0);
control group, 6.9% (n= 2) (p = 0.4569)
Van Putten 2010.101 Ulcer incidence: intervention group, 10% (n= 28);
control group, 11% (n = 30) (p = 0.89). Severe ulcers: (infected or deep
ulcers): intervention group, 11% (n = 3/28); control group, 37%
(n = 11/30) (p = 0.03). Amputation: intervention group, 1% (n= 2);
control group, 2% (n = 6) (p = 0.29)
Cisneros 2010.90 Ulcer intervention group, 38.1% (8/30); control
group, 5.1% (8/23) (p = 0.29)
Plank 2003.94 Recurrence (per patient): intervention group, 38%
(n = 18); control group, 57% (n= 25) (HR 0.60, 95% CI 0.32 to 1.09;
p = 0.9). Ulcer recurrence (per foot): intervention group, 22% (n= 20);
control group, 38% (n = 32) (RR 0.52, 95% CI 0.29 to 0.93; p = 0.03).
Amputation: intervention group, 4% (n= 2); both minor); control
group, 2% (n= 1, minor). Mortality: intervention group, 4% (n = 2);
control group, 9% (n = 4). Aggregated DFUs, amputation and mortality:
intervention group, 38% (n= 18); control group, 66% (n = 29)
(HR 0.54, 95% CI 0.30 to 0.96; p = 0.03)
Narrative reported in
discrete sections
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SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Self-management
Armstrong 2005.102 Ulcer: intervention group, 5.9% (n = 2); control
group, 5.6% (n = 2) (p = 0.9). No difference in unexpected visits or
missed appointments
Armstrong 2007.89 Ulcer: intervention group, 4.7% (n = 5); control
group, 12.2% (n= 14) (OR 3.0, 95% CI 1.0 to 8.5; p = 0.038)
Lavery 2004.87 Ulcer/Charcot fracture: intervention group, 2.4%
(n = 1); control group, 20.0% (n= 9) (p = 0.0; RR 10.3, 95% CI 1.2 to
85.3). Ulcer: intervention group, 2.4% (n = 1); control group, 1.6%
(n = 7) (p < 0.05). Amputation: intervention group, 0% (n = 0); control
group, 2.3% (n = 1)
Lavery 2007.88 Ulcer/Charcot fracture: intervention group, 8.5%
(n = 5); control group 1, 30.4% (n= 17); control group 2, 29.3%
(n = 17). Intervention vs. control group 1; OR 4.71 (95% CI 1.60 to
13.85) (p = 0.0061). Control group 1 vs. control group 2: OR 4.48
(95% CI 1.53 to 13.14) (p = 0.008). Time to ulceration: intervention vs.
control group 1 vs. control group 2; p = 0.011
Patient education
Gershater 2011.79 Ulcer recurrence: intervention group, 48% (n= 19);
control group, 38% (n = 22) (p > 0.05). Time to recurrence not
significantly different between intervention group and control group
(no p-value reported)
Lincoln 2008.80 Recurrent ulcers: intervention group, 41.4% (n = 36);
control group, 41.2% (n = 35) (RR 0.997, 95% CI 0.776 to 1.280).
Amputation: intervention group, 10.3% (n= 9) (one major, eight minor)
(RR 1.003, 95% CI 0.905 to 1.111). Recommended foot care
behaviours were better in the intervention than in the control group
at 12 months
Footwear and orthoses
Scirè 2009.97 Ulcer incidence: intervention group, 1.1% (1/89); control
group, 15.4% (12/78) (p < 0.001)
continued
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TABLE 19 Summary of results of overview: SRs of studies including different designs (continued )
SR (first author and
year of publication) Intervention/control/risk status Outcomes Synthesis of data
Lavery 2012.95 Ulcer recurrence: intervention group, 2.0% (n = 3);
control group, 6.7% (n= 10) (p = 0.08)
Rizzo 2012.96 Ulcer incidence at 1 year: intervention group, 12.8%;
control group, 38.6% (p = 0.0001). Ulcer incidence at 3 years:
intervention group, 17.6%; control group, 61.0% (p = 0.0001). Ulcer
incidence at 5 years: intervention group, 23.5%; control group, 72.0%
(p = 0.0001)
Ulbrecht 2014. Ulcer/Charcot fracture: intervention group, 2.4%
(n = 1); control group, 20.0% (n= 9) (p = 0.01; RR 10.3, 95% CI 1.2 to
85.3). Ulcer: intervention group, 2.4% (n = 1); control group, 1.6%
(n = 7) (p < 0.05). Amputation: intervention group, 0% (n = 0); control
group, 2.3% (n = 1)
Bus 2013.99 Ulcer recurrence: intervention group, 33 of 85 (38.8%);
control group, 38 of 86 (44.2%) (p = 0.48; OR 0.80, 95% CI 0.44 to
1.47). Ulcer recurrence in 79 adherent patients (i.e. > 80% of steps in
prescribed footwear): intervention group, 9 of 35 (25.7%); control
group, 21 of 44 (47.8%) (p = 0.045; OR 0.38, 95% CI 0.15 to 0.99)
Reiber 2002.86 Number of recurrent ulcers in 2 years: interventon
group 1, 26; intervention group 2, 31, control group, 38 (not
significant). Number of patients with an ulcer in 2 years: intervention
group 1, 14.9% (18/121); intervention group 2, 14.3% (17/119); control
group, 16.9% (27/160). RR ratio: intervention group 1 vs. control group
0.88 (95% CI 0.51 to 1.52); intervention group 2 vs. control group 0.85
(95% CI 0.48 to 1.48)
Uccioli 1995.85 Ulcer recurrence: intervention group, 27.7%; control
group, 58.3% (p = 0.009)
HR, hazard ratio; PPT, professional protective technology; RR, relative risk.
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care knowledge, behaviour, self-confidence scores and common foot disorders including callus and nail
dystrophies. With regard to foot ulceration and amputation, the authors concluded that only two
sufficiently powered trials reported the effect of education and that there was insufficient robust
evidence that it was effective. The risk of bias in the RCTs was assessed using the Cochrane risk-of-bias
tool. Our assessment of review quality using the ROBIS tool found the review to be at low risk of bias.
A group of researchers from Ya’an, China, conducted a SR61 that was published in Chinese and translated
for our team by a researcher fluent in Chinese (Xin Wang) and using the translate function of Google
(Google, Inc., Mountain View, CA, USA). A search of five databases from inception to 2012 identified two
RCTs (n = 231 people with diabetes mellitus). The participants’ risk of foot ulceration was not reported.
The meta-analysis (n = 1189) showed that the incidence of foot ulcers was lower in the diabetes mellitus
education group than in the control group (64/610 vs. 102/579), and the difference was statistically
significant [relative risk (RR) 0.51, 95% CI 0.30 to 0.84]. The reviewers used the Cochrane risk-of-bias
tool to assess the quality of the included trials and found them to be mainly at high risk of bias. The
reviewers concluded that, compared with routine education, intensive education could reduce the
incidence of DFUs but that this needed to be verified in high-quality studies.
We were unable to replicate this meta-analysis because we could not obtain three of the RCTs from
the British Library.104–106 In our assessment of the risk of bias of this SR, the search strategy was judged
to be weak because of limited search terms and because restrictions on search dates may have led to
trials being missed.
A team of researchers from Selangor, Malaysia,71 undertook a SR to assess the effectiveness of health
education programmes in improving foot self-care practices and foot problems among older people
with diabetes mellitus.85 A search of six databases between January 2000 and March 2015 found
one RCT that met our eligibility criteria (n = 172). The reviewers also included one RCT that explicitly
excluded people with diabetes mellitus, despite the review title indicating that this was the population
of interest.107 The reviewers assessed study quality using the Cochrane risk-of-bias tool.52 The
reviewers found no statistical differences between the groups in terms of foot ulcer and amputation
incidence at 6 or 12 months. The reviewers concluded that education programmes showed an
improvement in self-care scores and foot problems but further evaluations are required.
In our assessment of the quality of this review, we found several threats to the validity of the findings:
the approach to applying the review eligibility criteria was ambiguous, and the inclusion of a trial that
excluded patients with diabetes mellitus appeared to contradict the eligibility criteria of the review.
A team of researchers from Nottingham, UK,66 undertook a SR to assess the effectiveness of education
interventions in preventing or reducing the incidence or recurrence of foot ulcerations or amputations
in adults with diabetes mellitus. A search of six databases from inception to September 2017 identified
six RCTs, only three of which met our eligibility criteria (n = 423). The reviewers assessed study quality
using the Cochrane risk-of-bias tool and a Critical Appraisal Skills Programme (CASP) tool. Three
forest plots presented pooled outcomes. The first pooled RR of foot ulceration collected from people
receiving education versus usual care (RR 0.52, 95% CI 0.23 to 1.15). The second pooled estimate
evaluated the effect of education on foot ulcer and amputation rate combined (RR 0.37, 95% CI
0.14 to 1.01). The third assessed foot ulcer and amputation rates among people receiving intensive
education compared with the rates among those receiving brief education interventions (RR 0.57,
95% CI 0.20 to 1.63). The reviewers concluded that the education interventions led to a statistically
significant effect based on a p-value of 0.05.
In our assessment of the quality of this review, we found all three CIs from the meta-analyses included 1.
Despite this, the researchers concluded that, overall, an intensive education approach offered a
positive effect.
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Footwear and offloading
A team of researchers from Amsterdam, the Netherlands, carried out a SR of footwear and offloading
interventions to prevent or heal foot ulcers or to reduce mechanical pressure.65 An updated search of
eight databases of articles published between May 2006 and July 2014 identified a further seven RCTs
(n = 1476).64 The interventions were casting, footwear and surgical offloading. The reviewers used the
Cochrane risk-of-bias tool to assess trial quality and found it to be variable. The reviewers concluded
that therapeutic footwear leads to a reduction in plantar pressure, which they suggest will, in turn,
prevent plantar foot ulcer recurrence. The reviewers also concluded that there is no evidence that
therapeutic footwear prevents first foot ulcers, only recurrent ulcers, and that custom-made footwear
results in fewer ulcers than no prescribed footwear among people with a history of foot ulceration.
Our risk-of-bias assessment judged this review to be at a low risk of bias.
A group of researchers from Staffordshire, UK, reported a SR that examined the quality and
effectiveness of footwear to prevent DFU or to reduce biomechanical risk factors for ulceration.66
A search of three databases identified two RCTs relevant to our overview (n = 469). Quality was
assessed based on three criteria (sampling method, inclusion criteria and the approach to statistical
analysis) and the two included RCTs were reported to be of poor quality. The authors’ conclusions
were based on the findings from observational studies, but the authors did acknowledge the need for
further randomised trials.
Our assessment of the bias of this trial found a risk of bias arising from study selection, which was carried
out by one reviewer, and from the fact that the searches were limited to English-language studies.
Researchers in Adelaide, Australia, undertook a SR to identify, critically appraise and synthesise the
best available evidence for offloading interventions to prevent the development and reduce the risk
of primary foot ulceration in adults with diabetes mellitus who were at low risk of foot ulceration. The
review identified no RCTs that were relevant to our review from a literature search of 14 databases
(until November 2013), but the eligibility criteria did match that of our overview.67 The reviewers
used the Joanna Briggs Institute’s critical appraisal checklist108 to assess study quality.
The reviewers concluded that there is limited evidence that offloading prevents the development and
reduces the risk of primary foot ulceration in adults with diabetes mellitus at low risk of foot ulceration.
A research team from Washington, USA, published a SR in 2004 that aimed to review the evidence of
the effectiveness of therapeutic footwear in preventing re-ulceration in people with diabetes mellitus
and to discuss factors influencing study findings.68 A search of one database (1980 to ‘the present’)
identified two RCTs relevant to our overview (n = 469) evaluating therapeutic footwear. There was an
assessment of study validity.109 The reviewers found no consistent evidence to support the use of
therapeutic shoes and inserts to prevent DFU, owing to methodological weaknesses in the studies,
and so concluded that there is no significant therapeutic benefit from therapeutic footwear. Nor did
they identify evidence to support the practice of dispensing free therapeutic shoes with insoles to all
patients with diabetes mellitus.
In a SR, a team from Plymouth, UK, evaluated the effectiveness of insoles in the prevention of ulcers in
people with a history of foot ulceration.70 A search of two databases (from inception to 2008) identified
only one RCT that met our eligibility criteria (n = 69). This trial evaluated the effect of a magnetic insole
constructed using Professional Protective Technology, Inc. (Deer Park, NY, USA). The trial investigators
reported a reduction in foot ulcer relapses [27.7% vs. 58.3%; p = 0.009; OR 0.26 (95% CI 0.2 to 1.54)].85
The reviewers assessed the quality of studies using an assessment tool for use in randomised and
non-randomised studies.110 They concluded that insoles designed to prevent ulceration in the diabetic
neuropathic foot appear to be of some value and should be considered as part of a prevention strategy.
It was not possible for these reviewers to recommend any particular type or specification of insoles.
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Complex interventions
A research group from Utrecht, the Netherlands, published a SR in the Cochrane Library. The review
aimed to evaluate the effectiveness of complex interventions in comparison with a single intervention
for the prevention of DFU.16 The review included trials that involved people with diabetes mellitus with
different levels of ulcer risk. A search of nine databases identified three RCTs relevant to our overview.
The Cochrane risk-of-bias tool52 was used to assess trial quality.
The reviewers defined a complex intervention as an integrated care approach combining two or more
prevention strategies on at least two different levels of care (patients, health-care providers and/or
structure of health care). The review included three trials with DFUs as an outcome that compared the
effect of educationally oriented complex interventions plus either screening tests or follow-up or more
intensive complex interventions that included screening and multidisciplinary care for those at risk.84,91,92
The review concludes that there is insufficient evidence to support the effectiveness of complex
interventions, but this should be interpreted as a lack of evidence rather than as evidence of no effect.
Our assessment of the risk of bias found the review to be at a low risk.
Screening
Reviewers in Washington, USA, conducted an evaluation of the effect of Semmes–Weinstein
monofilament and other threshold testing in preventing foot ulcers and amputations.69 Their search of
one database from 1985 to 2000 found one RCT84,100 (n = 2001). The trial recruited and screened 2001
people with diabetes mellitus. Those at risk of ulceration were enrolled in a specialist foot care service.
The quality assessment tool that the reviewers used was suitable for assessing the quality of studies
of diagnostic tests. The authors concluded that the Semmes–Weinstein monofilament has excellent
predictive ability for the risk of foot ulceration in diabetes mellitus but that the value of repeated tests
for assessing established neuropathy is unknown.
Mixed interventions
An international group of researchers undertook a SR to determine the effectiveness of interventions
to prevent foot ulceration in people at high risk of ulceration.72 A search of eight databases from
inception until 2014 without restrictions identified 17 RCTs that were relevant to our overview
(n = 3107 people with diabetes mellitus). Randomised and non-randomised studies were eligible for
inclusion. All trial participants were reported to be at risk of ulceration at the time of recruitment.
The assessment of study quality was conducted using the Cochrane risk-of-bias tool. The included
interventions were patient education, self-management, therapeutic footwear, surgical interventions
and integrated foot care. A narrative synthesis was conducted and the authors concluded that there
was no evidence of a preventative effect on the development of a first foot ulcer but that there was
strong evidence that footwear interventions are effective in preventing recurrent foot ulcerations.
This review presents data that appear to be amenable to meta-analysis, but no a priori plan for the
analysis is included in the review methods and the reviewers present their results as a narrative.
Otherwise, this review was judged to be at a low risk of bias.
Researchers from Los Altos, USA, published a SR that evaluated trials of interventions to prevent foot
ulcers in diabetes mellitus.59 The reviewers searched six databases (search dates 1960 to April 2010)
and found eight RCTs (n = 3520). The interventions included enhanced patient education and caretaker
monitoring, therapeutic footwear and insoles, surgical interventions (debridement and surgical Achilles
tendon lengthening) and plantar foot temperature-guided avoidance therapy. No information about
the control interventions was provided. The assessment of trial quality was performed using the
Amsterdam–Maastricht consensus list.111 The reviewers concluded that the foot temperature-guided
avoidance therapy was beneficial and was applicable to similar populations at risk of foot ulceration.
Our assessment of the risk of bias revealed a high risk as a result of restricted search dates, ambiguous
eligibility criteria and the absence of a table of study characteristics.
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A group of researchers from Sheffield, UK, conducted an overview to critically review evidence of the
effectiveness of interventions for treating and preventing DFUs.62 The reviewers stated that it was not
their intention to conduct their review systematically, but because their approach meets the widely
accepted definitions of a SR we included it in our overview.52 The reviewers searched eight databases
(from 1986 to 1996) and identified two RCTs that met our overview criteria (n = 464). The review
focused on trials of education and therapeutic footwear. The assessment of study quality was
conducted using the Jadad checklist.112 The reviewers concluded that, currently, few interventions to
prevent foot ulceration are supported by evidence, but therapeutic shoes appear potentially beneficial.
Our risk-of-bias assessment judged this review to be at a high risk because of the restrictions on search
dates and language.
A SR by researchers based in York, UK, sought to identify effective interventions for the management of
the diabetic foot.18 The reviewers searched eight databases (from 1983 onwards) and identified three
RCTs evaluating preventative strategies that met the eligibility criteria of our overview (n = 2465).
The interventions were patient education, screening for risk assessment and footwear incorporating
an orthotic device and custom-moulded insoles.84,85,92 Quality was assessed using a checklist of four
items: blinding level, baseline comparability, numbers randomised and loss to follow-up. The reviewers
concluded that there is no evidence that foot risk assessment is of benefit and findings about the value
of education are inconsistent.
Our risk-of-bias assessment found that the SR was at a high risk regarding eligibility criteria because
there was insufficient information about the search strategy and the process for selecting studies.
Researchers in Leeds, UK,49 searched 19 databases for studies of preventative interventions for foot
ulceration in diabetes mellitus and found four RCTs84,85,92,93 that met the eligibility criteria of our overview
(n = 2625). The interventions studied were orthoses, education, footwear with custom-moulded insoles,
below-knee elastic stockings and complex interventions including screening. Assessment of study quality
was based on an assembled checklist of items including concealment of allocation, a priori sample size
calculation, baseline comparability of groups, inclusion/exclusion criteria, adequate follow-up period,
withdrawals and follow-up stated with reasons, and intention-to-treat analysis. The reviewers concluded
that there is much uncertainty about the most clinically effective and cost-effective interventions for
the prevention of DFU and that further and more rigorous evaluations are needed. The review strongly
recommended more good-quality RCTs of interventions to prevent and treat foot ulcers in diabetes
mellitus, with concurrent economic evaluations. We judged the risk of bias of this review to be low.
A team in Newcastle upon Tyne, UK, conducted a SR of the effectiveness of pressure-relieving
interventions that was published in the Cochrane Library.50 The reviewers searched 10 databases (search
dates: MEDLINE, 1946 onwards; EMBASE, 1974 onwards; EBSCOhost, 1982 onwards; other databases,
not reported). The searches identified one RCT that met our eligibility criteria (n = 69).85 Study quality
was assessed using a standard checklist that included allocation concealment, intention-to-treat analysis,
loss to follow-up and blinding. The reviewers concluded that footwear and customised insoles provide
some benefit but there was uncertainty about the most beneficial type of orthotic device.
A group of researchers in Cork, Ireland, conducted a SR of the effects of podiatric care on the incidence
of LEAs.63 The reviewers searched four databases (from inception to 2011) and included a single trial
that reported the incidence of foot ulceration as an outcome.94 The intervention was podiatric care at
least once per month and the comparison was ad hoc podiatric. Quality was assessed using a modified
version of the checklist created by Downs and Black.110 The reviewers found insufficient evidence to
determine whether or not contact with a podiatrist can be effective in reducing amputation rates. Our
assessment of the risk of bias found that the exclusion of non-English-language studies was a weakness.
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Discussion
A key step in the process of systematic reviewing is to establish whether a review with the same,
or similar, objectives exists before embarking on a new review.113 In undertaking an overview of SRs
to prevent foot ulceration in diabetes mellitus, we found examples of SRs of varying quality. Those
published in the Cochrane Library were considered to be at a low risk of bias, as was a previous
Health Technology Assessment (HTA) programme-funded review.
Although the 20 reviews do not all share the same scope with regard to interventions or populations
of people with diabetes mellitus, there is a great deal of overlap in the RCTs that they include, and the
majority of reviewers concluded that more primary research is required. Although no robust pooled
estimates of effect were identified, the majority of SRs by researchers globally to identify preventative
interventions for DFUs reflects the high degree of clinical uncertainty among those delivering care and a
clear desire to establish an evidence-based approach to the prevention of foot ulcers.
Many of these SRs were accepted for publication before the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) statement was widely adopted. The older reviews lacked
features, such as flow diagrams and search strategies, that are now demanded by journal editors,114
and other important items were also absent from many of the reports published since 2009.
Search strategies and date and language restrictions in the database searches plus our own lack of
access to sources of biomedical information from China meant that we could not re-run the searches
and update the reviews to the same point in time. This presented a major barrier to our conducting a
thorough overview of SRs.
Systematic reviews require considerable resources and support from information specialists,
statisticians, experienced reviewers and clinical experts.113 The majority of reviews in this overview
did not report any source of funding, and this may have had a detrimental effect on the reviewers’
ability to conduct the research to the highest methodological standards.
Although one review presented suitable data in a format amenable to recalculating estimates of effect,72
the scope of the review focused on those at high risk of foot ulceration, and we concluded that a new
SR to obtain estimates of effect on a wide population of people with diabetes mellitus was justified.
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Chapter 5 Preventative interventions
for foot ulceration in diabetes mellitus:
a systematic review
Background
Systematic reviews have played an important role in the creation of evidence-based health care,115
and there has been a proliferation in the number published in the biomedical literature since the early
1990s. In Chapter 4, we presented the results of an overview of 20 SRs of interventions to prevent
foot ulceration in diabetes mellitus from which up-to-date and reliable estimates of effect could not
easily be obtained; therefore, we undertook a new SR to produce RRs and 95% CIs with which to
populate an economic model to assess the cost-effectiveness of preventative interventions.
Review question
Aim
The aim was to conduct a SR of the evidence of preventative effects of interventions for foot
ulceration in diabetes mellitus that have been evaluated in RCTs.
Objective
The objective was to produce estimates of the effect of interventions with which to populate an
economic model.
Method
Searches
We searched for eligible RCTs of interventions using search strategies created for Ovid MEDLINE
(from inception to February 2019), Ovid EMBASE and Central Register of Controlled Trials (CENTRAL)
without restrictions (from inception until October 2018). Randomised controlled trials in progress
were identified via the International Standard Randomised Controlled Trial Number (ISRCTN) registry
(searched to February 2019).
Eligibility criteria
Participants
The participants were people of any age with a diagnosis of diabetes mellitus, either type 1 or type 2,
who had participated in RCTs of interventions to prevent foot ulceration in diabetes mellitus.
Interventions
Eligible interventions were considered either simple or, if several interacting components were evident,
complex.116 We defined a complex intervention as an integrated care approach combining two or more
prevention strategies at least two different levels of care: the patient, the health-care provider and/or
the structure of health care. Randomised controlled trials of interventions to manage established
wounds (e.g. dressings) were excluded.
Comparators
We included RCTs that compared the effects of interventions with those of standard care or
active comparators.
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Outcomes
Primary outcomes
The primary outcomes were incident (new) and recurrent foot ulcers reported as binary outcomes
(present or absent):
l absolute numbers of incident ulcers
l absolute numbers of recurrent ulcers.
We accepted a variety of definitions of foot ulceration, including ‘a full thickness skin defect that requires
more than 14 days to heal’,117 or an objective scoring system such as an ulcer classification system.56
Secondary outcomes
l Amputation [minor, intrinsic to the foot (i.e. below the ankle), or major, involving the foot and leg].
l Mortality.
l Gangrene.
l Infection.
l Adverse events.
l Harms.
l Time to ulceration.
l QoL (assessed using the EQ-5D, SF-12 or SF-36).
l Timing of screening.
l Self-care.
l Hospital admissions.
l Psychological (knowledge/behaviour).
Study selection and data extraction
One reviewer screened all RCT titles and abstracts to identify potentially relevant literature. A second
reviewer screened a 10% random sample of the yield. Two reviewers scrutinised the full text of trials
thought to meet the eligibility criteria. Disagreements were resolved by discussion with a third
reviewer. Data were extracted into a review-specific data extraction tool by two reviewers working
independently. The following data were extracted:
l study authors and funders’ details
l study objectives
l eligibility criteria for trial participants
l trial setting, the population, numbers randomised, a description of interventions and comparators,
the included population’s level of risk of ulceration, absolute numbers for the primary outcome,
number of foot ulcers, amputations and secondary outcomes.
Risk-of-bias (quality) assessment
For RCTs, we carried out an assessment of the risk of bias using the recommended items in the
Cochrane Handbook for Systematic Reviews of Interventions.52
Plan for data analysis
For each included trial, we calculated the pooled RRs of effects and 95% CIs using a frequentist
meta-analytical approach with data analysed on an intention-to-treat basis. Trials were weighted in
accordance with the inverse variance method for the dichotomous primary outcome of the review,
namely foot ulceration. Heterogeneity was assessed using the I2 statistic.
PREVENTATIVE INTERVENTIONS FOR FOOT ULCERATION IN DIABETES MELLITUS: A SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
To examine the effects of heterogeneity on patient characteristics, such as baseline risk of foot
ulceration, and trial quality, we intended to use meta-regression techniques when sufficient data
were available.52
Results
Twenty-two RCTs met the review eligibility criteria; the characteristics of the included trials are in
Table 20, the risk-of-bias assessments are in Table 21, the process of selection is presented in Appendix 4,
Figure 51, and a flow diagram showing the flow of literature can be found in Appendix 5, Figure 52. A list
of excluded RCTs is in Table 45 in Appendix 4.
Risk of bias
We identified eight separate interventions:
1. antifungal treatment
2. elastic compression stockings
3. digital silicone device
4. education alone
5. podiatric care
6. digital thermometry
7. complex interventions
8. custom-made footwear and offloading.
Antifungal treatment
One trial evaluating the effect of antifungal treatment was identified by our searches.102 Thirty-four
participants in the intervention group received self-management advice (daily foot inspection) and
antifungal nail lacquer (8% ciclopirax) for daily application, while 36 participants in the control group
received only advice about foot self-inspection. Almost all patients (97%) were male; patients’ mean age
was 70 years, and 57% had experienced previous foot ulcers. Their mean duration of diabetes mellitus
was 12 years, but it was not reported how many had type 2 diabetes mellitus (T2DM). Standard care
was reported to be a preventative care programme and telephone support, but the exact arrangements
for this were unclear. At 12-month follow-up, there were two ulcerations in each group (RR 1.06,
95% CI 0.19 to 5.76). The concealment of the allocation and the blinding of the outcome assessor
were unclear and the trial was rated as being at risk of selection and performance bias. No secondary
outcomes were reported.
Elastic compression stockings
In one RCT evaluating the effect of elastic compression stockings,93 160 participants were randomised
in equal numbers to the intervention or the control group for 48 months. Half of the trial participants
were male; patients’ mean age was 53 years and none had a history of foot ulcers. Their mean duration
of diabetes mellitus was 15 years, but the number with T2DM was not reported. The intervention
group received knee-length elastic stockings with compression at the ankle of 25 mmHg, worn for at
least 6 hours per day. There was a difference in the number of limbs that ulcerated in each group
(three in the intervention group and 10 in the control group), but this did not reach statistical
significance (RR 0.37, 95% CI 0.11 to 1.02). It was unclear how the random allocation was generated,
and the nature of the intervention meant that it was not possible to blind patients to the allocation. The
outcome assessment was not conducted by an investigator blinded to the random allocation, and the trial
was judged to be at risk of selection bias and performance bias.
Secondary outcomes: elastic compression stockings
Thirteen amputations were reported during the 48-month trial: 3 out of 74 in the intervention arm and
10 out of 75 in the control arm.
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TABLE 20 Characteristics of included RCTs
First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Antifungal nail lacquer
Armstrong 2005102 n = 70 (intervention group,
n = 34; control group, n= 36)
Male: 97%
Mean age: 70 years
Previous ulcer: 57%
T2DM: NR
Mean diabetes duration: 12 years
Ulcer risk: high (IWGDF risk
group 2/3)
Intervention: antifungal treatment
(ciclopirox 8%) and self-management
(daily inspection)
Control: self-management (daily inspection)
A staff podiatrist examined each patient
recruited
A clinician-to-staff 24-hour/day foot hotline
with staff familiar with the care and status
of these patients. But it was unclear who
provided training regarding the intervention
Preventative care programme and
telephone support
Ulcers (number of patients),
one or more unexpected visits,
missed appointments, tinea/HK
at the start and end of the
study
All in (%)
12 months
Elastic compression stockings
Belcaro 199293 n = 160 (intervention group,
n = 80; control group, n= 80)
Male: 50%
Mean age: 53 years
Previous ulcers: none
T2DM: NR
Mean diabetes duration: 15 years
Ulcer risk: microangiopathy
measured with laser Doppler,
VPT also measured
Intervention: knee elastic stockings with
compression at the ankle of 25 mmHg
worn at least 6 hours per day while active
and/or working
Control: no stockings (no other information)
Not reported Number of ulcers (%), number
of limbs (n)
Deterioration of
microcirculation
RF (mean and SD)
VAR (median and range)
48 months
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First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Digital silicone device
Scirè 200997 n = 167 (intervention group,
n = 89; control group, n= 78)
Male: NR
Mean age: 56.5 years
Previous ulcers: unclear
T2DM: 88%
Mean diabetes duration: 16 years
Ulcer risk: high (VPT ≥ 25 V)
Intervention: partial digital silicone orthoses
(Podikon®, Saccolongo, Italy) and regular
care at the diabetic foot clinic
Control: no orthoses but regular care at the
diabetic foot clinic
Callus management.
Soft insole and extra-deep shoe
Ulcers (%)
Hyperkeratosis [plantar, dorsal,
interdigital (%)]
Skin hardness (%)
Stable deformities (%)
Podobarometric evaluationa
(pre and post evaluation,
mean and SD)
3 months
Education alone
Monami 201578 n = 121 (intervention group,
n = 61; control group, n= 60)
Male: 60%
Mean age: 71 years
Previous ulcers: 11%
T2DM: 100%
Mean diabetes duration: 15 years
Ulcer risk: high
Participants defined as ‘high risk’
if neuropathy diagnosed, previous
DFUs or foot abnormalities
Intervention: brief educational programme
(2-hour programme provided to groups
of 5–7 patients, 30-minute face-to-face
lesson on risk factors for foot ulcers and
90-minute interactive session with practical
exercises on behaviours to reduce risk)
Control: brief leaflet and standard care
Physician (for 15 minutes) and a nurse
(for the remaining 105 minutes)
provided this
All patients had previously received
standard multidisciplinary education
for diabetes (with a structured group
programme at diagnosis or first contact,
and follow-up meetings every 2 years)
Ulcers at 6 months, amputation,
mortality, knowledge score
(all absolulte numbers)
Time spent for intervention and
ulcer care in control (minutes
per patient)
6 months
continued
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TABLE 20 Characteristics of included RCTs (continued )
First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Gershater 201179 n = 131 (intervention group,
n = 61; control group, n= 70)
Male: 73%
Mean age: 64 years
Previous ulcers: 100%
T2DM: 67%
Mean diabetes duration: NR
Ulcer risk: high (IWGDF)
Intervention: group-session discussions
Foot care education (60 minutes) from a
registered nurse in the diabetes department
including oral and written instructions
based on International Consensus on the
Diabetic Foot118 plus standard care.
Provided by diabetes specialist nurse
Control: standard information, oral and
written instructions, on self-care based
on the International Consensus on the
Diabetic Foot118
Routine care from staff
Adjusted shoes for indoor and outdoor
use and individually fitted insoles
New ulcers
Cause of ulcers (stress, trauma,
other)
Location of ulcer (big toe or
other, plantar, other including
heel)
All in (n) (%)
6 months
Lincoln 200880 n = 172 (intervention group,
n = 87; control group, n= 85)
Male: 67%
Mean age: NR
Previous ulcers: 100%
T2DM: 77%
Mean diabetes duration: NR
Ulcer risk: high (10-g
monofilament, Neurotip™ (Owen
Mumford Ltd, Woodstock, UK),
VPT ≥ 25 V)
Intervention: structured foot care education
session. Provided by general practitioner,
specialist clinic or both – according to
individual circumstances
Control: standard care and the same foot
care leaflets as the intervention group
Regular podiatry and suitable orthoses
when appropriate. Overall medical care
followed national UK guidelines
Incidence of ulcer (n)
Incidence of amputation (n)
QoL (DFS-SF)
Mood (HADS), HAD-A, HAD-D
Protective foot care behaviours
(NAFF)
6 and 12 months
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First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Podiatric care
Plank 200394 n = 91 (intervention group,
n = 47; control group, n= 44)
Male: 56%
Mean age: 65 years
Previous ulcers: 100%
T2DM: 93%
Mean diabetes duration: 16 years
Ulcer risk: high (reduced
sensation assessed by 128-Hz
tuning fork, 5.07-g monofilament)
Intervention: chiropodist care and
standard care
Control: standard care and chiropodist care
only if patient was interested
Instructed on the possible benefits of
regular chiropody care
Ulcers: intention to treat, per
protocol (feet, patients)
Death and amputation (n)
Aggregated end points for all
above (HR, CI, p-value)
12 months
Complex interventions
Cisneros 201090 n = 53 (intervention group,
n = 30; control group, n= 23)
Male: 62%
Mean age: 62 years
Previous ulcers: 28%
T2DM: 96%
Mean diabetes duration:
14.5 years
Ulcer risk: IWGDF risk group
(intervention/control) 1 (6/10),
2 (15/7), 3 (3/3) or 4 (6/3)
Intervention: complex
Four 90-minute sessions of therapeutic
education in groups of eight, two pairs of
protective shoes, testing for neuropathy
Provided by researcher
Control: participants received information
on regular foot care and footwear use
according to spontaneous demand during
the individual consultations with the
researcher
Routine care from staff
Instructions on foot care when requested
Testing for neuropathy
Occurrence (n)
Recurrence (n)
Time until foot ulceration
(survival time)
24 months
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TABLE 20 Characteristics of included RCTs (continued )
First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
LeMaster 2008119 n = 79 (intervention group,
n = 41; control group, n= 38)
Male: 51%
Mean age: 66 years
Previous ulcers: 42%
T2DM: 94%
Mean diabetes duration: 11 years
Ulcer risk: moderate or high
Intervention: complex
Part 1 (1–3 months), physical therapist-led
exercises to strengthen lower extremity
muscles and promote balance over eight
sessions. Part 2 (4–12 months) increased
moderately intense activity by 50% over
12 months among community-dwelling.
Provided by physical therapist and
study nurse
Control: standard care
Foot-related self-care skills education,
daily foot examination. Usual medical care
from participants’ own health-care
providers
Participants referred to local orthotists or
podiatrists to obtain therapeutic footwear
at enrolment
Foot ulcer rates (lesions/lesion
episodes, full-thickness ulcer/
ulcer episode, weight-bearing
full-thickness plantar ulcer/
ulcer episode)
Step activity – person-year at
risk (all means and 95% CIs)
12 months
Liang 201291 n = 62 (intervention group,
n = 31; control group, n= 31)
Male: 56%
Mean age: 56 years
Previous ulcers: 0%
T2DM: 87%
Mean diabetes duration: 11 years
Ulcer risk: ADA risk
category 1/2/3
High risk: 100%
Intervention: session, foot care kit
(foot care cream, 10-g monofilament, a
thermometer for the temperature of the
water for washing feet, alcohol cotton
pieces and a mirror)
Daily foot care, diabetes education classes.
Provided by diabetes nurse-led
multidisciplinary team – three
endocrinologists, four nurses and one
dietitian
Control: standard care
Conventional care alone according to ADA
standards; medication adjustment, foot
assessment, and 2 hours of education
about diabetes foot care
Incidence of foot ulcer (n, %)
Incidence of amputation (n, %)
HbA1c level (mmol, %)
Diabetes knowledge
Foot care behaviour (baseline,
1 year, 2 years; all means
and SDs)
24 months
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First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Litzelman 199392 n = 396 (intervention group,
n = 191; control group, n = 205)
Male: 19%
Mean age: 60 years
Previous ulcers: NR
T2DM: 100%
Mean diabetes duration: 10 years
Ulcer risk: NR
Intervention: patient education sessions,
self-foot care, reinforced through telephone
follow-up (2 weeks) and postcard reminder
(1 month and 3 months)
Informational flow sheets on foot-related
risk factors for amputation in diabetic
patients
Prompts for health-care providers to:
1. ask that patients remove their footwear
2. perform foot examinations
3. provide foot care education
Provided by nurse clinicians
Control: care as usual plus standard care
1 year after the initial assessment, all
patients underwent a repeated history
and physical examination, performed by
nurse clinicians blind to patients’
randomised allocation
Patient outcomes: patient
behaviour (5-point scale)
Behaviour of health-care
provider
Physical findings (ulcers,
physical examination, dry/
cracked skin, corns, calluses,
ingrown nail, fungal infections,
improperly trimmed nails, foot/
leg cellulitis, leg deformity,
sensory examination)
12 months
McCabe 199884 n = 1997 (intervention group,
n = 997; control group, n = 1000)
Male: 53%
Mean age: 60 years
Previous ulcers: unclear
T2DM: 80%
Mean diabetes duration: NR
Ulcer risk: low, moderate, high
ABI ≤ 0.75, history of foot
ulcers = high risk
Intervention: primary foot screening
examination, the biothesiometer and
palpation of pedal pulses
Foot pressures, subcutaneous oxygen levels,
ABIs and radiography, and weekly diabetic
foot clinic for high-risk patients. Provided
by general diabetic outpatient clinic
Control: patients were silently tagged and
continued to attend the general outpatient
clinic but received no special care
Patients were advised to inspect and
wash their feet daily, to avoid wearing
constricting clothing and footwear, to
wear prescribed footwear at all times and
to contact the clinic whenever they felt it
to be necessary
Patient outcomes [ulcer
(number of patients), ulcer
progressing to amputation (%),
amputation (%)], process
outcomes [screening cost (£),
compliance with follow-up/
treatment (%)]
24 months
continued
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TABLE 20 Characteristics of included RCTs (continued )
First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Digital infrared thermometry
Armstrong 200789 n = 70 (intervention group, n = 34,
control group, n= 36)
Male: 97%
Mean age: 70 years
Previous ulcer: 57%
T2DM: NR
Mean diabetes duration: 13 years
Ulcer risk: high (IWGDF risk
group 2/3)
Intervention: infrared dermal thermometry
and a complex intervention. Attending
physicians provided this
Control: a complex intervention only
Therapeutic footwear, diabetic foot
education, regular foot care
Footwear, education and professional
foot care
Ulcers (n, %)
Rate of ulcer (HR)
Temperature difference at ulcer
site (survival curve)
18 months
Lavery 200487 n = 85 (intervention group,
n = 41; control group, n= 44)
Male: 49%
Mean age: 55 years
Previous ulcers: 41%
T2DM: NR
Mean diabetes duration: 14 years
Ulcer risk: IWGDF risk group 2/3
Intervention: infrared skin thermometer and
a complex intervention provided by treating
physician – evaluation, nurse case manager –
contact and podiatrist follow-up
Control: a complex intervention – foot
evaluation by a podiatrist every
10–12 weeks, therapeutic footwear,
diabetic foot education
Footwear, education and professional
foot care
Foot complication: ulcers,
Charcot foot, infection and
amputation (n)
QoL [pre and post physical
functioning, role physical, bodily
pain, general health, vitality,
social functioning, role
emotional, mental health
(SF-36 scores)]
6 months
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First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Lavery 200788 n = 173 (intervention group,
n = 59; intervention group 2,
n = 56, control group, n = 58)
Male: 54%
Mean age: 65 years
Previous ulcers: 100%
T2DM: 95%
Mean diabetes duration: 13 years
Ulcer risk: high (10-g
monofilament, VPT ≥ 25 V,
palpation of pulses, Doppler,
ABI ≥ 0.07)
Digital infrared skin thermometer and a
complex intervention. Study nurse for
contact, treating physician for foot
evaluations, podiatrist for assessing
shoes/insoles
Intervention 1: enhanced care
Intervention 2: structured care
Control: standard care
Lower extremity evaluation, education
programme, therapeutic insoles and
footwear. All participants received a
pedometer to record their daily activity in
a log book. Patients told to inspect their
feet daily and to contact a nurse if
need be
Foot ulcers
Foot trauma
Fracture
Death
Osteomyelitis but no ulcer
(all in n %)
Time to ulcerate (mean and SD)
15 months
Skafjeld 2015120 n = 41 (intervention group,
n = 21; control group, n= 20)
Male: 56%
Mean age: 58 years
Previous ulcers: 100%
T2DM: 71%
Mean diabetes duration: 18 years
Ulcer risk: IWGDF risk group 3
Intervention: foot skin temperature
monitoring, theory-based counselling,
contact study nurse if increase in
temperature for more than 2 days.
Study nurse provided this
Control: standard care
Foot care, daily recording of observations,
customised footwear
Incidence of foot ulcer
Increased skin temperature
Use of customised footwear
> 12 hours/day
Patients contacted study nurse
(worried, ulcer, foot ulcer)
(all n %)
12 months
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TABLE 20 Characteristics of included RCTs (continued )
First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Custom-made footwear and offloading
Bus 201399 n = 171 (intervention group,
n = 85; control group, n= 86)
Male: 82.5%
Mean age: 62 years
Previous ulcers: 100%
T2DM: 71%
Mean diabetes duration: 17 years
Ulcer risk: high (assessed with
10-g monofilament and vibration
perception plus dorsalis pedis tests)
Intervention: custom-made footwear of
which the offloading properties were
improved and subsequently preserved
based on in-shoe plantar pressure
measurement and analysis. Local
specialist provided the footwear and
local orthopaedic shoe technician
manufactured the footwear
Control: custom-made footwear that was
not improved based on in-shoe pressure
measurement (i.e. usual care)
Each patient received written and verbal
instructions on foot care and on proper
use of footwear. All footwear in both
study groups was evaluated at delivery
and at 3-month follow-up visits (pressure
measurements, temperature monitor and
activity monitor)
Ulcer recurrence (patients with
ulcer, previous ulcer location,
complicated foot ulcers)
Ulcer recurrence according to
adherence, non-ulcerative
lesions (all in n %)
In-shoe peak pressure,
daily step count, adherence
(mean and SD)
18 months
Reiber 200286 n = 400 (intervention group 1,
n = 121; intervention group 2,
n = 119; control group, n = 160
Male: 77%
Mean age: 62 years
Previous foot ulcers or infection
requiring antibiotics: 100%
T2DM: 93%
Mean diabetes duration:
l < 6 years: 33%
l 6–24 years: 11%
l ≥ 25 years: 56%
Ulcer risk: high (assessed by 10-g
monofilament and presence of
foot deformity)
Therapeutic shoes with two types of inserts
and standard care. Study pedorthist
provided this and panel of three foot care
specialists evaluated
Intervention 1: three pairs of therapeutic
shoes and customised medium-density cork
inserts with a neoprene closed cell cover
Intervention 2: three pairs of therapeutic
shoes and prefabricated, tapered polyurethane
inserts with a brushed nylon cover
Control: usual footwear and standard care
Participants continued to receive regular
health care and foot care from the VA or
GHC. No participants received such
education or care at the study site. A
lightweight terry-cloth house slipper (Tru
Stitch Footwear Inc., Malone, NY, USA)
with no internal seam and textured sole
was designed for all participants to use to
minimise differences in out-of-shoe
exposure
Lesions and ulcers (ulcers, non-
ulcerative, total, person-years
of follow-up)
Incidence per person (number
of persons ≥ 1 ulcer, cumulative
incidence per person, risk ratio)
Incidence per person-year
(ulcer and ulcer episode –
total number, incidence rate,
risk ratio)
Pivotal events for ulcer
episodes (shoe and non-shoe
related). All in (n and 95% CI)
24 months
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First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Rizzo 201296 n = 298 (intervention group,
n = 148; control group, n = 150)
Male: NR
Mean age: 67 years
Previous ulcers: 20%
T2DM: 84%
Mean diabetes duration: 18 years
Ulcer risk: high (IWGDF risk
group ≥ 2)
Intervention: orthoses and shoes, in-depth
education, daily feet checks, referral to
clinic for urgent consultations and standard
care. Screened by experienced podologist,
evaluation of foot and current DFU risk:
team of diabetologist, podologist and
orthopaedic technician provided this
Control: standard care
Received an in-depth education on how to
prevent ulceration, advice regarding
footwear
Urgent consultation within 24 hours if
ulcers developed
Foot ulcer (number of patients)
New foot ulcers (n)
Cumulative incidence of ulcers
and recurrences (3 years,
5 years – χ2, % and p-value)
DFUs due to trauma or
hyperpressure (n %)
VPT (mean and SD) and cost
evaluation (euros)
12 months
Lavery 201295 n = 299 (intervention group,
n = 149; control group, n = 150)
Male: 67%
Mean age: 70.5 years
Previous ulcers: 26.95%
T2DM: NR
Mean diabetes duration:
12.5 years
Ulcer risk: high (IWGDF risk
group 2/3)
Intervention: a shear-reducing insole and a
complex intervention. Provided by study
nurse for concerns and patient evaluation
by a physician
Control: standard care
Foot and lower extremity evaluation
by a physician every 10–12 weeks, an
education programme that focused on
foot complications, self-care practices
Therapeutic shoes and standard insoles.
Education, contact with study nurse if
concerned
Ulcers
Footwear compliance (4, 4–8,
8–12, 12–16 hours/day)
Time to ulcer (Cox proportional
hazards regression) (all n %)
18 months
continued
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TABLE 20 Characteristics of included RCTs (continued )
First author and
year of publication, Population characteristics
Details of experimental interventions and
control interventions Standard care
Outcome (unit of analysis)
and length of follow-up
Uccioli 199585 n = 69 (intervention group,
n = 33; control group, n= 36)
Male: 62%
Mean age: 60 years
Previous ulcers: 100%
T2DM: 75%
Mean diabetes duration: 17 years
Ulcer risk: high (mean VPT
≥ 25 V)
Intervention: therapeutic shoes with custom
insoles specially designed for diabetic
patients (Podiabetes by Burrato, Italy)
Control: participants were free to wear
ordinary shoes/their own non-therapeutic
shoes unless these were clearly dangerous
All patients received the same educational
guidelines on foot care and general
information on the importance of
appropriate footwear (i.e. proper size,
durability and sole)
Ulcer relapses (n %)
Cumulative incidence of relapse
(multiple regression analysis)
Ulcer relapse between groups
(χ2, % and p-value)
Ulcer-free time, peripheral
neuropathy – VPT, peripheral
vascular disease – ABI (mean
and SD)
Use of therapeutic shoes (scale)
12 months
Ulbrecht 201498 n = 150 (intervention group
n = 79; control group, n= 71)
Male: 68%
Mean age: 59.5 years
Previous ulcers: 100%
T2DM: NR
Mean diabetes duration: NR
Ulcer risk: high (inability to feel a
10-g monofilament, high plantar
pressure, ABI)
Intervention: bespoke orthoses with
offloading properties. Study co-ordinator
(clinicians) provided this
Control: three different manufacturers’
orthoses along with three pairs of identical
orthoses to be rotated while using the
primary study footwear in accordance with
a written rotation protocol, changing the
numbered orthoses in a set rotation every
month. Participants were also offered one
of two types of footwear models
Self-care behaviours with all participants
with a focus on wearing the study shoes
for all steps taken and on examining the
feet daily to note and report problems
An educational brochure to
reinforce advice
Primary end point occurrence,
ulcers, (n %); peak barefoot
plantar pressure vs. lesion
(ulcer, non-ulcerative, no lesion)
(kPa)
Questionnaires for QoL (scaled
to 100), foot self-care (0–1),
fear of falling (scale to 100),
subject satisfaction (five-level
Likert scale)
16.5 months (follow-up at
+ 1 week, + 3 weeks, + 6 weeks,
then every 3 months for
another 15 months, potential
16.5 months)
ADA, American Diabetes Association; DFS-SF, Diabetic Foot Scale-Short Form; GHC, Group Health Cooperative; HADS, Hospital Anxiety and Depression Scale; HAD-A, Hospital
Anxiety and Depression Scale-Anxiety; HAD-D, Hospital Anxiety and Depression Scale-Depression; HK, hyperkeratosis; NAFF, Nottingham Assessment of Functional Footcare;
NR, not reported; RF, supine resting flux; SD, standard deviation; VA, Veterans Administration; VAR, venoarteriolar response.
a Includes total surface of the foot (cm2), average weight-bearing pressure (kPa), weight distribution compared with the total (%), weight distribution compared with the rear foot (%),
static maximum peak pressure (kPa), dynamic maximum peak pressure (kPa).
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Digital silicone device
One RCT evaluated the effect of digital silicone devices.97 One hundred and sixty-seven participants
with forefoot deformities who were considered to be at high risk of ulceration, as defined by a VPT
of ≥ 25 V, were recruited into the trial. Their mean age was 56.5 years but gender was not reported.
Eighty-eight per cent had T2DM and their mean duration of diabetes mellitus was 16 years. Participants
in the intervention arm (n = 89) received a bespoke silicone digital orthotic with a variety of therapeutic
intents and densities depending on the characteristics of the deformity. The patients in the intervention
group received instructions about maintaining the orthotic and were advised to wear it until the end of
the follow-up period. The 78 people in the control arm received standard therapy, which comprised the
same examinations and procedures as the intervention group, but silicone orthotics were not provided.
Both groups also received an accommodating soft insole and an extra-deep shoe. Outcomes collected
at 3 months showed a statistically significant difference in the numbers of foot ulcers, with the digital
orthotic group experiencing a beneficial effect (RR 0.07, 95% CI 0.01 to 0.55). Concealment of the
allocation was not possible because of the nature of the intervention, and the trial was at risk of
selection bias. No secondary outcomes were reported.
TABLE 21 Risk of bias in included RCTs studies
Trial (first author and
year of publication)
Type of potential bias
Adequate sequence
generation
Adequate allocation
concealment
Adequate outcome
assessor blinding
Incomplete
outcome data
Armstrong 2005102 + ? ? +
Armstrong 200789 + + + ?
Belcaro 199293 ? – – +
Bus 201399 + + + +
Cisneros 201090 ? ? + ?
Gershater 201179 + + – +
Lavery 200487 ? ? + +
Lavery 200788 + + + +
Lavery 201295 ? ? + +
LeMaster 2008119 + + + +
Liang 201291 ? ? ? ?
Lincoln 200880 + + + +
Litzelman 199392 ? ? + +
McCabe 199884 ? ? ? +
Monami 201578 + + – –
Plank 200394 + + ? +
Reiber 200286 + ? + +
Rizzo 201296 + ? – +
Scirè 200997 + ? + +
Skafjeld 2015120 + ? + +
Uccioli 199585 ? ? ? +
Ulbrecht 201498 + + + +
+, present; –, absent; ?, uncertain.
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Podiatric care
Plank et al.94 compared free chiropody care (n = 47) with no recommendation for chiropody care (n = 44)
for 12 months. Fifty-six per cent of the 91 participants were male and their mean age was 65 years.
All participants had a history of foot ulceration and were at high risk of another ulcer. Their mean
duration of diabetes mellitus was 16 years, and 93% had T2DM. Those receiving free chiropody were
recommended to seek care at least once per month. No recommendation was given to patients in
the control group, but they could seek chiropody care if they were willing to pay for it. Standard
care consisted of instructions on the possible benefits of regular chiropody care. It was unclear if
both groups received standard care. There was no statistically significant difference in effect of
number of foot ulcers (RR 0.67, 95% CI 0.43 to 1.05). In addition, there were fewer ulcerations in
the intervention group (n =18) than in the control group (n = 25) but there were more amputations in
the intervention group than in the control group (two vs. one, respectively). Fewer people died in the
intervention group (n = 2) than in the control group (n = 4). It was not reported whether or not the
outcome was assessed by an investigator who was blind to the allocation and, therefore, the trial data
are at risk of performance bias.
Secondary outcomes: podiatric care
Two amputations occurred among 47 participants in the intervention arm and one amputation
occurred among 44 participants in the control arm. Two people in the intervention arm died and four
people in the control arm died.33
Data on other secondary outcomes of interest, such as gangrene, self-care, hospital admissions, timing
of screening and adverse events or harms, were absent from the trial reports.
Education alone
Three RCTs78–80 evaluated education alone.
One hundred and twenty-one people were followed up for 6 months.78 Most of the individuals were
male (60%); participants’ mean age was 71 years, and almost 11% had a history of foot ulceration. All
had T2DM and their mean duration of diabetes mellitus was 15 years. The 60 people in the intervention
group received a 2-hour group education programme (in groups of 5–7 patients). This comprised
30-minute face-to-face lessons on risk factors for foot ulcers, instructions on how to check their feet
regularly, and information on ulcers and other foot conditions. In an additional 90-minute interactive
session, health-care professionals demonstrated practical actions that would reduce the risk of foot
ulcers. The 60 people in the control arm received a leaflet with recommendations for preventing foot
ulcers. People in both arms received a standard multidisciplinary general education about diabetes
mellitus at diagnosis, but they did not receive foot-specific education. At the 6-month follow-up, no
statistically significant beneficial effect was observed in the intervention group (RR 0.08, 95% CI 0.00 to
1.31). The trial quality was compromised by a lack of concealment of the random allocation schedule,
lack of collection of outcomes by an independent investigator and incomplete outcome data.
The RCT by Gershater79 comprised 131 people who had previously received treatment for a foot ulcer
in a diabetes specialist foot clinic. They were recruited after the ulcers had healed and most of them
were men (73%); their mean age was 64 years. The majority had T2DM, but the overall mean duration
of diabetes mellitus was not reported. Those in the intervention group (n = 61) received foot care
education led by a diabetes specialist nurse, designed to improve participants’ confidence in managing
their foot health. This consisted of one 60-minute group session with 2–5 participants of the same
gender in each group. The group discussions took place in the diabetes foot clinic conference room and
were facilitated by a diabetes specialist nurse. Participants could choose to adopt a set of predefined
actions/goals.
The 70 people in the control arm received standard, oral and written instructions on self-care based
on the International Consensus on the Diabetic Foot.118 Both arms received standard care, which
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comprised adjusted shoes and individually fitted insoles, and the recommendation for regular
chiropody. All participants also received standard oral and written instructions on self-care provided by
a diabetes specialist nurse. The trial quality was compromised by a lack of concealment of the random
allocation schedule (selection bias) and lack of the collection of outcomes by an independent
investigator (performance bias).
Lincoln et al.80 randomised 172 people (two-thirds of whom were male) who had previously had ulcers
to an intervention or a control group. Eighty-seven people in the intervention arm received a single
1-hour structured foot care education session from a researcher at home. The session included an
explanation of the main causes of foot ulcers and a foot examination to identify risk factors (deformity,
ischaemia or neuropathy), and advice was reinforced with written information. Shoes and insoles were
examined for suitability and participants were advised to contact the clinic immediately if any new
or recurrent foot problem emerged. The control group (n = 85) received standard care, consisting of
unstructured and opportunistic foot care and the same written information as given to the intervention
group. Standard care included podiatry and suitable orthoses when appropriate. At the 12-month
follow-up, there was no statistically significant difference in the number of patients with foot ulceration
between the two groups (RR 1.00, 95% CI 0.70 to 1.44). All quality assessment items were judged to be
at a low risk of bias.
Education alone: meta-analysis
A pooled estimate of the effect of education on the incidence of foot ulceration at 6 months found that
foot ulceration was not statistically significantly reduced in three trials of 423 people with diabetes
mellitus (RR 1.04, 95% CI 0.55 to 1.97) (Figure 12).78–80 The heterogeneity (I2) was 54%.
Secondary outcomes: education alone
Two trials of education interventions reported data on amputation,78,80 mortality,78 knowledge,78
behaviour80 and/or QoL.80 One trial78 reported no amputations in either of its arms after 6 months’
follow-up. The other trial80 reported three amputations among 85 participants in the intervention arm,
compared with no amputations among the 85 participants in the control arm at 6 months; by 12 months
there was no difference between the arms (nine amputations in both).
One trial78 reported that two participants, one in each arm, had died by 6 months. In the same trial,
a statistically significant difference in knowledge (as measured with the Patient Interpretation of
Neuropathy knowledge score) was observed in the intervention arm.78
One trial80 reported on QoL and found no differences between the two arms on the Diabetic Foot
Scale, but scores on the Nottingham Assessment of Functional Footcare questionnaire, which assesses
behaviour, were higher in the education arm than in the control arm.
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FIGURE 12 Meta-analysis: education alone.
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Digital thermometry
Four RCTs87–89,120 involving 468 patients were identified by our searches.
Armstrong et al.89 followed up 225 people (approximately 69 years of age) for 18 months. Their mean
duration of diabetes mellitus was 13 years, but the authors did not report how many had T2DM.
The number of participants randomised to the intervention group or the control group is not known.
The intervention was an infrared skin thermometer to measure temperatures on six sites on the foot
twice per day. Patients were told that, if they recorded a temperature difference of > 4 °F between
feet at the same site, they should contact the study co-ordinator and reduce activity until their
temperature normalised. Patients also received standard care consisting of footwear, education
and professional foot care. The control group also received standard care and were advised to
contact the study co-ordinator if they had any foot abnormalities. Participants’ feet were also
checked for any signs of irritation from shoes or signs of impending ulcer. The number of ulcers
in the intervention and control groups was reported to be 5 and 14, respectively, but the absence
of the denominators for each group prevents the calculation of an effect. The quality of the trial is
compromised because there was no allocation concealment, and because of the incompleteness of
data reporting (selection and attrition bias).
A second RCT (i.e Lavery et al.87) recruited 85 people (49% were male) with a mean age of 55 years.
The mean duration of diabetes mellitus was 14 years, but it was not reported how many had T2DM.
The participants were randomised to digital thermometry or standard care and followed up for 6 months.
Forty-one participants received a hand-held infrared skin thermometer to measure the temperature
at six predetermined sites on the sole of each foot in the morning and the evening. They received
additional standard footwear, education and professional foot care, and were advised to contact a
nurse case manager and to significantly reduce walking if they recorded a temperature difference
of > 4 °F between feet at the same site. The control group received standard care footwear, education
and professional foot care. No statistically significant difference was observed between the two groups
(RR 0.15, 95% CI 0.02 to 1.19). There was a risk of bias from the generation and concealment of allocation
being unclearly reported and there were incomplete outcome data. The method of generating the random
sequence and the concealment of the allocation were both unclear and the trial data were at risk of
selection bias.
The same authors (i.e. Lavery et al.88) conducted a three-arm trial over 15 months. Of the 173
participants, 54% were male; participants’ mean age was 65 years and all had a history of foot
ulceration. Approximately 95% of participants had T2DM, and their mean duration of diabetes mellitus
was 13 years. The 59 participants in the first intervention arm received standard care plus a digital
infrared skin thermometer and were asked to measure the temperature on the sole of their foot in
the morning and the evening and record this information in a logbook. The participants were advised
to contact a nurse manager if the difference in temperature between feet was > 4 °F and to reduce
their activity until their temperature normalised. A video was used to teach participants how to use
the infrared thermometer. In the second intervention arm, 56 participants received standard therapy plus
training to conduct a structured foot examination twice daily using a mirror (to identify redness, swelling,
inflammation, etc.). These participants could also could contact a nurse if they detected any abnormalities.
The 58 participants in the control received standard care (including lower extremity evaluation by a
physician every 8 weeks, an education programme focused on foot complications and inspection, and
therapeutic insoles and footwear). A podiatrist replaced or repaired insoles or footwear if needed.
There was also an education component provided by video, and the participants were told to inspect
their feet daily and to contact a nurse if necessary. There was statistically a significant difference
between the digital thermometry group and the standard care group (RR 0.29, 95% CI 0.11 to 0.73).
This trial was at a low risk of bias in all four quality assessment items.
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Skafjeld et al.120 followed up 41 participants (56% male; mean age of 58 years) for 12 months. All
participants had previously had ulcers (71% had T2DM), and their mean duration of diabetes mellitus
was 18 years. The 21 people randomised to the intervention group received a hand-held device with
an infrared heat sensor to monitor their foot temperature. Participants recorded their daily physical
activity using a step counter during the first week of the study, and throughout the study their recorded
temperature at the same six places on the sole of each foot. Patients were advised that if the recorded
skin temperature at the same spot differed by > 4 °F between their feet on 2 consecutive days they
should contact the study nurse and reduce their physical activity until their temperature normalised.
The control group of 20 participants received standard care, which involved inspecting their feet under
the toes, below the toes and between the toes. Participants could contact the study nurse if they noticed
changes in their feet, including a new ulcer. They were advised to always wear their customised footwear
and consult their general practitioner if necessary. No statistically significant difference was observed in
the number of ulcers between the intervention group and the control group (RR 0.67, 95% CI 0.32 to
1.41). Whether or not the allocation was concealed was not clear; in addition, the outcome data were
incomplete and the trial data were at risk of selection and performance bias.
Digital thermometry: meta-analysis
A pooled analysis of data from three RCTs87,88,120 found that the use of digital infrared skin thermometry
reduced the number of foot ulcers among 243 people with a history of foot ulceration (RR 0.41, 95% CI
0.19 to 0.86) (Figure 13). An I2 of 33% was observed.
Secondary outcomes: digital thermometry
Trials of dermal thermometry variously reported on amputation following infection,89 QoL (assessed
using the SF-36),37 adherence to therapy87,88 and time to ulceration.39,40
In one trial, amputations following infections were required in 0 out of 41 participants in the intervention
group and in 2 out of 44 in the comparator group.38 In the same trial, there was no statistically significant
difference in QoL measured using SF-36 in any category or in the overall score.87
Two trials88,120 found no statistically significant difference between the dermal thermometry group and
the comparator group in the time for which prescribed footwear and insoles were worn, as measured
using a self-report questionnaire with an ordinal scale of < 4 hours to > 12 hours per day. The time to
ulceration was statistically significantly longer in the dermal thermometry treatment group than in the
standard care group in one trial88 but not in another.120
Complex interventions
Five RCTs evaluated the effects of complex interventions on the development of foot ulcer.84,90–92,119
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Cisneros90 recruited 53 participants (62% were male) with a mean age of 62 years, of whom 28% had
previously had ulcers and 96% had T2DM. They had a mean duration of diabetes mellitus of 14.5 years.
The 24-month intervention (n = 30) was a researcher-led preventative programme comprising
therapeutic education (weekly group meetings) and the provision of two pairs of special protective
shoes. The education component was delivered over four meetings, each lasting 90 minutes, in groups
of up to eight participants; this addressed, with discussion, issues around the prevention of foot ulcers,
inspection and foot hygiene, and the choice and use of footwear. Bespoke games were used as teaching
aids to prompt individual reflection about lifestyle and diabetes mellitus, and there was a discussion
at the end of each meeting between health professionals and individual patients. The pedagogical
technique was based on communications and learning. Footwear was provided after completion of
the educational programme, at the beginning of the study and after the fourth re-evaluation.
The control group (n = 23) received information on regular foot care and footwear use in response to
demand during the individual consultations with the researcher. Both groups received standard care
monitoring of their feet to survey the incidence and recurrence of neuropathic injury. Monofilament
testing was performed using the monofilament Semmes–Weinstein 5.07 (10 g) to identify risk at three
sites on the foot the (digital pulp of the hallux and the first and fifth metatarsal heads). All items in
the quality assessment were unclear and the trial was possibly at risk from selection, performance,
attrition and selective reporting bias.
A second RCT119 followed 79 participants (51% were male) with a mean age of 66 years for 12 months.
It was reported that 42% of participants had previously had ulcers. The majority (94%) had T2DM, and
their mean duration of diabetes mellitus was 11 years. Forty-one patients in the intervention received
care in two parts. For the first 3 months, they worked with a physical therapist in exercise sessions to
strengthen their lower extremity muscles and promote balance. In the second part, over 4–12 months,
they increased their exercise activity by 50%. In addition, they received training in self-care and foot
examination skills. The 38 participants in the control group were taught foot-related self-care skills,
including daily foot examination, and could access their usual medical care from their own health-care
providers. Every participant was referred to a local orthotist or podiatrist at enrolment and received
therapeutic footwear to wear when weight bearing inside and outside the home. There was no
statistically significant difference in the number of foot ulcers between the two groups (RR 0.19,
95% CI 0.02 to 1.52). All quality assessment items were rated as being at a low risk of bias.
A third RCT91 evaluating a complex intervention comprised 62 participants (56% were male) with
a mean age of 56 years. Twenty-five per cent of participants had previously experienced an ulcer,
and 87% were classified as having T2DM. On average, they had had diabetes mellitus for 11 years.
Thirty-one participants in the intervention group received a foot care kit that contained nail clippers,
foot care cream, a monofilament with 10-g pressure, a thermometer to measure the temperature of
water for foot washing, alcohol cotton pieces and a mirror. They were shown how to use the kit and
asked to carry out daily foot care, checking their feet every day with a mirror. Participants could
attend diabetes education classes every 3–6 months and were followed up every month for 2 years
by a nurse and an endocrinologist performing a foot examination. Both the control group and the
intervention group received standard care consisting of medication adjustment, foot assessment and
2 hours of diabetes education. No statistically significant effect in the number of foot ulcers was
evident (RR 0.07, 95% CI 0.00 to 1.12). All items in the quality assessment were unclear and the trial
may be at risk from selection, performance, attrition and selective reporting bias.
In a fourth RCT92 evaluating a complex intervention, 396 participants were followed up for 12 months.
Most of the participants were women (81%) and they had a mean age of 60 years; it was unclear
whether or not they had previously experienced foot ulcers. Every patient had T2DM and had received
a diagnosis at least 10 years before. The 191 patients in the intervention group received nurse-led
patient education sessions involving one to four patients and covering appropriate foot care behaviours
and footwear. Patients entered into a behavioural contract for desired self-foot care. A systems
intervention was designed to prevent patient-specific risks using information flow sheets on foot-related
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risk factors for amputation in diabetic patients. Health-care providers used prompts to ask patients to
remove their footwear and perform foot examinations, and patients were also given foot care education.
Both groups received standard care, which consisted of a physical examination performed by nurse
clinicians who were blind to patients’ randomised treatment. There was no statistically significant
difference in the number of foot ulcers between the two groups (RR 0.47, 95% CI 0.20 to 1.12).
All items in the quality assessment were judged to be unclear and the trial was possibly at risk from
selection, performance, attrition and selective reporting bias.
In a RCT evaluating a complex intervention,84 the majority of the 2001 participants were male (53%)
and the participants’ mean age was 60 years. It was not reported how many had previously had foot
ulcers. Eighty per cent had T2DM, but their mean duration of diabetes mellitus was not reported.
The 1001 participants in the intervention group received a foot risk assessment comprising testing of
sensitivity to Semmes–Weinstein monofilaments, measurement of VPT using a biothesiometer and the
palpation of pedal pulses. Those deemed to be at high risk of foot ulceration were invited to attend a
weekly diabetic foot clinic, where they were provided with self-care advice, chiropody care and support
hosiery and/or protective shoes. The 1000 participants in the control group continued to attend the
general outpatient clinic and had ulcer and amputation outcomes collected but received no special
care. The diabetes outpatient service advised those in the control group about the importance of daily
foot inspection and washing, appropriate hosiery and footwear and making contact with the clinic
whenever they deemed it necessary. No statistically significantly different effect in the number of
foot ulcers was observed between the two groups (RR 0.69, 95% CI 0.41 to 1.15). Generation and
concealment of allocation and blinding were unclear. Three items in the quality assessment were
rated as unclear (apart from incomplete outcome data, which was rated as high risk) and the trial
was rated as being at possible risk of selection, performance, attrition and selective reporting bias.
Complex interventions: meta-analysis
A pooled analysis of data from the 2587 people with diabetes mellitus in five RCTs showed that
complex interventions statistically significantly reduced the number of foot ulcers in the intervention
groups (pooled RR 0.59, 95% CI 0.38 to 0.90) (Figure 14). The ulcer risk category of those who took
part was not reported in three trials,84,92,119 but two trials included 44 patients who had not previously
experienced a foot ulcer.90,91 Heterogeneity was found to be I2 10%; however, with the exception of one
trial,119 the validity of these data may be affected by bias.
Secondary outcomes: complex interventions
Amputation,84,91 time to ulceration90 and/or knowledge of foot care91 were reported in three trials.
In one trial,91 amputations occurred only in the control arm (two among 31 participants, compared
with none among the 31 participants in the intervention arm) and in a second trial84 there were fewer
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FIGURE 14 Meta-analysis: complex intervention.
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amputations in the intervention group (one major and six minor) than in the control group (12 major
and 13 minor).84 The time to ulceration was shorter in the control group than in the intervention group
in one trial, but this finding did not reach statistical significance.90
In one trial, participants’ knowledge of foot care (as measured using a diabetes knowledge questionnaire)
was statistically significantly better in the intervention group than in the control group.91
Custom-made footwear and offloading
We identified six RCTs evaluating custom-made footwear and offloading devices.
Bus et al.99 recruited, and followed up for 18 months, 171 participants, most of whom were men
(82.5%), with a mean age of 62 years. All had previously had ulcers. Nearly three-quarters (71%) of
participants had T2DM, and their mean duration of diabetes mellitus was 17 years. Eighty-five people
in the intervention arm received either custom-made footwear or semi-customised footwear with
offloading properties improved, which was prescribed by a specialist in physical and rehabilitation
medicine and manufactured by a local orthopaedic shoe technician. The custom-made shoes were
created from a plaster-cast mould of the foot or from three-dimensional digital scans. Participants
received orthoses made from either a cork base with added microcork and a mid-layer of ethylene
vinyl acetate or a Plastazote leather. Participants were permitted to wear any additional custom-made
footwear they owned at study entry or that was prescribed during follow-up. The 86 people in
the control group wore footwear that was not improved based on in-shoe pressure measurement.
Both groups received written and verbal instructions on foot care and on proper use of footwear as
standard practice. No statistically significantly different effect was detected (RR 0.88, 95% CI 0.61 to
1.26). All four quality assessment items were judged to be at a low risk of bias.
A three-arm trial of footwear and orthoses86 recruited, and followed up for 24 months, 400 participants
(77% were male) with a mean age of 62 years, all of whom had experienced a foot ulcer. The majority of
participants (93%) had T2DM and the duration of diabetes mellitus was > 25 years in 56% of the trial
population. Participants were randomly allocated to a group receiving three pairs of therapeutic shoes
with medium-density cork inserts and a neoprene closed-cell cover or to a group receiving three pairs of
therapeutic shoes with prefabricated, tapered polyurethane inserts and a brushed nylon cover or to the
control group, who received usual footwear. All groups received standard professional foot care and a
lightweight terry-cloth house slipper. There was no statistically significant difference in number of foot ulcers
between those who received therapeutic shoes with either neoprene inserts or polyurethane inserts and
the control group (RR 1.00, 95% CI 0.70 to 1.43). The reporting of concealment of allocation was unclear.
A third RCT, of footwear and pressure-relieving devices,96 included 298 participants, with a mean
age of 67 years, of whom 20% had had a previous ulcer. The majority (84%) had T2DM, for a mean
duration of 18 years. One hundred and forty-eight participants were randomised to the intervention
group and received custom-made orthoses and shoes. Shoes were mostly semi-orthopaedic footwear,
available on the open market, or craft-made orthopaedic shoes. Each patient also received additional
education session about the need to wear the shoes and to inspect their feet daily. Patients could
receive an urgent consultation within 24 hours if they developed a new foot ulcer. Follow-up took
place every 3 months to assess the feet and the condition of the footwear. Standard care for 150
people in the control group comprised education to prevent foot ulcers and advice about footwear.
A statistically significant difference between groups was observed (RR 0.30, 95% CI 0.18 to 0.49),
with custom-made orthoses and shoes producing a beneficial effect. The concealment of allocation and
outcome assessor blinding were unclear and the trial data are at risk of selection and performance bias.
A fourth RCT, of custom-made footwear and insoles,95 comprised 299 participants (67% were male
and the mean age was 70.5 years). Twenty-five per cent had experienced a foot ulcer and, on average,
they had had diabetes mellitus for 12.5 years, but the number with T2DM was not reported. The
149 participants in the intervention group received therapeutic shoes in which the standard insole
had been replaced with an insole designed to reduce shear. The control group (n = 150) received the
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same brand of therapeutic shoes containing the standard insole. In both groups insoles were replaced
every 4 months and the shoes were replaced once per year. Both groups also received standard care
comprising a foot and lower extremity evaluation by a physician every 10–12 weeks and an educational
video that focused on foot complications and self-care practices. The video addressed the aetiology of
DFUs, risk factors, self-care practices and early warning signs of diabetic foot disease. Patients were to
contact the study nurse if they identified an area of concern on their feet. After 18 months’ follow-up,
no statistically significant difference in effect was detected (RR 0.30, 95% CI 0.08 to 1.08). The
generation and concealment of allocation were unclearly reported, as was the completeness of the
outcome data, and the validity of the trial data may be compromised by selection and reporting bias.
Uccioli et al.85 randomised 69 participants (62% were male and the mean age was 60 years). All
participants had experienced a foot ulcer, 75% had T2DM, and the mean duration of diabetes mellitus
of those recruited was 17 years. The period of follow-up was 12 months. The intervention arm
comprised 33 people who received therapeutic shoes made from soft thermoformable leather with
semirocker soles and custom-moulded insoles (which were of extra deep fit customised insoles
and accommodate toe deformities) plus standard care. The 36 people in the control group were free
to wear ordinary shoes, unless it was clearly dangerous for them to do so, and received only standard
care, which comprised educational guidelines on foot care and general information about the importance
of appropriate footwear. A statistically significant effect was observed (RR 0.47, 95% CI 0.25 to 0.87).
Generation of the random allocation was judged to be at a high risk of bias, and concealment of allocation
and blinding and completeness of the outcome data were unclear; consequently, the trial data may be at
risk of selection, performance, attrition and reporting bias.
The sixth RCT98 randomised 150 participants (68% were male) with foot ulcers who had a mean age
of 59.5 years. The number of participants with T2DM and the duration of diabetes mellitus were not
reported. All participants were advised to remain in their healing devices or removable cast walkers
until their foot ulcers healed and before shoes were dispensed at ≈7 weeks after randomisation.
Seventy-nine people in the intervention group were randomised to receive bespoke orthoses with
offloading properties to reduce pressure on the metatarsal heads. Modified using a computer-aided
design process, the orthoses were milled from a block of ethylene vinyl acetate foam and covered with
a polyurethane foam top cover. Seventy-one people in the control group received standard orthoses
from three different manufacturers. Both groups were provided with extra-depth shoes from PW
Minor (Batavia, NY, USA) but a different specification was required to accommodate the bespoke
orthoses (DX2 as opposed to the extra-depth specification that was received by the control group).
Study co-ordinators discussed self-care behaviour with all patients, focusing on wearing the study
shoes for all steps taken and examining the feet daily to note and report problems to the study team.
There was a statistically significant difference in effect at 15 months (RR 0.34, 95% CI 0.14 to 0.81).
The risk of bias was low for all four quality assessment items.
Secondary outcomes: custom-made footwear and offloading
Adherence95,96,99 and/or cost96 data were reported in four trials. One trial measured adherence
using a temperature-based monitor placed inside the shoe, and found that 35 out of 85 participants
in the intervention group and 42 out of 86 participants in the control group adhered to wearing their
allocated footwear.99 The trial authors conducted a subgroup analysis in participants who wore their
allocated footwear, which showed a statistically greater reduction in ulcer recurrence in the intervention
group; however, the analysis using data from the entire trial population failed to detect a beneficial
association. A second trial of custom-made footwear and offloading insoles measured adherence using
a self-reported physical activity questionnaire, and found that footwear and insole use was high in
the groups that received cork inserts (83%) and prefabricated insoles (86%).86 A third trial measured
participant compliance with footwear using self-reports of the number of hours per day that the shoes
were worn. There were no statistically significant differences between the groups in the number of
people who wore the shoes for < 4 hours per day (23/149 vs. 16/150), 4–8 hours per day (77/149 vs.
83/150), 8–12 hours per day (38/149 vs. 46/150) or 12–16 hours per day (10/149 vs. 6/150).95
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Cost data collected in one trial published in 2012 showed that supplying footwear and insoles cost
€675 per person per year.96
Custom-made footwear and offloading: meta-analysis
A pooled estimate of data collected from trials evaluating custom-made footwear and offloading insoles
showed a reduction in the number of foot ulcers (pooled RR 0.53, 95% CI 0.33 to 0.86) in 1387 people,
of whom 464 had no history of foot ulceration; however, there was a high level of heterogeneity
(I2 = 78%) possibly arising from variation in the construction of the shoes and insoles as well as the
difference in risk (Figure 15).
Custom-made footwear and offloading: subgroup analyses
A subgroup analysis of data collected only from patients with a history of foot ulceration (n = 424) did
not find a statistically significantly different effect in these patients (RR 0.71, 95% 0.47 to 1.06), and
the degree of heterogeneity was I2 of 61% (Figures 16 and 17). Conversely, the RR of pooled data from
two RCTs that included patients with no history of foot ulceration (n = 297) was 0.30 (95% 0.19 to 0.47)
with I2 of 0%. It should be noted that many of the data in these analyses may be affected by biases
emanating from the conduct of the trials, as only two trials were judged to be completely free of bias.98,99
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FIGURE 16 Subgroup analysis: custom-made footwear and offloading in patients with a history of foot ulceration.
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Table 20 shows the outcomes from the quality assessment process. Only 5 of the 23 trials were judged
to be free of bias.
Ongoing randomised controlled trials
The searches for ongoing trials to prevent foot ulceration in diabetes mellitus from the ClinicalTrials.gov
website found 24 studies being conducted worldwide, the details of which are presented in Appendix 4.
Discussion
The purpose of this SR was to evaluate the evidence base and obtain summary statistics for preventative
interventions for foot ulceration in diabetes mellitus to create a cost-effective, evidence-based care
pathway. The meta-analyses of dermal infrared thermometry, complex interventions and therapeutic
footwear with offloading insoles suggest that these interventions can help prevent foot ulceration in
people with diabetes mellitus.
The meta-analysis of data from RCTs of dermal infrared thermometry in people with a history of foot
ulceration and a moderate to high risk of ulceration indicates that this is a promising intervention
deserving of further evaluation in randomised trials with larger participant samples, and we note from
our search of the ClinicalTrials.gov trial registry that new trials are currently under way. If foot ulcer
prevention can be confirmed in large, well-conducted trials, this form of self-monitoring could relieve
pressure on health-care systems; however, advising individuals to abstain from all weight-bearing
activities when the difference in foot temperature exceeds 4 °F may prove challenging, and poor
adherence might diminish any benefit in a real-world context outside a trial setting.
Specialist foot care of the type evaluated in the included trials of complex interventions is considered a
marker of good-quality diabetes service delivery, and it is intuitively correct to suppose that this leads
to improved outcomes. Although a statistically significant reduction in foot ulcers was apparent in our
meta-analysis, such an effect was not evident in any single trial. This does support the suggestion of
others that very large sample sizes may be needed for trials of this nature.13 Surprisingly, there was a
low level of statistical heterogeneity in the pooled data, despite quite marked differences in the clinical
care provided in the intervention arms of the trials and the inclusion of people with three different
levels of ulcer risk.
Our review did not identify any trials of complex interventions that reflect the composition of
multidisciplinary foot services as recommended in clinical guidelines.11,12 These influential documents
advise that the core team in a diabetes foot care service should include diabetologists, podiatrists,
vascular surgeons, diabetes specialist nurses and orthotists, but patient outcomes from such health-
care service arrangements have not been evaluated in RCTs. An evaluation of outcomes for people at
different levels of ulceration risk who receive care in specialist foot care settings would be worthwhile.
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The true value of therapeutic footwear and offloading insoles in preventing foot ulcers has been
obscured by contradictory trial results and poor interpretation of data in SRs; two larger trials
involving only those with a history of foot ulcers both failed to detect evidence of effectiveness,86,99
and visual inspection of our analyses of pooled data from all six trials found that the greatest beneficial
effect was in trials in which the majority of participants were considered to be at high or moderate
risk but had not experienced a foot ulcer,95,96 although the results reached statistical significance in
only one trial.18 Our subgroup analysis of data from four trials of participants with a history of foot
ulceration found no statistically significant difference in the number of recurrent ulcers between the
custom-made footwear groups and the control groups.
This observation calls into question the conclusions of several SRs evaluating footwear and insoles for
the prevention of foot ulcers.59,64,72 The most recent SR included randomised and non-randomised data
and adopted a consensus approach to analysis. The reviewers concluded that there is strong evidence
that footwear interventions prevent recurrent plantar foot ulcers but no evidence that they prevent a
first foot ulcer.72 An individual participant data analysis using data from these six trials together with
data from the 10 ongoing studies of offloading insoles identified by our search of the ClinicalTrials.gov
database could allow for subgroup analyses to explore the value of footwear and offloading insoles in
people with different baseline risks and, potentially, resolve these ongoing uncertainties.
The marked reduction in ulcerations reported with the use of a dermal silicone device by individuals at
high risk of ulceration is encouraging.97 These devices are simple to make at the chair-side and easy for
wearers to keep clean. Although they are a type of offloading intervention, we did not include these
data in the meta-analysis of footwear and offloading insoles because these devices differ substantially
in that they are worn only around the toes.
Three separate small trials evaluating the effects of daily application of an antifungal nail lacquer
(ciclopirox 8%) plus daily foot inspections,89 the use of elastic compression stockings93 and podiatry94
all failed to show a reduction in foot ulcers, possibly as a result of small sample sizes.
The standard care arrangements in the control arms of the included trials trial varied greatly, and no
coherent conclusions can be drawn about current clinical practice from the trial reports.
We have comprehensively reviewed a body of evidence from RCTs and made the fullest use of the
data currently available to derive the best estimates of treatment effects to inform a wider piece of
work. In so doing, we have highlighted uncertainties, gaps and limitations in the existing evidence base
to inform practice, generated new research hypotheses and added value to this area of research.
The weaknesses of this review arise from the potential biases identified in many of the trial reports,
especially for complex interventions, which may have produced unreliable results. Previous authors of SRs
have cited a lack of similarity between studies,49 a lack of standardisation in terminology, prescription,
manufacture and material properties of interventions,65 heterogeneity in study designs, methodology and
participant populations,66 and differences in participant demographics70 as reasons for not conducting
meta-analyses, and we are aware of the potential limitations in the pooled analyses that we present here
in both the number and the quality of trials. We have tried to produce conservative, less biased summary
measures by adopting an intention-to-treat approach and a random-effects model. We acknowledge
criticisms about the use of the latter,52 but believe that the insights gleaned and the generation of
new research hypotheses justify our decision to pool data. Our analyses found evidence of beneficial
effects of four types of intervention to prevent foot ulcers in people with diabetes mellitus, but
considerable uncertainty remains about what works and who is most likely to benefit. Attention should
be given to recommendations for the conduct of trials of interventions for the foot in diabetes mellitus,
and researchers conducting future trials should endeavour to complete the trial to target recruitment as
informed by an a priori sample size calculation.103
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Chapter 6 Economic model:
evidence-based pathway
Background
Diabetes-related foot ulcers give rise to considerable morbidity and generate a high monetary cost for
health and social care services. They precede 80% of diabetes-related LEA; hence, the clinical need to
identify patients at risk of DFUs as early as possible is clear.
We have developed and validated a CPR suitable for routine practice that can help to identify a patient’s
risk status for future diabetic foot ulceration (see Chapter 4). In addition, our SR on the prevention of
DFU (see Chapter 6) has identified three interventions that have the potential to reduce the risk of
DFUs in patients at risk. Drawing together the CPR and the results of the SR allows us to develop an
evidence-based care pathway for the treatment of patients at risk of DFUs.
In this chapter, we report an economic evaluation of this evidence-based care pathway. The purpose of
our analysis was to provide an economic rationale for the choice of preventative treatment and optimal
monitoring frequency for patients at risk of DFU. We then assess the value of further research in this
area and identify particular areas of uncertainty around which future research should be focused.
Objectives
l Question 1: what is the potential cost-effectiveness of the use of a validated CPR as part of
structured care to reduce the incidence of DFU?
l Question 2: what is the potential cost-effectiveness of alternative strategies, including
monitoring intervals?
l Question 3: is there potential worth in undertaking further research, particularly a RCT?
To address these questions, we first conducted a SR of published health economic models used to
estimate the cost-effectiveness of DFU prevention. Informed by the review of the literature, we then
developed a de novo health economic model capable of estimating the potential cost-effectiveness of
alternative care pathways for the prevention of DFUs. This model was informed by epidemiological
modelling of clinical data from a diabetes register in Fife (NHS Fife SCI-Diabetes), Scotland, between
2010 and 2018. Value-of-information analysis was then used to quantify the value of conducting
further research and to suggest where such research should be focused.
Literature review of cost–utility analyses
Aim
The aim was to undertake a review of published cost–utility analyses of the prevention of DFUs.
Methods
We undertook a review to identify (1) costs and outcomes of relevant interventions for the prevention
of diabetic foot ulceration and (2) published cost–utility analyses of such interventions. The review
methods are provided in Appendix 5.
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Results
Our search returned 11 relevant papers to be reviewed. Four other relevant papers were identified by
‘hand-searching’ the references of the 11 papers identified. Of these 15 papers, five were cost–utility
analyses of the prevention of DFUs.121–125 The remaining papers either were concerned with the
cost–utility of treatments for patients who had already experienced DFUs or were papers relating to
the cost burden of DFUs.126–134 Further hand-searching did identify other studies in which an economic
analysis was undertaken (i.e. some assessment of costs and outcomes); however, as these papers were
not cost-effectiveness papers and were beyond the scope of this review, they were excluded.
We review here the five papers that were cost–utility analyses of the prevention of DFUs.
Full details of the papers reviewed are given in Appendix 6, Table 52.
Quality of economic evaluations
All five cost–utility papers were quality assessed using the Drummond checklist135 for economic
evaluations. All studies were deemed to be of high quality.
Review of papers
Eastman et al.121 used a Markov model to simulate the natural history of diabetic patients and the
rate of complications (including DFUs and LEA) and to evaluate the impact of preventative treatments.
Information on age, sex, ethnicity and incidence and prevalence rates were based on US community
and population studies. The authors then estimated the cost-effectiveness of glycaemic control for
reducing diabetes-related complications. Costs and outcomes were estimated for patients aged
between 25 and 74 years. The authors found that treatment that maintains an HbA1c value of 7.2% is
associated with a reduction in LEA of 67%. They found the cost per additional quality-adjusted life-year
(QALY) of treatment was £16,002.
Ragnarson Tennvall and Apelqvist122 used a Markov model to assess the cost–utility of an ‘optimal’
prevention programme for patients at risk of DFUs and amputation. The prevention programme
included foot inspection, appropriate footwear and education. Patients were stratified in the model
according to their risk of ulceration. The treatment effect of the preventative programme was based
on RCTs and observational studies reported in the literature (see Table 21). Costs and outcomes were
assessed over a 5-year time horizon. The study found that optimal preventative treatment of high-risk
patients was cost saving based on the achievement of a 25% lower incidence of DFUs and extremity
amputation than in baseline prevention scenarios. Similarly, Ortegon et al.123 used a Markov model
to assess the cost–utility of optimal prevention and treatment of diabetic foot. The preventative
programme included protective foot care, education, regular inspection, risk identification and the
involvement of a multidisciplinary team. Treatment effect was based on a study that reported a
reduction in LEA of between 49% and 85%.135 Patients were stratified in the model according to risk.
Costs and outcomes were measured over the lifetime of a patient. The study found that, based on the
achievement of a reduction in ulceration incidence of 10%, preventative treatment was cost-effective,
with a cost per QALY gained of < US$25,000 (2003 prices).
Rauner et al.124 used a Markov model to assess the cost–utility of preventative education programmes to
reduce DFUs. Treatment effect was based on the assumption of a 25–50% reduction in DFUs, based on
estimates obtained from the literature.82,136 The authors’model built on previous work by stratifying patients
according to not only risk but also age, allowing for the potential for more targeted decision-making. Costs
and outcomes were assessed over a 10-year period. Their results suggest that preventative programmes are
highly cost-effective when targeted at patients at high risk of DFUs and LEAs.
Barshes et al.125 used a Markov model to assess the cost–utility of primary prevention programmes aimed
at reducing the incidence of DFUs. In contrast to the other papers under review, which took the cost and
effectiveness of treatment as given and estimated the cost-effectiveness, Barshes et al.125 sought to
estimate the effectiveness target necessary for a treatment to be considered cost saving. Costs and
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outcomes were estimated over a 5-year period. The study found that preventative programmes had a
> 90% probability of being cost-saving when the annual prevention costs were <US$50 per person and/or
when DFUs are reduced by at least 25%. If patients were deemed to be at high risk, programmes were
cost-saving when incidence of DFU reduced by 10%.
All studies, with the exception of Eastman et al.,121 used a Markov model to simulate the clinically relevant
states experienced by patients at risk of developing DFUs. All of these studies included clinical states
representing pre-ulceration, ulceration and post-ulceration outcomes; however, they varied in terms of
which other relevant clinical factors they included in the modelling. The studies by Ortegon et al.123 and
Rauner et al.124 were the only ones to stratify patients according to risk state. Three studies123–125 included
additional clinical states associated with diabetic foot, such as ischaemia (e.g. neuropathy, peripheral
vascular disease). Eastman et al.121 used a Monte Carlo simulation to estimate the rate of complications,
including DFUs and LEAs, associated with all patients with T2DM.The disparity in modelling strategies
among these studies is a natural consequence of the complexity of the disease and the range of possible
complications. Furthermore, the choice of modelling strategy, and the clinical events included, is a function
of the specific decision problem addressed in each study; however, the result is that uncertainty about the
most appropriate choice of model for estimating the cost-effectiveness of strategies to prevent DFUs.
All of the papers reviewed found that preventative treatment for DFUs was cost-effective or, in some
cases, cost saving. However, the evidence on effectiveness in these studies comes from research
conducted some time ago and/or studies that have small sample sizes; therefore, significant uncertainty
remains about the treatment efficacy of potential interventions.
Only the model of Ortegon et al.123 estimated the lifetime costs and outcomes relating to DFUs. As the
costs (in terms of the ongoing care required) and outcomes (in terms of fewer DFU and amputations),
and the significant morbidity associated with these, will have an impact over a patient’s full lifespan,
it is necessary to take a lifetime perspective when estimating cost-effectiveness.
All the studies reviewed suggest that the effectiveness (and cost-effectiveness) of treatments is likely
to vary according to patient risk, and that treatment is most likely to be considered cost-effective in
the subgroup of patients at high risk. However, none of the papers reviewed have modelled how often
a patient’s risk should be assessed (risk monitoring frequency).
Summary
Our review highlights considerable heterogeneity in how the clinical and cost consequences of treatments
to prevent DFUs have been modelled in the literature. Furthermore, at the time these studies were
published, there was little consensus about the efficacy of treatments available for preventing DFUs;
therefore, existing models of cost-effectiveness rely on assumptions about treatment effect. Another
important limitation of current models is that risk monitoring frequency has not been considered.
Development of health economic model
Overview
There is a lack of consensus among clinical guidelines about the monitoring frequency required for patients
who are at risk of developing DFUs. NICE currently recommends annual monitoring of patients at low risk,
and monitoring as frequently as once every 1 or 2 weeks for patients at high risk. SIGN recommends that
the monitoring take place at least annually, but concedes that the optimal monitoring frequency is unknown;
hence, there is a need for new economic evaluations to consider the impact of alternative monitoring
frequencies on DFU outcomes and the implications for cost-effectiveness. As discussed in Review of papers,
the choice of modelling strategy will depend on the specific decision problem at hand and, thus, clinical input
into the model choice is crucial from an early stage. The literature review of economic models has shown
that interventions that are able to reduce the incidence of DFUs in at-risk patients have the potential
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to be cost-effective. Based on our review of the literature, and on advice from our clinical colleagues,
we developed a de novo health economic model to answer the questions stated in our objectives.
Cost perspective
This economic evaluation was undertaken from the perspective of the UK NHS and Personal Social
Services137 that is, the costs relevant to the economic analysis were those incurred by the NHS and
Personal Social Services.
Time horizon
This economic evaluation investigated the costs and health outcomes associated with each clinical
pathway over a 20-year time horizon.
Discount rate
Future costs and health outcomes were discounted at 3.5%, in line with recommended practice.137
Conceptual model of disease and treatment pathways
Our task was to undertake an economic evaluation of an ‘evidence-based pathway’ for the prevention
of DFUs. To do so, we had to understand the important clinical and economic events in the care
pathway. The conceptual model in Figure 18 is a visual representation of the events we sought to
capture in our model and how these events relate to costs and QALY outcomes.
Conceptual model implemented as a Markov model
The model was implemented as a semi-Markov model, as the survival analyses used to estimate
transitions indicated that transition probabilities varied according to time in state. Submodels were
developed to estimate total discounted costs and QALYs for ulceration and amputation events to
simplify the implementation of the model. Figure 19 illustrates graphically the transitions we require to
estimate this conceptual model as a Markov model.
NHS Fife Scottish Care Information – Diabetes Collaboration data set
NHS Fife SCI-Diabetes is an electronic patient record used in the routine management of NHS patients
with diabetes mellitus. The data set we obtained contained information about individual patients who
received foot care in NHS Fife foot monitoring clinics over a 12-year period. The data contained the
results of risk assessments of the risk factors recommended by the SIGN guideline,12 only three of which
are required in our validated CPR as reported in Chapter 4: monofilament sensitivity, pedal pulses and
history of ulceration (all binary variables). Data were available from the beginning of 2005 until the end
of 2017. A separate data set from NHS Fife SCI-Diabetes provided death data that were merged with
the SCI-Diabetes foot monitoring data. No death data were recorded before 1 March 2009 in the data
set; therefore, this date was used as the entry point into the defined cohort as we would not know
whether or not patients with records that stopped before that date had died. The use of the SCI-Diabetes
anonymised data set was approved by the information governance department of NHS Fife.
Clinical prediction rule definition of risk status
The economic model includes the use of the CPR, which defines a patient’s DFU risk status as follows:
l Low risk [CPR score of 0 or 1; probability of ulcer at 2 years ≤ 0.05 (see Table 10)] – negative for
history and also negative for at least one of monofilament sensitivity and pedal pulses.
l Moderate risk (CPR score of 2; probability of ulcer at 2 years = 0.12) – positive for history but
negative for both monofilament sensitivity and pedal pulses, or negative for history but positive for
both monofilament sensitivity and pedal pulses.
l High risk (CPR score of 3 or 4; probability of ulcer at 2 years ≥ 0.25) – positive for history and also
positive for at least one of monofilament sensitivity or pedal pulses.
ECONOMIC MODEL: EVIDENCE-BASED PATHWAY
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FIGURE 18 Conceptual model of decision problem.
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   1. Low risk to death
   2. Moderate risk to death
   3. High risk to death
   4. Ulceration to amputation
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   6. Amputation to death
   7. Low risk to medium risk
   8. Low risk to high risk
   9. Moderate risk to high risk
10. Low risk to ulceration
11. Moderate risk to ulceration
12. High risk to ulceration
13. Low risk to amputation
14. Moderate risk to amputation
15. High risk to amputation
16. Moderate risk plus treatment to ulceration
17. High risk plus treatment to ulceration
18. Moderate risk plus treatment to high risk + treatment
19. Moderate risk plus treatment to amputation
20. High risk plus treatment to amputation
21. Moderate risk plus treatment to death
22. High risk plus treatment to death
Transitions:
1–15 informed by survival analysis
16–22 informed by meta-analysis
FIGURE 19 Schematic of semi-Markov model and submodel.
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This categorisation, although arbitrary, was chosen for ease of use in a clinical setting (just three
categories of risk) and was decided on following group discussions at project team meetings.
NHS Fife Scottish Care Information – Diabetes Collaboration population
Patients who were recorded in the data before 1 March 2009 and were attending foot monitoring
clinics on or after 1 March 2009 (prevalent patients) or who started to attend foot monitoring clinics
after this date (incident patients) were defined as eligible for analysis. Having a mix of prevalent and
incident patients is appropriate as any changes in the monitoring policy would apply to all patients.
In the case of patients whose first recorded appointment was before 1 March 2009, the date of entry
to the analysis cohort was considered to be 1 March 2009 and their CPR status was the last recorded
CPR status before 1 March 2009. In the case of those patients whose first recorded appointment
was on or after 1 March 2009, the date of entry to the cohort was taken as that date, alongside the
patient’s CPR status at that date. Use of these criteria resulted in 26,154 patients being included in the
cohort used to inform important parameters of the economic evaluation model. Table 22 summarises
the key demographics of this cohort.
Figure 20 shows the total number of clinical visits per patient in the cohort over the period of
approximately 8 years. The follow-up time varied considerably between each patient depending on
whether they were a prevalent or an incident patient (and when they became an incident patient) and
also if the patient died. As can be seen from Figure 20, almost 80% of patients in the data set had more
than one visit to the foot assessment clinic, and it was not uncommon for a patient to have more than
10 clinical encounters.
TABLE 22 Descriptive statistics for cohort used in economic
evaluation model
Characteristic n (%)
Age (years)
Mean (SD) 68 (14)
Sex
Male 14,053 (54)
Female 12,101 (46)
SIMD deciles (socioeconomic deprivation)
1 (most deprived) 1628 (6)
2 3324 (13)
3 3009 (12)
4 3017 (12)
5 2959 (11)
6 2633 (10)
7 2069 (8)
8 2539 (10)
9 2415 (9)
10 (least deprived) 1488 (6)
Missing SIMD data 1073 (4)
Total 26,154 (100)
SD, standard deviation; SIMD, Scottish Index of Multiple
Deprivation.
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Table 23 presents the number of key events of interest for the economic model that occurred during
the follow-up of the identified cohort. Among the 26,154 patients, approximately 4% developed an
ulcer, 1% required an amputation and almost 24% died.
If the only record for a patient in the data set was of their death (and hence there were no risk assessment
data), we excluded that patient from the cohort used for analysis (analysis cohort, n = 26,086).
Missing data
There were significant numbers of missing data in the NHS Fife SCI-Diabetes data set. This was
particularly an issue with regard to records for patients’ test results for the three CPR predictors
(monofilament sensitivity, pedal pulses and history of ulceration) that were used to estimate risk status
in the cohort. To determine the most likely mechanism for the occurrence of missing data, regression
modelling was used to investigate the association between patient demographics and missingness.
Patients’ characteristics were found to be associated with missingness, ruling out the possibility that
the missing data mechanism was missing completely at random.138 After consultations with clinicians
and data controllers, we considered that MAR was also unlikely and, therefore, ruled out a multiple
imputation approach to account for missing data. After consultating with NHS colleagues, we
proceeded with the following rules.
When a patient had a missing record for one of their CPR predictor variables, the patient was
recorded as not being at risk from this predictor (i.e. if the record for monofilaments was left blank,
we assumed that the patient was sensitive to monofilaments). When a patient had a valid recording
(positive or negative) followed by missing data in subsequent visits, we assumed that the patient did
not change risk status for this variable unless indicated otherwise. Full details of the missing data
approach are given in Appendix 6, Table 54.
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FIGURE 20 Histogram of total number of clinical visits per patient in the cohort.
TABLE 23 Number of key events observed in the cohort used in the economic evaluation model
Event
Number of
events
% of population
having event
Ulceration 980 3.8
Amputation 286 1.1
Death 6213 23.8
ECONOMIC MODEL: EVIDENCE-BASED PATHWAY
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Clinical prediction rule risk status over time
Table 24 shows that, at the first clinic appointment, 25,003 patients (96%) were classified as at low risk.
This decreased to 23,867 patients (91%) by the final clinic appointment. Over time, there was an
increase in patients classified as at moderate risk (first visit, 3%; final visit, 4%) and at high risk (first visit,
1%; final visit, 4%). Overall, 1397 (5%) of the cohort changed their risk status between their first visit and
their final visit. The numbers in Table 24 that indicate a change in risk category are shown in italics.
Estimation of transition probabilities
Transition probabilities required for the model were estimated based on a set of parametric survival
models built on the aforementioned analysis cohort (Table 25). We tested the following parametric
models: exponential, Weibull, Gompertz, log-logistic, log-normal and generalised gamma. The choices of
distribution were determined by a visual examination of Kaplan–Meier plots and log-cumulative hazard
plots and Akaike information criterion (AIC)/Bayesian information criterion (BIC) tests of model fit,
as recommended by NICE Decision Support Unit Technical Support Document on survival analysis
methodology (see Appendix 6).139 Kaplan–Meier survival plots for the key transitions in the economic
model are presented in Appendix 6.
Results
Estimating costs and utilities
Costs
We calculated total costs by attaching unit costs to resource use per patient with the relevant clinical
event. Unit cost estimates were identified from the literature and from microcosting based on input
from clinical experts.131 The inclusion and exclusion of resource use items were validated with the
project team and diabetic foot clinicians. All unit costs were presented in Great British pounds for the
price year 2017. Table 26 provides a list of the unit cost estimates, unit of measurement and source
for each resource included in the model. Further details regarding costs are given in Appendix 6.
Health utilities
Health utilities were identified from the SR of economic models of the prevention of DFU. Utility
estimates from Redekop et al.132 were obtained from the general population (the Netherlands), making
them particularly suitable for economic evaluation, which requires the relative preferences for health
states across multiple disease areas (Table 27).
TABLE 24 Frequency of patients by CPR risk status at first clinical appointment and final clinical appointment
First visit
Final visit (n)
Total (N)Low Moderate High
Low 23,867 639 497 25,003
Moderate 0 452 261 713
High 0 0 370 370
Total 23,867 1091 1128 26,086
Text in italics indicates a change in risk category.
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TABLE 25 Numbers of events and estimated survival probabilities (from which transition probabilities are obtained) for all economic model transitions
Transition required Estimation procedure
Number
of events
Survival probability at (95% CI)
1 year 2 years 8 years
Transitions 1–3: time to
death conditional on
CPR state
n= 26,086
Population: patients in low-, moderate- or high-risk states
Event: death. t0 = time of entry into cohort
Censoring events: ulceration, amputation
Time-varying covariate: CPR state
Accelerated failure effects:
l Moderate risk 0.18 (95% CI 0.15 to 0.19) (interpretation: mean
survival time reduced by 82% for moderate vs. low risk)
l High risk 0.10 (95% CI 0.08 to 0.11)
5877 0.973 (0.971 to 0.975) 0.947 (0.944 to 0.950) 0.767 (0.761 to 0.773)
Transition 4: time from
ulceration to amputation
n= 927
Population: patients in ulceration state
Event: death. t0 = time of entry into ulceration state
Censoring events: death
100 0.94 (0.930 to 0.959) 0.922 (0.903 to 0.938) 0.880 (0.861 to 0.904)
Transition 5: time from
ulceration to death
n= 980
Population: patients in ulceration state
Event: death. t0 = time of entry into ulceration state
Censoring events: amputation
517 0.983 (0.973 to 0.990) 0.943 (0.927 to 0.956) 0.494 (0.461 to 0.525)
Transition 6: time from
amputation to death
n= 286
Population: patients in amputation state
Event: death. t0 = time of entry into amputation state
Censoring events: none
131 0.996 (0.975 to 0.999) 0.975 (0.943 to 0.988) 0.545 (0.484 to 0.602)
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Transition required Estimation procedure
Number
of events
Survival probability at (95% CI)
1 year 2 years 8 years
Transitions 7: time from
low to moderate risk
n= 25,000
Population: patients in low-risk state
Event: change to moderate risk. t0 = time of entry into
low-risk state
Censoring events: ulceration, amputation, death, change to
high risk
564 0.995 (0.994 to 0.996) 0.990 (0.989 to 0.996) 0.973 (0.970 to 0.975)
Transitions 8: time from
low to high risk
n= 25,000
Population: patients in low-risk state
Event: change to high risk. t0 = time of entry into low-risk state
Censoring events: ulceration, amputation, death, change to
moderate risk
0 1 1 1
Transitions 9: time from
moderate to high risk
n= 1041
Population: patients in moderate risk state
Event: change to high risk. t0 = time of entry into low-risk state
Censoring events: ulceration, amputation, death
163 0.955 (0.939 to 0.967) 0.913 (0.893 to 0.931) 0.778 (0.745 to 0.807)
Transitions 10–12: time
to ulceration conditional
on CPR state
n= 26,086
Population: patients in low-, moderate- or high-risk states
Event: ulceration. t0 = time of entry into cohort
Time-varying covariate: CPR state
Censoring events: death, amputation
Accelerated failure effects:
l Moderate 0.01 (95% CI 0.01 to 0.02)
l High 0.07 (95% CI 0.03 to 0.14)
666 0.992 (0.991 to 0.993) 0.989 (0.988 to 0.991) 0.974 (0.971 to 0.976)
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TABLE 25 Numbers of events and estimated survival probabilities (from which transition probabilities are obtained) for all economic model transitions (continued )
Transition required Estimation procedure
Number
of events
Survival probability at (95% CI)
1 year 2 years 8 years
Transitions 13–15: time
to amputation
conditional on CPR state
n= 26,086
Population: patients in low-, moderate- or high-risk states
Event: amputation. t0 = time of entry into cohort
Time-varying covariate: CPR state
Censoring events: death, ulceration
Hazard ratios:
l Moderate 13.72 (95% CI 9.23 to 20.30)
l High 20.51 (95% CI 13.58 to 30.97)
169 0.999 (0.998 to 0.999) 0.998 (0.997 to 0.998) 0.994 (0.993 to 0.995)
Note
The results of the SR and meta-analysis (see Chapter 5) suggested that the following interventions may be effective at preventing DFUs: (1) custom-made footwear and offloading,
(2) digital infrared thermometry and (3) complex interventions. The results of the survival analyses provided ‘base case’ scenarios for the transitions between health states in the model,
in terms of event rates (see Appendix 6, Figure 53). We then converted these rates into transition probabilities.140 In addition to the transition probabilities, we also used the results of
the SR and meta-analysis of preventative interventions for DFUs to estimate the transition probabilities for transitions 16–22 in the model. Results from the SR and meta-analysis
were given in terms of a RR reduction, and these were then applied to the required transition probabilities from the survival analysis. This procedure was undertaken for all three
potential interventions.
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Cost-effectiveness analysis
Costs and effects were measured for each potential treatment strategy. The cost-effectiveness of the
alternative treatment pathways were evaluated based on their incremental cost-effectiveness ratio
(ICER) and their net monetary benefit (NMB). ICERs are calculated as follows:
ICER = ΔCosts/ΔQALYs, (5)
where ΔCosts is the difference in total costs between interventions and ΔQALYs is the difference in
QALY gain between interventions.
If a new treatment is found to be more costly and less effective than the current treatment, the new
treatment is said to be ‘dominated’. Conversely, if the new treatment is more effective and less costly
than the current treatment, the new treatment is said to dominate the current treatment.
The NMB is a measure of the health benefit, expressed in monetary terms, which incorporates the
cost of the new strategy, the health gain obtained and the societal willingness to pay for health gains.
The NMB is expressed using the following formula:
NMB = (E × WTP)–C, (6)
where E is effectiveness, WTP is the willingness-to-pay threshold (£20,000 in the UK) and C is cost.
The NMB approach is recommended when comparing more than one intervention and provides a clear
decision rule (i.e. if NMB > 0, the new strategy is cost-effective).
Comparators
The base-case treatment strategy in all scenarios is current practice. Current practice is defined as the
natural history of the disease, with no CPR to monitor risk, and will involve whatever interventions are
TABLE 26 Unit costs
Cost item Cost estimate (base year 2017) Unit of measurement Source
Ulceration £3751 Per patient, annually Kerr 2017131
Amputation £8916 Per patient, annually Kerr 2017131
Off-the-shelf footwear plus insole £100 Per patient, annually Microcosting
Digital infrared thermometry £26 Per patient, annually Microcosting
Complex intervention £561 Per patient, annually Microcosting
Monitoring cost £26 Per patient, per visit Microcosting
TABLE 27 Health utilities
Health state Base case Source
Low risk 0.84 Redekop 2004132
Moderate risk 0.84 Redekop 2004132
High risk 0.84 Redekop 2004132
Ulceration 0.73 Redekop 2004132
Amputation 0.61 Redekop 2004132
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currently offered in practice and hence captured in the health outcomes of the current analysis cohort.
Current practice is taken as the base case and is compared with the treatment strategies outlined
in Table 28.
This modelling strategy allows us to incorporate the recommendations of clinical guideline bodies
such as NICE and SIGN. Our model included the use of a CPR that is based on a patient’s response
to monofilaments, presence or absence of pedal pulses and history of ulceration. These risk factors
are recommended, although not exclusively, by NICE and SIGN. There is no evidence-based consensus
on the most appropriate strategy for managing patients at risk of DFUs. Although both NICE and SIGN
recommend that specialist footwear be considered, only SIGN recommends the use of multidisciplinary
care teams. The use of digital thermometry is not recommended in clinical guidelines and is currently the
focus of RCTs. SIGN notes that there is no evidence on the ideal monitoring frequency for patients at risk
of DFUs; however, it advises annual monitoring. NICE, on the other hand, recommends monitoring annually
for low-risk patients, every 3–6 months for patients at moderate risk, every 1–2 months for patients at
high risk and every 1–2 weeks for patients for whom there is an immediate, pressing risk of DFUs. By
investigating the use of the CPR at 2 years, 1 year and 6 months, our model allows the costs and outcomes
associated with a range of preventative strategies recommended by clinical guideline bodies to be explored.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was used to explore uncertainty in the model input parameters and to
describe the impact that this uncertainty has on the model outcomes, namely costs and QALYs gained.
A 1000-iteration Monte Carlo simulation was undertaken. Gamma distributions were used to represent
uncertainty in the cost parameters; multivariate, normal distributions were used for (log-)survival
regression parameters; beta distributions were used for health utility parameters; and a log-normal
distribution was used to represent treatment effect parameters.
The distribution of ICERs produced by the Monte Carlo simulation was presented on the
cost-effectiveness plane. Cost-effectiveness acceptability curves (CEACs) were used to present the
uncertainty in the decision regarding the most cost-effective option, over a variety of monetary
willingness-to-pay thresholds.140
TABLE 28 Clinical pathways considered in the health economic model
Clinical pathway Description
Current practice Natural history of the disease, as observed in the cohort derived from NHS Fife NHS
Fife SCI-Diabetes population (analysis cohort). No CPR to monitor risk. No additional
intervention given
Monitoring every 2 years Natural history of the disease, as observed in the analysis cohort. Plus use of the CPR to
assess risk every 2 years. Interventiona is given to patients classified as at moderate or
high risk
Monitoring annually Natural history of the disease, as observed in the analysis cohort. Plus use of the CPR
to assess risk annually. Intervention is given to patients classified as at moderate or
high risk
Monitoring every 6 months Natural history of the disease, as observed in the analysis cohort. Plus use of the CPR to
assess risk every 6 months. Intervention is given to patients classified as at moderate or
high risk
Treat all Natural history of the disease, as observed in the analysis cohort. No CPR to monitor
risk. Intervention is given to all patients attending foot-risk assessment clinics, regardless
of CPR risk category
a Each potential intervention, custom-made footwear and offloading, infrared digital thermometry and complex
intervention, is considered separately.
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Value-of-information analysis
We conducted a value-of-information (VOI) analysis to determine the value to society of collecting
further information on the effectiveness, costs and cost-effectiveness of alternative clinical
pathway strategies.
To order to establish whether or not future research would be worthwhile, we calculated the
expected value of perfect information (EVPI), which is the difference in net benefit of a decision based
on our current information (evidence) and a decision with perfect information (i.e. no uncertainty).
The situation of perfect information can be thought of as reducing the width of CIs around all of our
model parameters to zero. We estimated the EVPI summed across the potential DFU population in
NHS Fife and for a time period during which we expect this treatment strategy to remain the ‘gold
standard’. In our analysis, we assumed that a reasonable time period for estimating the VOI would
be 10 years. We also assumed that the number of patients in the NHS Fife SCI-Diabetes data set
would be the number of eligible patients over a 10-year period (26,086 patients over 8 years in
NHS Fife SCI-Diabetes, and hence 3261 patients per year). This equates to an ‘effective population’
(e.g. discounted population) of 15,239 patients, or 1524 patients per year, eligible in Fife. If the EVPI
for the population is greater than the costs of carrying out the additional research, then carriyng out
this research is potentially cost-effective. To determine what type of new evidence would be most
valuable, we calculated the expected value of partial perfect information (EVPPI) for parameters of
interest. Owing to the non-normal distribution of NMB, we estimated the VOI using a non-parametric
simulation approach.141
Results
Custom-made footwear and offloading
Table 29 presents the results of the economic model in which patients are monitored with the CPR and
treated with custom-made footwear and offloading. The results suggest that, in this scenario, treating
all patients with special footwear is the most cost-effective strategy.
Digital infrared thermometry
Table 30 presents the results of the economic model in which patients are monitored with the CPR and
treated with digital infrared thermometry. The results suggest that, in this scenario, treating all patients
with digital thermometry is the most cost-effective strategy.
TABLE 29 Base-case results for patients treated with custom-made footwear and offloading
Model outcomes
over 20 years
Expected
cost
Expected
QALYs
Incremental
costs
Incremental
QALYs
Incremental
ICER
Incremental
mean NMB
(WTP= £20,000)
Current practice £290 6.791 – – – –
Monitoring every 2 years £423 6.804 £133 0.013 Extendedly
dominated
£120.39
Monitoring annually £520 6.805 £230 0.014 Extendedly
dominated
£43.16
Monitoring every 6 months £708 6.805 £418 0.014 Extendedly
dominated
–£134.25
All patients treated £999 6.865 £709 0.074 £9615 £765.91
WTP, willingness to pay.
Extendedly dominated: of a treatment, one with an ICER that is higher than the ICER of the next most effective alternative.
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Complex interventions
Table 31 presents the results of the economic model in which patients are monitored with the CPR and
treated with complex interventions. It can be seen that the expected costs of the different strategies
with complex interventions are higher than for the others, but with no advantage in QALYs. As a result,
at a willingness to pay of £20,000, current practice is the preferred option.
Probabilistic sensitivity analysis
Cost-effectiveness planes
Figures 21–23 are graphical illustrations of the uncertainty surrounding the ICERs produced from a
1000-iteration of a Monte Carlo simulation. All three simulations suggest that there is considerable
uncertainty surrounding the QALYs associated with each treatment strategy; however, there is
comparatively less uncertainty around the total costs. Figure 23 shows that treating all with complex
interventions is likely to have a significantly higher total cost than other treatment strategies.
TABLE 30 Base-case results for patients treated with digital infrared thermometry
Model outcomes
over 20 years
Expected
cost
Expected
QALYs
Incremental
costs
Incremental
QALYs
Incremental
ICER
Incremental
mean NMB
(WTP= £20,000)
Current practice £290 6.791 – – – –
Monitoring every 2 years £386 6.807 £97 0.016 Extendedly
dominated
£231.19
Monitoring annually £481 6.809 £191 0.018 Extendedly
dominated
£161.29
Monitoring every 6 months £668 6.809 £370 0.018 Extendedly
dominated
–£12.01
All patients treated £381 6.886 £92 0.095 £967.91 £1801.86
WTP, willingness to pay.
Extendedly dominated: of a treatment, one with an ICER that is higher than the ICER of the next most effective alternative.
TABLE 31 Base-case results for patients treated with complex interventions
Model outcomes
over 20 years
Expected
cost
Expected
QALYs
Incremental
costs
Incremental
QALYs
Incremental
ICER
Incremental
mean NMB
(WTP= £20,000)
Current practice £290 – – – – –
Monitoring every 2 years £624 6.801 £334 0.011 £29,618 –£108.61
Monitoring annually £729 6.802 £439 0.012 Extendedly
dominated
–£196.51
Monitoring every 6 months £922 6.802 £632 0.013 Extendedly
dominated
–£379.45
All patients treated £4699 6.857 £4410 0.066 £74,805 –£3094.17
WTP, willingness to pay.
Extendedly dominated: of a treatment, one with an ICER that is higher than the ICER of the next most effective alternative.
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Cost-effectiveness acceptability curves
Figures 24–26 show the probability that each treatment strategy is considered cost-effective, compared
with the alternatives, for a range of thresholds of willingness to pay for a single QALY gain. Figures 24
and 26 show considerable uncertainty surrounding which intervention is most likely to be deemed
cost-effective, with no clear strategy producing the greatest probability at a willingness-to-pay threshold
of £20,000 per QALY gained. Only in the case of digital infrared thermometry (see Figure 25) does the
treat-all strategy emerge as having the greatest probability of being cost-effective, although, even
for this intervention, the CEAC suggests a probability of just over 30% that this strategy is the most
cost-effective at a willingness-to-pay threshold of £20,000 per QALY.
One-way sensitivity analysis
One-way sensitivity analysis assessed the impact on cost-effectiveness of varying our chosen willingness-
to-pay threshold from £20,000 per QALY gained (as recommended by NICE) to £13,000 per QALY gained
(Claxton et al.142). This had the effect of reducing the cost-effectiveness of custom-made footwear and
offloading (from an incremental NMB of £766 to £250) and of infrared thermometry (from an incremental
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FIGURE 21 Distribution of incremental costs and QALYs associated with custom-made footwear and offloading.
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FIGURE 22 Distribution of incremental costs and QALYs associated with digital infrared thermometry.
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NMB of £1802 to £1139). The use of complex interventions is still considered not to be cost-effective.
There was no change in the relative position of the cost-effectiveness of screening intervals.
Value of information
The VOI analysis is conducted for the three potential interventions separately, as these are mutually
exclusive. In all VOI analyses that follow, the most cost-effective option for each intervention is
considered against current practice.
The EVPI per patient affected by the decision to recommend treatment based on a strategy of treating
all with custom-made footwear and offloading is estimated to be £9226.
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FIGURE 23 Distribution of incremental costs and QALYs associated with complex intervention.
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Based on our assumptions of an effective population of 1218 eligible patients per year in NHS Fife
and at a willingness-to-pay threshold of £20,000 per QALY gained, this equates to an EVPI of £11.2M
per year. (Figure 27 shows how this varies with willingness-to-pay threshold.) If we assume that the
period of time for which this treatment strategy would be expected to be considered ‘gold standard’ is
10 years, then the estimated total population EVPI is £112.4M over a 10-year period for the NHS Fife
diabetes mellitus population.
The EVPPI suggests that the majority of the value of reducing parameter uncertainty in our model
would be in reducing uncertainty around the parameters obtained from our survival analysis of NHS
Fife SCI-Diabetes data (Figure 28). This suggests that the uncertainty having the greatest impact on our
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FIGURE 25 The CEAC for digital infrared thermometry.
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decision problem is related to the number of events (ulceration, amputation, death) in the NHS Fife
SCI-Diabetes data set.
Digital infrared thermometry
The EVPI per patient affected by the decision to recommend treatment based on a strategy of treating
all with digital infrared thermometry is estimated to be £8533.
Based on the same assumptions as above with regard to eligible population, time horizon and
willingness to pay for QALY gains, we estimate an EVPI of £10.4M per year and of £104M over
10 years. Figure 29 illustrates how this EVPI varies with willingness-to-pay threshold.
The EVPPI suggests that the majority of the value of reducing parameter uncertainty in our model
would be generated from reducing uncertainty around the parameters obtained from our survival
analysis of NHS Fife SCI-Diabetes data (Figure 30).
Complex intervention
The EVPI per patient affected by the decision to recommend treatment based on a strategy of treating
all with complex interventions is estimated to be £8968.
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FIGURE 27 The EVPI (population, £), based on custom-made footwear and offloading.
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Based on the same assumptions as above with regard to eligible population, time horizon and willingness
to pay for QALY gains, we estimate an EVPI of £10.9M per year and of £109M over 10 years. Figure 31
illustrates how this EVPI varies by willingness-to-pay threshold.
The EVPPI suggests that the majority of the value of reducing parameter uncertainty in our model would
be generated from reducing uncertainty around the parameters obtained from our survival analysis of
NHS Fife SCI-Diabetes data (Figure 32).
Across all three interventions available, the VOI analysis suggests that there is value in reducing
the uncertainty related to the decision problem (i.e. whether or not it is cost-effective to use this
treatment strategy). In terms of the specific groups of parameters we looked at, there was value in
reducing the uncertainty relating to all of them, but reducing the uncertainty relating to the NHS Fife
SCI-Diabetes data had the greatest value across all three analyses. This suggests that increasing our
knowledge of the epidemiology of DFUs, in terms of how patients move between risk states and how
often events occur will allow us to better capture the true cost and outcomes associated with our
proposed treatment strategy, and allow us to minimise the health losses from choosing the wrong
treatment strategy.
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FIGURE 29 The EVPI (population, £), based on infrared digital thermography.
0
500
1000
1500
2000
2500
3000
4000
3500
Costs Utilities SCI-Diabetes
data set
Thermometry
intervention
E
V
P
P
I p
er
 p
at
ie
n
t 
(£
)
Parameter group
FIGURE 30 The EVPPI per patient (£), based on digital infrared thermometry.
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Discussion
Summary of principal findings
l Our analysis of the NHS Fife SCI-Diabetes population that attend foot clinics suggests that patients’
DFU risk does not readily change over time.
l Despite the significant uncertainty, our health economic model suggests that preventative DFU
interventions have the potential to be considered cost-effective.
l The CPR developed in this study can be used as a tool for identifying patients who are suitable
for treatment.
In this chapter, we have (1) undertaken a review of published cost–utility models for the prevention of
DFUs; (2) used this information, alongside input from clinical experts, to develop a health economic model
capable of estimating the cost-effectiveness of DFU prevention treatments and alternative monitoring
frequencies with a CPR; and (3) estimated the value of further research and suggested where this
research should focus. Our results suggest that preventative treatments for DFUs have the potential to
be considered cost-effective at a willingness-to-pay threshold £20,000 per QALY gained.
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Our model included the use of annual monitoring with the CPR, as recommended by NICE and SIGN.
We also looked at the impact of biannual monitoring and monitoring every 6 months; however, our
model did not look at the strategy of monitoring only high-risk patients as often as every 1–2 months
or monitoring patients of immediate concern every 1–2 weeks. As noted Chapter 3, Methods, our
design of the economic model was influenced by the results of the survival analysis of the NHS Fife
SCI-Diabetes data. Analysis of these data suggests that patients do not readily change risk status
(i.e. move from low to moderate risk or from moderate to high risk). Indeed, over the 8 years for
which we had data, just 5% of individuals changed risk status; therefore, it is unlikely that increasing
the monitoring frequency from 6-monthly (which is included in the model) to, for example, every
1–2 months or every 1–2 weeks, will capture enough additional events to offset the additional
monitoring costs.
Further research aimed at predicting which patients will change risk status is warranted, as these are
the patients best placed to benefit from preventative treatment. Further research, for example in the
form of developing a prognostic model capable of predicting the patients whose risk status is likely to
change, rather than those who are likely to develop ulceration, would be welcome.
In conducting an economic evaluation of the introduction of the CPR, we needed to compare the effect
of directing therapy with and without the CPR. In the model, we have assumed that if we do not have
the CPR we have two options: give no-one the intervention(s) or give everyone the intervention(s).
This is rather simplistic given that some kind of risk assessment currently takes place;28 however,
given the multiple combinations of treatment strategies across both the NICE and the SIGN guidelines,
in terms of risk factors, methods of assessment, and interventions and monitoring frequencies, it
would have been challenging to define a specific strategy including a CPR that could constitute
‘current practice’. Hence, our comparison with ‘no CPR’ allows us to estimate the potential value
of the new CPR and the value of further research into the new CPR.
In our analysis, we investigated the impact of introducing a CPR based on three risk factors. Current
guidelines on how patients should be assessed for risk involve a greater range of potential risk factors
(NICE: insensitivity to a 10-g monofilament, absence of pedal pulses, presence of significant structural
abnormality, neuropathy disability score (> 5), history of ulceration, more formal assessments using a
biothesiometer, Doppler ultrasound and/or an ABI test; SIGN: insensitivity to a 10-g monofilament,
limb ischaemia, ulceration, callus, infection or inflammation, deformity, gangrene, amputation, Charcot
arthropathy). Given the range of potential risk factors suggested by NICE and SIGN, and the lack of
clarity about the adherence of clinicians to any particular strategy, it was not possible in our study
to include the use of a current prognostic model to identify patients at risk of DFUs, with which we
could compare the new CPR model developed in this study. Further research aimed at comparing
different prognostic models would be welcome. Treating all patients attending a foot screening clinic
is not currently recommended by the NICE or the SIGN guidelines; however, considering a ‘treat
all patients attending foot screening’ strategy, and hence not using a CPR, allows us to distinguish
between the value of introducing the CPR and the value of the interventions themselves.
The meta-analysis and economic modelling of potential preventative treatments suggests that custom-
made footwear and offloading and digital thermometry have the potential to be cost-effective; however,
given that patient adherence to both of these treatments is unknown and likely to be a critical factor,
further research into patient acceptability of and adherence to these treatments would be welcome.
Our VOI analysis suggests that reducing the uncertainty about the epidemiology of DFUs is likely
to produce the greatest value. This may be partly explained by the small number of ulceration and
amputation events in this data set and, hence, the associated uncertainty. To reduce this uncertainty,
a study similar to the one presented in this chapter could be run using diabetes mellitus register data
for the whole of Scotland or the UK, and for longer follow-up periods, to reduce the uncertainty
related to the number of events.
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Our VOI analysis also suggested that there was little value in further research relating to evidence on
the treatment effect of interventions; however, it should be stressed that only one form of uncertainty
is captured by the VOI analysis, namely the uncertainty related to the parameters estimated and used
in the health economic model (i.e. the CIs around the estimate). The analysis does not capture the
uncertainty related to issues such as publication bias and heterogeneous populations in the original
studies that informed the treatment effect estimates. Hence, the decision uncertainty relating to the
treatment effect in our VOI analysis (and the value of reducing this) is likely to be an underestimate.
It should also be noted that in our analysis the treatments were regarded as mutually exclusive; however,
in reality a combination of these treatments could be offered to patients. Our analysis also assumed that
treatment effect remained constant across level of patient risk, as the relative effectiveness of these
treatments in patients with different levels of risk is unknown. In addition, the effectiveness of any of
these treatments used at alternative monitoring frequencies is also unknown; hence, the effectiveness
of combined treatments (for specific risk groups, and used at alternative frequencies) should be explored
further. To address the uncertainty surrounding treatment efficacy, a RCTwould be required; however,
we found that, in an at-risk population of (approximately) 26,000, few patients changed risk status, or
developed ulceration, or received amputations over an 8-year follow-up period. Given this, the size,
duration and cost of a RCT in this area, and what it would add compared with a large observational
study (based on routine data sources), would need to be considered carefully.
Strengths of this study
The NHS Fife SCI-Diabetes data set was obtained from monitoring patients in routine clinical practice.
This has given us an insight into the treatment of patients in a ‘real-world’ setting. The data set contained
> 26,000 patients followed up over an 8-year period. This allowed us to assess empirically how risk of
ulceration changes over time.
As part of this study, we developed a de novo health economic model (guided by the advice of clinicians
involved in the prevention of DFUs) capable of including both the use of a CPR and the costs and
outcomes associated with alternative clinical pathways.
Limitations of this study
The NHS Fife SCI-Diabetes data set was obtained by monitoring patients in routine clinical practice
(i.e. it was not designed to be used for research); therefore, considerable data cleaning and manipulation
was required. Despite this, issues of missing data remained in the data set. In particular, patients’ results
for the three predictive tests included in the CPR were frequently missing. Furthermore, the project
team’s clinicians suggested that amputation events may be under-recorded. This is because patients who
progress to the stage of requiring an amputation may no longer be seen by the foot care team and, as a
result, their data are not captured by risk assessment monitoring. For each variable in our analysis, we
have chosen what we believe to be the most appropriate form of imputation – that is, what we believe
is most likely to produce a consistent and plausible record of patient monitoring, reflecting what is most
likely to have happened in clinical practice.
Costs of ulceration were identified from the literature.131 As patients may be treated either in an
inpatient setting or in an outpatient setting, our cost of ulceration is a weighted average of the two
costs, assuming that 90% of patients are treated in an outpatient setting (based on clinical expert
opinion). Amputation costs were weighted according to which type of amputation was required.
Based on the literature, we assumed that two-thirds of amputations that are required are minor
and that one-third are major.143 There was also some uncertainty about the costs of interventions.
Digital infrared thermometry involves a relatively inexpensive device; however, because of the lack of
data on its use in routine practice, it is not clear what other resource may be required to implement
this treatment strategy (e.g. contacting nurses to report high temperatures and to seek further advice).
The precise elements of a ‘complex intervention’ vary across the UK, with no single agreed-on approach
or clarity about the best types of specialist care required; therefore, our estimate of resource use for
complex intervention may differ from that delivered in practice across the UK.
ECONOMIC MODEL: EVIDENCE-BASED PATHWAY
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The diabetes mellitus population used in our analysis was a mix of an incident and prevalent population.
This was justified on the grounds that any new monitoring policy would probably be introduced for all
patients, rather than only for new patients; however, it should be noted that we do not explicitly model
the process of patient entry and we take the estimates from the survival analysis as representing a
static cohort. Although this is not strictly technically correct, we believe that this is a reasonable
compromise to simplify the modelling.
Our choice of low, moderate and high risk of DFUs was based on the predicted probabilities of DFUs
from the CPR and was agreed in consultation with the wider project team; however, it should be noted
that, based on our definitions of risk, the proportion of patients classified as high risk is lower than
that found in other studies. This may have implications for our findings regarding the lack of movement
between risk states over time. Further work on this model should include investigating the impact on
cost-effectiveness of alternative definitions of risk according to the CPR; however, we do not believe
that this is likely to significantly alter our overall results owing to the significant uncertainty in the
epidemiology of the NHS Fife SCI-Diabetes data, the true costs of interventions and the effectiveness
of potential interventions.
Implications of our findings
l The finding that patients’ DFU risk status does not change readily suggests that a move towards
less frequent risk monitoring of at-risk patients would be acceptable.
l As the proportion of patients whose DFU risk status changes over time is low (5%), but the costs
and health outcomes associated with this group are significant, further work to predict those
patients whose risk score is most likely to change would be welcome.
l There is a need for further research into the effectiveness and acceptability of and adherence to
potential preventative DFU interventions.
l There is a need to better understand what constitutes ‘current practice’ in DFU prevention across
the UK, in terms of risk assessment methods (risk factors and how they are assessed), interventions
offered and adherence to clinical guidelines.
Conclusion
Our analysis suggests that DFU treatments have the potential to be cost-effective at a willingness-to-
pay threshold of £20,000 per QALY gained. In the case of custom-made footwear and offloading and
digital infrared thermometry, our results suggest that treating all patients attending routine foot
monitoring is likely to be considered the most cost-effective strategy, with the additional cost of these
strategies compensated for by the additional increase in QALYs. In the case of complex interventions,
our results suggest that these treatments are not likely to be considered cost-effective, regardless of
monitoring frequency. This is because of the significant cost associated with complex interventions.
Our probabilistic sensitivity analysis suggests that there is considerable uncertainty surrounding which
treatment strategy is most likely to be considered cost-effective at our willingness-to-pay threshold.
This is driven primarily by the uncertainty surrounding the QALY gain associated with each treatment
strategy. Our VOI analysis suggests that there is value in conducting further research in this area and,
specifically, in reducing the uncertainty about how many patients experience ulcers, require an
amputation or die over a given time horizon.
Given our findings, we believe that preventative treatments for patients at risk of DFUs have the
potential to be cost-effective, but that significant uncertainty remains surrounding these findings;
therefore, further research would need to be undertaken before we could recommend an optimal
treatment strategy.
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Chapter 7 Overall discussions
It is widely believed that stratifying people with diabetes mellitus according to their risk of developinga foot ulcer and providing a suitable programme of care will reduce the incidence of foot ulcers and,
ultimately, reduce diabetes-related LEA. The absence of robust empirical evidence of such a direct effect
has overshadowed the considerable efforts of those providing foot-related health care worldwide.
For risk assessment programmes to be effective, simple clinical assessments that can be used by
health-care staff with varying degrees of skill are needed.103 The CPR developed and validated by
our group is based on only three risk factors that can be assessed cheaply, easily and accurately and
used to identify those at risk of ulceration, especially those at low risk (i.e. the vast majority of people
with diabetes mellitus). The use of CPR in clinical practice could simplify current approaches to risk
assessment, which could reduce the time spent testing, the costs associated with expensive tests and
the time needed to train staff to perform more complex diagnostic procedures.10–12,144
To our knowledge, the time between foot risk assessments has not been subject to evaluation before.
By using data from the electronic health record (EHR) of people with diabetes mellitus in one health
board area in Scotland, we are able to show that the foot ulcer risk status of most people with
diabetes mellitus does not readily change over time, and a move towards less frequent risk assessment
is indicated for the majority. Because the proportion of patients in the low-risk group whose ulcer risk
status changed over time was small (5%), and because of the significant costs and health outcomes
associated with this group, further work to improve the accuracy with which we can identify which
patients’ risk score is most likely to change is merited. The use of data from EHRs to answer research
questions is often compromised by missing data;45 therefore, improving the recording of patients’ test
results and the number of important events in the SCI-Diabetes data set and EHR more generally
would be of value.
Clinical prediction rules by themselves do not automatically produce improvements in patients’
outcomes, and risk assessment in the absence of effective treatments is not recommended. The large
number of SRs aiming to identify effective interventions to prevent foot ulceration did not reach clear,
reproducible conclusions about the effect of treatments. As most of the researchers undertaking these
summaries lacked sources of funding, this is possibly unsurprising. The absence of meta-analyses of
data in the SRs may also have contributed to the opacity. It was by pooling data that we were able to
detect effective interventions for reducing the incidence of foot ulcers.
The trials of digital infrared thermometers showed that these are effective in reducing foot ulcers
if activity is reduced when foot temperature increases. It is to be hoped that these effects can be
replicated in currently ongoing trials. Assessing trial populations’ levels of compliance with advice to
rest will also be important.
The marked difference in effect in the subgroup analysis between data from two trials of footwear
and offloading devices that involved mostly people with no history of ulcers and data from another
four trials that included people who had previously developed ulcers is interesting. It seems reasonable
to suppose that the ability to influence patient outcomes will diminish as the risk of foot ulceration
increases. During the process of developing the CPR we found that those with a history of foot
ulceration are at much greater risk of ulceration than those either with a lack of sensation or in
whom pedal pulses are absent. If an agreement to share data among the investigators of the trials of
footwear and offloading could be reached, a comparison of outcomes from subgroups of people in
these six trials in an IPD meta-analysis and in the 10 ongoing studies could bring further clarity
without incurring the high cost of a new trial.
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The fact that individual trials of complex interventions failed to show beneficial effects until data were
pooled in a meta-analysis does support the opinion of others that trials of specialist foot care need to
recruit very large samples of patients.13 An IPD meta-analysis could also help to identify the benefits of
specialist foot centres; however, the two largest trials are among the oldest that we reviewed, so it
might not be possible to obtain the data.
There is a need to better understand what constitutes ‘current practice’ in foot care programmes
across the UK in terms of risk assessment methods (risk factors and how they are assessed),
interventions offered and level of adherence to clinical guidelines.
Education by itself appears to be ineffective in reducing foot ulcers, and the small trials of antifungal
nail lacquer and elastic stockings not only lacked evidence of effectiveness but seemed to us to lack
biological plausibility.
In considering whether or not there is potential worth in undertaking further research, particularly
a RCT, for further research is needed into the effectiveness and acceptability of and adherence to
potential preventative DFU interventions. However, it is clear that improving the recording of patient
data in EHRs will bring benefits to researchers and, ultimately, the public.
The economic evaluation showed that the DFU treatments identified by the SR have the potential to
be cost-effective, but uncertainty in model parameters and other elements (e.g. patient acceptability of
and adherence to interventions) prohibits a strong conclusion.
OVERALL DISCUSSIONS
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Chapter 8 Overall conclusions
Strengths and weaknesses of our research
The strengths of this research arise mainly from our access two large data sets: the PODUS data set
that was used to develop and validate the CPR and a SCI-Diabetes data set that was used to assess
the transitional probabilities of people with diabetes mellitus moving from one risk state to another.
The weaknesses of the research relate to the large numbers of missing data in the SCI-Diabetes data
set and the poor quality of some of the RCTs in the SR. It is also possible that the decision to separate
the comparators by intervention may have modified our VOI analysis. An approach in which all
interventions are considered together may well make RCTs more important in the VOI analysis, as
they would inform the differences between preventative interventions and allow any interactions
to be identified.
Overall conclusions
This research has led to development and validation of a simple CPR for use in clinical practice and an
analysis of EHR data to show that the risk of foot ulceration does not change over a 10-year period for
most people with diabetes mellitus. Our overview found that, although there are a large number of SRs
of preventative interventions for foot ulceration, clear, reproducible conclusions were rare. Our new SR
of trial data has allowed the identification of effective preventative interventions for foot ulceration
in diabetes mellitus; digital thermometry and meta-analyses revealed the potentially beneficial effect
of complex interventions and custom-made footwear and offloading. However, remains uncertainly
remains about the clinical effectiveness and cost-effectiveness of interventions to prevent foot ulceration
in diabetes mellitus.
We make the following recommendations for future research:
l There is a need for further research into the effectiveness and acceptability of and adherence to
potential preventative DFU interventions.
l There is a need to better understand what constitutes ‘current practice’ in DFU prevention across
the UK in terms of risk assessment methods (risk factors and how they are assessed), interventions
offered and adherence to clinical guidelines.
l There is a need for more complete EHR data to be collected, particularly on those parameters
relating to foot disease in diabetes mellitus.
l We recommend that researchers share their trial data for IPD analyses to explore subgroup effects
for interventions.
l Further research using the new CPR is merited, as is treating all patients attending a foot screening
clinic with a ‘treat-all patients attending foot screening’ strategy compared with care using a CPR.
l The effectiveness of combined treatments for specific risk groups and used at alternative
frequencies should be explored further. To address the uncertainty surrounding treatment efficacy,
a RCT would be required; however, the size, duration and cost of a RCT in this area require
careful consideration.
l Further research aimed at comparing different prognostic models would be welcome.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to make
better use of information from people’s patient records, to understand more about disease, develop
new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to
protect everyone’s privacy, and it’s important that there are safeguards to make sure that it is stored and
used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives
You can find out more about the background to this citation here: https://understandingpatientdata.org.uk/
data-citation.
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Appendix 2 Protocol changes (Scotland A –
Research Ethics Committee)
Substantial amendments
Objective II: the optimal monitoring interval
We will also investigate how frequently patients should be monitored. Three of the PODUS data sets
include time-to-ulceration, monofilament and pulses data. We can use these data to provide estimates
for the health economic model regarding optimal frequency of modelling.
Substantial amendment 1 (in italics and specific request underlined)
We suspect that the very small proportion of ulcers found in the Crawford dataset (n = 23) was due to the
short length of follow-up, which was only 1 year, whereas in the other datasets most ulcers develop more than
1 year post baseline tests. We are therefore planning to follow up this cohort of patients via their hand held
podiatry records to increase the length of follow-up in the Crawford (10) dataset and estimate that another
100 patients with ulcer will be identified.
Our favourable opinion from Scotland A REC (reference 16/SS/0213) approved the follow up of people with
diabetes who gave consent to their participation in the cohort study by Crawford (2011) using the routinely
collected data on SCI Diabetes and hand-held podiatry notes. The REC A specified that the project researchers
must first of all check the survival of those who gave consent in 2006/2007 in order to ensure that no deceased
patients relatives were contacted about the follow up study. Only then could the surviving participants be
contacted to obtain consent to follow up. After confirmation from the podiatry department that patients hand
held records are archived for at least 7 years after death we now seek approval to collected foot-related follow up
data from the podiatry notes of those participants who have deceased since being recruited to the original cohort
study. This amendment to our protocol has been recommended by our Study Steering Committee on 15th March
2017 and is justified as a result of the known association between foot ulceration and death in those with diabetes.
However, we have now had confirmation by the NHS Tayside MCN data facilitator that 45% of the original
cohort of patients has died in the intervening period and this will greatly reduce the statistical power of our
analysis. We now seek approval to collect foot ulcer data for those study patients who have deceased.
Substantial amendment 2 (in italics and specific request underlined)
In order to strengthen our analysis of the optimal risk assessment (monitoring) frequency we wish to obtain all
NHS Fife patients’ foot screening data from SCI Diabetes over a 10 year period. These data will be anonymised
by staff at the Health Informatics Centre at the University of Dundee (where NHS Fife routinely collected data
is stored). We have discussed the need for Caldicott approval [Public Benefit Privacy Panel (PBPP)] with the
NHS Fife Information Governance Advisor and attach her response to our enquiry for PBPP approval.
We can use these data to provide hazard ratios, estimates of the rates of ulceration, and estimates of sensitivity
and specificity of the CPR and other risk assessment tools (e.g. NICE and SIGN guidelines) calculated for
different time periods as required by the health economic model. The NHS Fife SCI Diabetes routinely collected
data will be used by the project statisticians and health economists to calculate the transitional probability
of a patient transitioning from one risk category to another and to a state of foot ulceration. We have been
advised by NHS Fife data manager the numbers of people with diabetes who have received foot risk assessments
are as follows:
2007 n = 10,405
2008 n = 10,829
2009 n = 12,413
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2010 n = 10,949
2011 n = 12,635
2012 n = 13,003
2013 n = 13,832
2014 n = 14,496
2015 n = 13,549
2016 n = 4249
The identification of the optimal screening interval base case will require an estimate of the potential
effectiveness and cost-effectiveness of the clinical risk score calculated during patients’ annual reviews
based on the PODUS time-to-event data and the NHS Fife SCI-Diabetes data. This corresponds to the
intent to develop a simple-to-use screen that can be used during routine assessments for people with
diabetes mellitus. We will then estimate the rate at which the risk score varies and will try to estimate
its effectiveness when applied more frequently at 6-monthly intervals and less frequently at biennial
intervals using a hidden Markov chain analysis.
Approval granted 17 October 2017 (REC reference: 16/SS/0213/AM01).
Substantial amendment 2 (in italics and specific request underlined)
In accordance with our favourable opinion from Scotland A REC we have now contacted 649 participants by
post and 243 gave written consent for the researchers to access their health records to obtain follow up data
relating to foot ulcerations. We now seek another substantial amendment to send out a second and third
invitation to participate in the follow up study for those who have not responded.
Approval granted 23 July 2018 (REC reference: 16/SS/0213/AM02).
Objective III: an overview of the evidence of the effectiveness of simple
and complex interventions (structured care) to prevent foot ulceration in
people with diabetes mellitus
Substantial amendment 3 (in italics and specific request underlined)
We also intend to conduct a search of electronic databases for individual randomised controlled trials which
meet the following eligibility criteria.
Participants and target condition
People of any age with a diagnosis of diabetes either type 1 or type 2.
Types of interventions
Simple interventions such as insoles or bespoke footwear, education packages tailored for patients or health
care professionals or complex interventions such as care from a specialist multidisciplinary team, used alone
or in combination will be considered for inclusion in the review.
Types of comparisons
We will include simple or complex interventions used alone or in combination and standard care comparators.
Types of outcomes
A foot ulcer has been defined as a full thickness skin defect that requires more than 14 days to heal.
Data collection
Two reviewers will screen review titles and abstracts to identify potentially relevant literature. They
will then screen the full text of reviews and RCTs deemed to be potentially relevant. Disagreement
will be resolved by discussion with a third author. Data will be extracted into a review-specific data
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extraction tool by a lead reviewer and checked by a second who will be unaware of the findings of the
lead reviewer. A second data extraction sheet and quality assessment tool will be created to capture data
from RCTs identified by our search for primary studies and an assessment of bias will be performed using the
following items:
1. Adequate sequence generation? (Yes/no.)
2. Allocation concealment? (Yes/no.)
3. Were participants and outcome assessors blind to the allocation? (Yes/no.)
4. Were incomplete outcome data adequately assessed? (Yes/no.)
5. Are reports of the study free of selective outcome reporting? (Yes/no.)
6. Free of any other bias? (Yes/describe the risk of bias.)
Amendment acknowledged by the CSO [Chief Scientific Officer] in feedback dated 30 January to the interim
report of 1 January 2018.
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Appendix 3 Clinical prediction rule
PODUS 1
PODUS 2015 was a NIHR HTA-funded project that aimed to identify the predictors of foot ulcer in
people with diabetes mellitus and to develop and validate a predictive model. This was published as a
NIHR monograph in the Health Technology Assessment journal.15 Details of the methodology and results
of that analysis that pertain to PODUS 2020 (a CPR based on the predictive model) are given here,
with emphasis on the predictor selection process for PODUS 2015 and the consequent methodological
choices made for PODUS 2020.
In PODUS 2015, we obtained IPD from eight studies.20–27 Another data set (i.e. Leese et al.28) was
available via a Safe Haven facility. A 10th data set (i.e. Boyko et al.29) could not be used directly by the
PODUS 2015 researchers, although we could request the results of the analyses of this data set, and
so we used it as an externally held validation data set. These 10 studies were identified through a SR
encompassing the stages of literature searching and critical appraisal using a bespoke tool, as at the
time no published critical appraisal tool for prognostic studies was available.15
In PODUS 2015, we had a large number of potential predictors. We knew that using data-driven
methods to select predictors can easily result in spurious findings that cannot be replicated in further
studies. There is a notable body of research advising against such practices.45,145 This ruled out methods
such as stepwise selection of predictors, or selecting predictors with small p-values in univariate
analyses for inclusion in multivariable models. We therefore needed our own criteria on which to base
our choice of predictors.
To maximise the number of data we could use, we used only predictors that had been collected in
at least three of the PODUS data sets. To aid interpretation, we required that predictors had been
consistently defined across studies, or could be recoded as such. We also required that the extent of
clinical heterogeneity did not rule out meta-analysis. Twenty-two predictors met the first two criteria
at a first pass through the data sets: age, sex, body mass index, smoking, height, weight, alcohol intake,
HbA1c level, insulin regime, duration of diabetes mellitus, eye problems, kidney problems, insensitivity
to monofilament, absence of pedal pulses, tuning fork, biothesiometer, ankle reflexes, ABI, peak plantar
pressure, prior ulcer, prior amputation and foot deformity.
The above predictors were presented as forest plots to the whole PODUS 2015 group, which comprised
methodologists and clinicians. Many predictors were dropped at this stage. For example, kidney problems
was removed from the primary analysis as in some studies it had been defined as nephropathy and in
others we had used estimated glomerular filtration rate as a proxy, and this may or may not have been
adequate.146 We were also in favour of having fewer rather than more predictors so that we could use
as many data as possible. In general, there was an inverse relationship between the number of predictors
we chose and the number of studies we could include; if we added a predictor to the model, but some of
the studies did not include that predictor, we had to remove those studies from the analysis. We were
aware of emerging research on the handling of studies with predictors entirely missing in meta-analysis
of IPD, but the methodology was new and is still largely untested.147 Only four predictors had been
collected in all 10 studies, namely age, sex, duration of diabetes mellitus and prior ulcer.
Six variables were chosen for inclusion in the primary model in PODUS 2015: age, sex, duration of
diabetes mellitus, insensitivity to a 10-g monofilament, absent pedal pulses, and history of ulcer or
amputation. These variables were chosen for clinical plausibility, availability in the data sets and
consistency of definition. Another consideration was ease of collection, with little burden to either the
patient or the podiatrist. Selection was not based on statistical significance; for example, age was
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retained despite not achieving statistical significance in four studies and achieving only borderline
significance in another two studies when looking at forest plots of univariate ORs.
For PODUS 2015, we conducted a two-step meta-analysis, which meant fitting a logistic regression
model in each data set with the six predictors and using the ORs from each study in a random-effects
meta-analysis. We used a two-step method so that we could include, in the second stage, aggregate
data (i.e. log-odds ratios and their variances) derived from the Leese et al.28 data set with over 3000
patients. The Leese et al.28 data set was housed on a different server and so could not be used in a
one-step meta-analysis, although this is the preference of some methodologists.33
Predictor replication in PODUS 2015
The Boyko et al.29 data set was not supplied to the PODUS 2015 team, but a SAS® software program
(SAS Institute Inc., Cary, NC, USA) was sent to the Boyko et al.29 team to be run in the data, and the
analysis results were sent back. The SAS program refitted the logistic regression model using the same
six predictors. This method meant that the Boyko et al.29 team were kept blind to the results of the
PODUS 2015 analyses and the Boyko et al.29 analysis was completely prespecified, and the predictors
were tested in a new data set.
Predictors were considered both predictive and replicated if the Boyko et al.29 ORs achieved statistical
significance and had the same direction as the PODUS 2015 ORs and if the CIs of the PODUS 2015
and Boyko et al.29 ORs overlapped.
We compared the summary ORs from the meta-analysis of estimates from multivariable logistic
regression using the data sets held by the PODUS 2015 researchers with the results of a multivariate
logistic regression conducted in the external Boyko et al.29 data set. The Boyko et al.29 analysis did
not replicate the results of the PODUS 2015 team for three predictors: age, sex and duration of
diabetes mellitus. The effect of age was small and not significant in both the PODUS 2015 and the
Boyko et al.29 data sets, and the estimates had different directions (increasing age in PODUS 2015,
but decreasing age in Boyko et al.29) and were associated with increased ulcer risk (PODUS 2015: OR
1.005, 95% CI 0.994 to 1.016; Boyko et al.:29 OR 0.993, 95% CI 0.977 to 1.009). In addition, age was
not a statistically significant predictor of ulceration in six of the nine studies held by the PODUS team.
The effect of duration of diabetes mellitus was also not replicated, being predictive in the PODUS
analyses and protective in the Boyko et al.29 analyses (PODUS 2015: OR 1.024, 95% CI 1.011 to
1.036; Boyko et al.:29 OR 0.981, 95% CI 0.968 to 0.994). However, it should be noted that the recorded
duration of diabetes mellitus is simply the known duration, and people may have had diabetes mellitus
for years before a diagnosis was made; in addition, the health-care systems in the Boyko et al.29 and
other PODUS data sets differed. The Boyko et al.29 data set was not suitable for testing sex as a
predictor, as the study recruited veterans and 98% of these veterans were male, which is not reflective
of the wider population of people with diabetes mellitus.15 All ORs taken from the Boyko et al.29 data
set and all ORs taken from the PODUS 2015 data sets were adjusted for the predictors specified for
the primary PODUS 2015 model.
The Boyko et al.29 analyses did replicate the PODUS 2015 results for three predictors: monofilament
sensitivity (PODUS 2015: OR 3.184, 95% CI 2.654 to 3.820; Boyko et al.:29 OR 3.489, 95% CI 2.486
to 4.896), pulses (PODUS 2015: OR 1.968, 95% CI 1.624 to 2.386; Boyko et al.:29 OR 2.557, 95% CI
1.220 to 5.361) and history (PODUS 2015: OR 6.589, 95% CI 2.488 to 17.45; Boyko et al.:29 OR 2.979,
95% CI 2.146 to 4.135).15
Therefore, at the end of the PODUS 2015 project, we knew that we had evidence of an association
between foot ulcer outcome and three binary variables in the internal data sets, and that the results
of these three binary variables were similar in external data.
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Crawford et al.21 follow-up study
Comparison of the three-predictor model (monofilament sensitivity, pulses,
history) with the six-predictor PODUS 2015 primary model (monofilament
sensitivity, pulses, history, sex, age and duration of diabetes mellitus)
This appendix compares the PODUS 2015 six-predictor model with the PODUS 2020 three-predictor
model by providing estimates for each study used in the development phase. We also investigated
non-linearity in the two continuous variables from the PODUS 2015 model, namely age and known
duration of diabetes mellitus.
Comparison of the three-predictor with the six-predictor PODUS model
Table 32 shows, for each study, the baseline risk of ulcer at 2 years predicted by the two models in
the case of a hypothetical 65-year-old female patient who has tested negative for monofilament
sensitivity, pulses and history and who was diagnosed with diabetes mellitus 1 month previously.
The three-predictor model comprises monofilaments, pulses and history, whereas the six-predictor
model also includes age, sex and duration of diabetes mellitus.
CHI available
(n = 1188)
CHI unidentif ied
(n = 80)
Duplicates
(n = 5)
CHI identified
(n = 1102)
Deceased
(n = 522)
Alive
(n = 559)
Moved
(n = 20)
Alive/deceased?
Crawford 201121 cohort
(n = 1192)
Data available in podiatry notes
Records checked in deceased
(yes and no)
(n = 178/520; 34.2%)
Outcome in deceased (yes)
(n = 30/520; 5.7%)
Consent refused
(n = 12)
Non-respondents
(n = 225)
Consent given
(n = 322/561; 57.3%)
Total available patient outcomes
(n = 500/1192; 41.9%)
FIGURE 33 Crawford et al.21 follow-up study: flow diagram. CHI, Community Health Index.
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Figure 34 shows the results for insensitivity to a 10-g monofilament and risk of developing an ulcer by
2 years, with the model fitted separately to each study. Estimates in the three-predictor group have
been adjusted for pulses and history and estimates in the six-predictor group have been adjusted for
pulses, history, sex, age and known duration of diabetes mellitus.
Figure 35 shows the results for absence of any pedal pulse and risk of developing an ulcer by 2 years,
with the model fitted separately to each study. Estimates in the three-predictor group has been
adjusted for monofilaments and history and estimates in the six-predictor group have been adjusted
for monofilaments, history, sex, age and known duration of diabetes mellitus.
Figure 36 shows the results for history of ulcer or amputation and association with ulcer by 2 years, with
model fitted separately to each study. Estimates in the three-predictor group have been adjusted for
monofilaments and pulses; estimates in the six-predictor group have been adjusted for monofilaments,
pulses, sex, age and known duration of diabetes mellitus.
Figures 34–36 suggest that the estimates of risk associated with positive results for monofilament
sensitivity, pulses and history vary little between the three-predictor and six-predictor model in each
study. There is, perhaps, greater variation in the estimate of baseline risk (the risk of ulcer at 2 years
when all predictors are test negative, sex is female, duration of diabetes mellitus is ≤ 1 month and age
is 65 years); however, all estimates are comparable.
TABLE 32 Baseline risk of ulcer at 2 years
First author and year of publication Number of predictors Baseline risk (%) 95% CI
Abbott 200220 3 1.7 1.4 to 2.1
Abbott 200220 6 1.3 1.0 to 1.7
Crawford 201121 3 0.5 0.2 to 1.2
Crawford 201121 6 0.3 0.1 to 0.9
Monteiro-Soares 201024 3 5.9 3.3 to 10.3
Monteiro-Soares 201024 6 4.7 2.0 to 10.5
Pham 200025 3 9.6 4.2 to 20.5
Pham 200025 6 5.1 1.8 to 13.7
0.2
Number of predictors (n = 3)
Abbott 200220
Crawford 201121
Monteiro-Soares 201024
Pham 200025
Number of predictors (n = 6)
Abbott 200220
Crawford 201121
Monteiro-Soares 201024
Pham 200025
0.14
0.47
0.34
0.45
0.14
0.48
0.34
0.47
3.44
3.12
0.90
3.09
3.27
2.64
0.91
2.81
2.62 to 4.53
1.24 to 7.84
0.46 to 1.75
1.28 to 7.46
Study Log-odds Standard error OR OR 95% CI
2.49 to 4.30
1.03 to 6.75
0.47 to 1.78
1.12 to 7.06
0.5 1 2 5
1.24
1.14
–0.11
1.13
0.19
0.97
–0.09
1.03
Favours intervention Favours control
FIGURE 34 Results for insensitivity to a 10-g monofilament.
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Figure 37 shows the forest plot for age (per year increase) and association with ulcer by 2 years, with
the model fitted separately to each study. Estimates have been adjusted for monofilament sensitivity,
pulses, history of ulcer or amputation, sex and known duration of diabetes mellitus.
Figure 38 shows the forest plot for sex and association with ulcer by 2 years, with the model fitted
separately to each study. Estimates have been adjusted for monofilament sensitivity, pulses, history of
ulcer or amputation, age and known duration of diabetes mellitus.
Figure 39 shows the forest plot for known duration of diabetes mellitus (per year increase) and association
with ulcer by 2 years, with the model fitted separately to each study. Estimates have been adjusted for
monofilament sensitivity, pulses, history of ulcer or amputation, age and sex.
Investigation of non-linearity
Non-linearity was investigated by using the Box–Tidwell method.148 In brief, this method involves
calculating a new variable from the variable thought to have a possibly non-linear effect. If this variable
is x, the new variable is x × log(x), where the log is the natural logarithm. Both the new and the original
variables are then included in the logistic regression model, and, if the new variable is statistically
significant, then there is evidence of a curvilinear effect. Our two candidate predictors for curvilinear
effects are age and duration of diabetes mellitus. Two models were fitted with all six predictors from
0.1
Number of predictors (n = 3)
Abbott 200220
Crawford 201121
Monteiro-Soares 201024
Pham 200025
Number of predictors (n = 6)
Abbott 200220
Crawford 201121
Monteiro-Soares 201024
Pham 200025
2.25
1.65
1.84
0.33
2.12
1.60
1.78
0.19
0.16
0.49
0.37
0.36
0.16
0.49
0.37
0.38
9.45
5.21
6.29
1.39
8.32
4.96
5.93
1.21
6.91 to 12.93
2.00 to 13.62
3.04 to 12.98
0.69 to 2.82
Study Log-odds Standard error OR OR 95% CI
6.08 to 11.39
1.90 to 12.95
2.87 to 12.25
0.57 to 2.55
0.5 1 2 10
Favours intervention Favours control
FIGURE 36 Results for history of ulcer or amputation.
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Number of predictors (n = 3)
Abbott 200220
Crawford 201121
Monteiro-Soares 201024
Pham 200025
Number of predictors (n = 6)
Abbott 200220
Crawford 201121
Monteiro-Soares 201024
Pham 200025
0.66
1.53
0.22
0.87
0.67
1.44
0.13
0.45
0.14
0.46
0.36
0.39
0.14
0.47
0.37
0.42
1.94
4.60
1.25
2.39
1.96
4.24
1.14
1.58
1.48 to 2.56
1.87 to 11.32
0.62 to 2.53
1.11 to 5.14
Study Log-odds Standard error OR OR 95% CI
1.49 to 2.58
1.69 to 10.65
0.55 to 2.36
0.69 to 3.59
0.5 1 2 10
Favours intervention Favours control
FIGURE 35 Results for absence of any pedal pulse.
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the PODUS 2015 model (monofilament sensitivity, pulses, history, sex, age and duration of diabetes
mellitus) and study as a fixed effect; one model had the Box–Tidwell age-transformed variable, and the
other had the Box–Tidwell known duration of diabetes-transformed variable.
Our tentative conclusion from Tables 33 and 34 and forest plots and the results given Appendix 3
PODUS 2015 is that there is no strong evidence that age is a predictor of ulcer at 2 years. The
evidence of an association with ulcer at 2 years is stronger for duration of diabetes mellitus, but, given
the result in the Boyko et al.29 study, that longer duration was protective against ulcer, this result may
not be generalisable to different settings.
Meta-analyses using three or six predictors
We also present results of meta-analyses using the method described in Chapter 3, where study is
fitted as a fixed effect in a logistic regression, using the four development data sets and either three or
six predictors (Tables 35 and 36).
The three-predictor plus study meta-analysis had a c-statistic of 0.813 (95% CI 0.790 to 0.835). The six-
predictor plus study meta-analysis had a c-statistic of 0.820 (95% CI 0.797 to 0.842). The performance
of the six-predictor model is slightly better, but ease of use of the three-predictor model in a CPR is
much greater. The results of the three- versus six-predictor analyses (see Figures 40–42) do not show
a huge advantage of the six-predictor model; the discrimination and calibration results are similar.
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Crawford 201121
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Pham 200025
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0.25
0.49
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FIGURE 38 Forest plot for sex.
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FIGURE 39 Forest plot for known duration of diabetes mellitus (per year increase).
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FIGURE 37 Forest plot for age (per year increase).
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TABLE 35 Results from a three-predictor plus study meta-analysis. The OR for a given study can be interpreted as the
OR for ulcer at 2 years when all other predictors are test negative
Predictor OR 95% CI
Abbott 200220 0.019 0.016 to 0.023
Crawford 201121 0.007 0.004 to 0.011
Monteiro-Soares 201024 0.023 0.015 to 0.034
Pham 200025 0.029 0.019 to 0.043
Monofilaments 3.00 2.39 to 3.77
Pulses 2.01 1.62 to 2.51
History 7.02 5.39 to 9.14
TABLE 36 Results for a six-predictor plus study meta-analysis. The OR for a given study can be interpreted as the OR for
ulcer at 2 years when all other predictors are test negative
Predictor OR 95% CI
Abbott 200220 0.013 0.010 to 0.017
Crawford 201121 0.005 0.003 to 0.008
Monteiro-Soares 201024 0.015 0.010 to 0.024
Pham 200025 0.021 0.013 to 0.033
Monofilaments 2.78 2.20 to 3.51
Pulses 1.98 1.58 to 2.48
History 6.23 4.76 to 8.16
Sex 1.43 1.15 to 1.79
Age 1.00 0.99 to 1.01
Known duration of diabetes mellitus 1.02 1.01 to 1.03
TABLE 34 Box–Tidwell results for investigation of non-linear effects for known duration of diabetes mellitus (the p-value
for Box–Tidwell duration is 0.15)
Variable OR 95% CI
Duration of diabetes mellitus 1.09 0.10 to 1.20
Box–Tidwell duration 0.98 0.96 to 1.01
TABLE 33 Box–Tidwell results for investigation of non-linear effects for age (the p-value for Box–Tidwell age is 0.22)
Variable OR 95% CI
Age 1.21 0.89 to 1.65
Box–Tidwell age 0.96 0.91 to 1.02
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Clinical prediction rule development: study estimates in the three-predictor
and clinical prediction rule logistic regression models
The development of the CPR involved fitting two logistic regression models with study fitted as a
fixed effect. The first logistic regression used monofilament sensitivity, pulses and history as predictors;
the second used CPR score as a predictor. We conducted random-effects meta-analyses of the study
estimates using the three studies with follow-up at 2 years to obtain an overall estimate of baseline risk.
The Crawford study21 was not used as its follow-up period was 1 year. We tried to obtain longer-term
follow-up (see Figure 33).
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FIGURE 40 Calibration plot for the three-predictor plus study meta-analysis.
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FIGURE 41 Calibration plot for the six-predictor plus study meta-analysis.
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As the CPR score model is a simplified version of the three-predictor model, it was important to check
that the study estimates did not vary much between the two models. Changes in study estimates
between the CPR score model and the three-predictor model would suggest that the CPR score was
not an adequate proxy for monofilament sensitivity, pulses and history; however, Figure 43 suggests
that the study estimates are similar.
Figure 44 suggests that the study estimates are similar; the corresponding ORs are identical to two
decimal places. Meta-analysis of the Abbott et al.,20 Monteiro-Soares et al.24 and Pham et al.25 estimates
from the three-predictor model gives a summary estimate of –3.81 (95% CI –4.04 to –3.58) on the
log-odds scale. The corresponding estimate from the CPR score model is –3.74 (95% CI –4.10 to –3.38)
on the log-odds scale. These estimates give ORs of 0.022 and 0.024, respectively.
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FIGURE 42 Discrimination plot for the three-predictor plus study meta-analysis vs. the six-predictor plus study meta-analysis.
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FIGURE 43 Study estimates from the three-predictor logistic regression and the CPR score logistic regression.
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Survival analysis
The CPR described in Chapter 3 is based on a logistic regression model. Logistic regression models can
be used to model the probability of a binary or a categorical outcome. Survival analysis is a branch of
statistics that can be used to model the time to a binary outcome. Both binary logistic regression and
survival analysis require data on the occurrence or not of an event. Survival analysis also requires the
time until the event occurred or the time until end of follow-up for each patient in whom the event
did not occur.
If a data set has time-to-event data, it is generally preferable to use survival analysis. It is a more
sophisticated model, uses more of the data and has greater statistical power. However, we used logistic
regression for the CPR, as the largest data set,20 constituting 75% of the CPR development data with
> 6000 patients, included outcome at 2 years but not when during that 2-year period the outcome had
occurred, ruling out survival analysis. The other three development studies21,24,25 did include time-to-
event data.
To allow comparison with the logistic regression model underlying the CPR, in particular the regression
coefficients for the three predictors used in the development of the CPR, we present survival analyses
here. We do not emphasise any differences in baseline risk estimates between the CPR logistic regression
model and the survival models because the survival analyses did not include the Abbott et al.20 data set.
The Abbott et al.20 data set was derived from a community-based low-risk patient sample. The Crawford
data set, with > 1000 patients, came from a similar setting, but the Monteiro-Soares and Pham et al.25
data sets came from relatively high-risk secondary care settings. We therefore would not expect the
baseline risk estimates to be similar, given that the proportion of low-risk patients dropped from 92% in
the CPR logistic regression analyses to 66% in the survival analyses.
Methods
In the time-to-event analyses undertaken, the outcome was the first foot ulcer that occurred during
follow-up. Follow-up is defined as the time from the date of recruitment into a study until the date
of the first foot ulcer. If no foot ulcer occurs, then follow-up is censored at the date of the last
appointment or the end date of the study, whichever occurs first, or at the date of death of the patient.
Hazard ratios for the predictors were derived using two different statistical techniques for time-to-event
analysis. Royston–Parmar flexible parametric survival analysis methods were used for the main analyses,
because this statistical technique includes the baseline hazard and baseline cumulative hazard functions
in the progression to ulceration during follow-up.148,149 The more common Cox proportional hazards
regression was used in sensitivity analyses; this modelling technique does not make any assumption
about the shape of the underlying hazard function and, thus, leaves the baseline hazard rate unspecified.
The proportional hazards assumption was checked for each predictor by using statistical tests and
graphically examining log-minus-log plots and scaled Schoenfeld residuals on functions of time.
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FIGURE 44 Random-effects meta-analysis of the baseline risk in the three studies with 2-years’ follow-up.
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Baseline hazard functions were created for each study using splines with differing numbers of knots, and
their shapes were examined. The three predictors (i.e. insensitivity to a 10-g monofilament, one or more
absent pedal pulses, and history of ulceration or LEA) were included in the flexible parametric survival
model, together with two dummy variables for each of two of the three studies, to take account of the
different study populations. Similar models were developed with one, two and three internal knots to
ascertain which model best fitted the data. The model with the lower AIC and lower log-likelihood value
was preferred, unless the two AIC and log-likelihood values were very close in size, in which case the
simpler model (with fewer degrees of freedom) was selected. Our final decision was to use the simplest
one-knot model (Figure 45). For the Cox regression models, the three predictors were included first in
a stratified model, to account for the differences between the studies, and then in a model that was
adjusted for study. In each model, the Monteiro-Soares study was taken as the reference study,
as the follow-up in this study was longer than those in the Crawford and Pham et al.25 studies.
All analyses were performed with IBM SPSS Statistics version 22 (IBM Corporation, Armonk, NY, USA)
(URL: www.ibm.com/products/spss-statistics) and RStudio version 1.0.143 (RStudio Inc., Boston, MA,
USA) (URL: www.rstudio.com/), which is an integrated development environment for R (The R Foundation
for Statistical Computing, Vienna, Austria) (URL: https://cran.r-project.org/).
Results
For basic demographic and predictor descriptive statistics for each study, see Tables 2–9 and Figures 1–4.
As expected, Figure 43 shows that the baseline hazard for the Crawford data set is lower than that
found in either the Monteiro-Soares or the Pham et al.25 data set. Univariate results for each of the
predictors are shown in Figures 46–48.
Flexible parametric model
The flexible parametric model comprises the three predictors and two dummy variables (labelled
Crawford study and Pham et al.25 study), and the results are given in Table 37. A pattern broadly similar
to that of the CPR logistic regression results is shown, with the coefficient for history approximately
twice the size of those for monofilament sensitivity or pulses.
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FIGURE 45 Baseline hazard function for three studies with one internal knot (k = 1). The dashed lines represent the
upper and lower confidence intervals for each of the baseline hazard functions for the individual studies.
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Cox proportional hazards model
Cox proportional hazards regression is most frequently used to create a time-to-event model, and two
analyses were undertaken: one adjusting for the Crawford and Pham et al.25 studies in a similar manner
to the flexible parametric models and the other stratified by ‘study’ (Table 38). In the model in which
the predictors were adjusted for study, the results for absent pedal pulses were identical to the results
of the model that was stratified by study.
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FIGURE 46 Kaplan–Meier plot for progression to foot ulceration, comparing adults who are sensitive with adults who
are insensitive to a 10-g monofilament.
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TABLE 37 Results of the multivariable flexible survival analysis with one internal knot
Predictor β Standard error (β) Hazard ratio= exp(β) 95% CI
Gamma 0 –1.516 0.804 – –
Gamma 1 2.198 0.402 – –
Gamma 2 0.047 0.019 – –
Monofilament, insensitive 0.703 0.190 2.020 1.393 to 2.929
Pulses, absent pedal 0.677 0.162 1.967 1.431 to 2.704
History of ulcer/LEA 1.159 0.193 3.188 2.185 to 4.651
Crawford 201121 –0.813 0.273 0.444 0.260 to 0.758
Pham 200025 –0.032 0.170 0.969 0.695 to 1.351
TABLE 38 Results of the three predictors for each survival analysis
Predictor
Final model: flexible
parametric survival analysis
with one internal knot
Final model: Cox regression
adjusted for study
Final model: Cox regression
stratified by study
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Monofilament 2.02 1.39 to 2.93 2.05 1.41 to 2.97 1.98 1.36 to 2.88
Pulses 1.97 1.43 to 2.70 1.94 1.41 to 2.67 1.94 1.41 to 2.67
History 3.19 2.18 to 4.65 3.23 2.21 to 4.71 3.30 2.26 to 4.81
DOI: 10.3310/hta24620 Health Technology Assessment 2020 Vol. 24 No. 62
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
143
Checking the proportional hazards assumption
It is important to check the proportional hazards assumption when using Cox proportional hazards
regression. Log-minus-log plots for the three pooled studies are in Figure 49. The results of additional
statistical tests and graphs based on the scaled Schoenfeld residuals are also given in Figure 49.
As the Schoenfeld residuals are independent of time, the plots of residuals should be randomly distributed;
if the plots of residuals are not randomly distributed, this would imply a violation of the proportional
hazards assumption. In the final column of Table 39, the p-values for all three predictors and the global
test are non-significant, which supports the proportional hazards assumption. We concluded from our
checks that there is no strong evidence that the proportional hazard assumption has been violated
(Table 39 and Figures 49 and 50).
The health economic model has considered three risk groups: low-risk people with CPR scores of
0 or 1, medium-risk people with CPR scores of 2, and high-risk people with CPR scores of 3 or 4.
We present the rates of ulcer per risk group in Table 40.
The survival analyses suggest broad agreement with the logistic regression analyses in terms of the
weighting of the coefficients of monofilament sensitivity, pulses and history. Across the entire follow-up
period, the risk categories have an overall percentage of ulceration of 3.4%, 16.2% and 38.6% for low-,
medium- and high-risk groups, respectively.
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FIGURE 49 Log-minus-log (LML) plots for the three predictors to check that the proportional hazards assumption holds.
(a) Sensitive vs. not sensitive; (b) pulses absent vs. pulses present; and (c) no ulcer vs. previous ulcer. (continued )
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TABLE 39 Results of statistical tests to check that the proportional hazards assumption holds
Predictor P χ2 p-value
Monofilament insensitivity 0.053 0.687 0.407
Absent pedal pulses –0.056 0.622 0.430
History of ulcer/LEA –0.066 1.087 0.297
Global – 1.991 0.574
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FIGURE 49 Log-minus-log (LML) plots for the three predictors to check that the proportional hazards assumption holds.
(a) Sensitive vs. not sensitive; (b) pulses absent vs. pulses present; and (c) no ulcer vs. previous ulcer.
DOI: 10.3310/hta24620 Health Technology Assessment 2020 Vol. 24 No. 62
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
145
0.64
–5.0
–2.5
0.0
B
et
a(
t)
 fo
r 
m
o
n
o
f i
la
m
en
t –
 y
es
2.5
5.0
1.5
(a)
1.9 2.8 3.5
Time (years)
4 5 5.6
0.64
–2
0
2
B
et
a(
t)
 fo
r 
p
u
ls
es
 –
 y
es 4
1.5
(b)
1.9 2.8 3.5
Time (years)
4 5 5.6
0.64
–4
–2
0
2
B
et
a(
t)
 fo
r 
h
is
to
ry
 –
 y
es
4
1.5
(c)
1.9 2.8 3.5
Time (years)
4 5 5.6
FIGURE 50 Plots of the scaled Schoenfeld residuals against transformed time to check that the proportional hazards
assumption holds. (a) Schoenfeld individual test: p = 4072; (b) Schoenfeld individual test: p = 0.4304; and (c) Schoenfeld
individual test: p = 0.2972. Global Schoenfeld test: p = 0.5743.
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TABLE 40 Patterns of ulceration in the three risk groups according to the length of follow-up
Risk group Length of follow-up (years) New foot ulcer, n (%) No new foot ulcer, n Total, n (%)
Low ≤ 1 20 (45) 704 724 (56)
1–2 15 (34) 415 430 (33)
2–3 3 (7) 67 70 (5)
≥ 3 6 (14) 78 84 (6)
Total 44 (100) 1264 1308 (100)
Medium ≤ 1 15 (52) 76 91 (51)
1–2 9 (31) 44 53 (29)
2–3 1 (3) 20 21 (12)
≥ 3 4 (14) 10 14 (8)
Total 29 (100) 150 179 (100)
High ≤ 1 57 (50) 50 107 (36)
1–2 25 (22) 53 78 (26)
2–3 16 (14) 60 76 (26)
≥ 3 17 (14) 20 37 (12)
Total 115 (100) 183 298 (100)
TABLE 41 The TRIPOD checklist: prediction model development and validation
Section/topic Item
Development/
validation Checklist item Section
Title and abstract
Title 1 D; V Identify the study as developing and/or validating a
multivariable prediction model, the target population
and the outcome to be predicted
Chapter 3,
Introduction
Abstract 2 D; V Provide a summary of objectives, study design, setting,
participants, sample size, predictors, outcome, statistical
analysis, results and conclusions
NA
Introduction
Background and
objectives
3a D; V Explain the medical context (including whether diagnostic
or prognostic) and rationale for developing or validating
the multivariable prediction model, including references
to existing models
Chapter 3,
Introduction
and Appendix 3
3b D; V Specify the objectives, including whether the study
describes the development or validation of the model
or both
Chapter 3,
Introduction
Methods
Source of data 4a D; V Describe the study design or source of data (e.g.
randomised trial, cohort or registry data) separately for
the development and validation data sets, if applicable
Chapter 3,
Methods
4b D; V Specify the key study dates, including start of accrual,
end of accrual and, if applicable, end of follow-up
Chapter 3,
Methods
continued
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TABLE 41 The TRIPOD checklist: prediction model development and validation (continued )
Section/topic Item
Development/
validation Checklist item Section
Participants 5a D; V Specify key elements of the study setting (e.g. primary
care, secondary care, general population) including
number and location of centres
Chapter 3,
Methods
5b D; V Describe eligibility criteria for participants Chapter 3,
Methods
5c D; V Give details of treatments received, if relevant Chapter 3,
Methods
Outcome 6a D; V Clearly define the outcome that is predicted by the
prediction model, including how and when assessed
Chapter 3,
Methods
6b D; V Report any actions to blind assessment of the outcome
to be predicted
Chapter 3,
Methods
Predictors 7a D; V Clearly define all predictors used in developing or
validating the multivariable prediction model, including
how and when they were measured
Chapter 3,
Methods
7b D; V Report any actions to blind assessment of predictors for
the outcome and other predictors
Chapter 3,
Methods
Sample size 8 D; V Explain how the study size was arrived at Chapter 3,
Methods
Missing data 9 D; V Describe how missing data were handled (e.g. complete-
case analysis, single imputation, multiple imputation) with
details of any imputation method
Chapter 3,
Methods
Statistical analysis
methods
10a D Describe how predictors were handled in the analyses Chapter 3,
Methods
10b D Specify type of model, all model-building procedures
(including any predictor selection) and method for
internal validation
Chapter 3,
Methods and
Appendix 3
10c V For validation, describe how the predictions were
calculated
Chapter 3,
Methods
10d D; V Specify all measures used to assess model performance
and, if relevant, to compare multiple models
Chapter 3,
Methods
10e V Describe any model updating (e.g. recalibration) arising
from the validation, if done
NA
Risk groups 11 D; V Provide details on how risk groups were created, if done Chapter 3,
Methods
Development vs.
validation
12 V For validation, identify any differences from the
development data in setting, eligibility criteria, outcome
and predictors
Chapter 3,
Methods
Results
Participants 13a D; V Describe the flow of participants through the study,
including the number of participants with and without
the outcome and, if applicable, a summary of the
follow-up time. A diagram may be helpful
Chapter 3,
Results
13b D; V Describe the characteristics of the participants (basic
demographics, clinical features, available predictors),
including the number of participants with missing data
for predictors and outcome
Chapter 3,
Results
13c V For validation, show a comparison with the development
data of the distribution of important variables
(demographics, predictors and outcome)
Chapter 3,
Results
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TABLE 41 The TRIPOD checklist: prediction model development and validation (continued )
Section/topic Item
Development/
validation Checklist item Section
Model development 14a D Specify the number of participants and outcome events
in each analysis
Chapter 3,
Results
14b D If done, report the unadjusted association between each
candidate predictor and outcome
NA
Model specification 15a D Present the full prediction model to allow predictions for
individuals (i.e. all regression coefficients, and model
intercept or baseline survival at a given time point)
Chapter 3,
Results
15b D Explain how to the use the prediction model Chapter 3,
Results and
Appendix 3
Model performance 16 D; V Report performance measures (with CIs) for the
prediction model
Chapter 3,
Results
Model updating 17 V If done, report the results from any model updating
(i.e. model specification, model performance)
NA
Discussion
Limitations 18 D; V Discuss any limitations of the study (such as non-
representative sample, few events per predictor,
missing data)
Chapter 3,
Discussion
Interpretation 19a V For validation, discuss the results with reference to
performance in the development data, and any other
validation data
Chapter 3,
Discussion
19b D; V Give an overall interpretation of the results, considering
objectives, limitations, results from similar studies and
other relevant evidence
Chapter 3,
Discussion
Implications 20 D; V Discuss the potential clinical use of the model and
implications for future research
Chapter 3,
Discussion
Other information
Supplementary
information
21 D; V Provide information about the availability of
supplementary resources, such as study protocol,
web calculator and data sets
Chapter 8
Funding 22 D; V Give the source of funding and the role of the funders
for the present study
Chapter 8
NA, not applicable; TRIPOD, Transparent Reporting of a multivariable prediction model for Individual Prognosis
Or Diagnosis.
Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a
prediction model are denoted by V, and items relating to both are denoted by D; V. We recommend using the TRIPOD
checklist in conjunction with the TRIPOD explanation and elaboration document.
DOI: 10.3310/hta24620 Health Technology Assessment 2020 Vol. 24 No. 62
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
149

Appendix 4 Chapter 4-related appendices
Search strategies
TABLE 42 MEDLINE
# Searches Results
1 exp Foot Orthoses/ 597
2 exp Shoes/ 5861
3 exp health education/ 155,049
4 exp primary health care/ 133,354
5 exp Emollients/ 4590
6 insole*.mp. 1429
7 footwear*.mp. 2732
8 educat*.mp. 808,235
9 specialist car*.mp. 1843
10 multi disciplinary team*.mp. 1041
11 multidisciplinary team*.mp 13,050
12 routine podiatry car*.mp. 4
13 exp general practice/ 71,783
14 exp community health services/ 280,617
15 off load*.mp. 516
16 offload*.mp. 618
17 emollient*.mp. 2517
18 shoe*.mp. 10,839
19 or/1-18 ALL INTERVENTIONS 1,211,803
20 exp Foot/ 47,255
21 exp Foot Diseases/ 20,474
22 exp Diabetic Foot/ 7470
23 exp Diabetic Neuropathies/ 20,272
24 exp Diabetes Mellitus/ 377,598
25 exp Diabetic Angiopathies/ 44,655
26 exp Diabetes Complications/ 119,833
27 exp Podiatry/ 2110
28 exp Foot Ulcer/ 8769
29 exp Skin Ulcer/ 40,829
30 exp Ischemia/ 55,699
31 exp Bacterial Infections/ 830,709
32 (diabet* adj3 ulcer*).mp. 4473
continued
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TABLE 42 MEDLINE (continued )
# Searches Results
33 (diabet* adj3 (foot or feet)).mp. 10,385
34 (diabet* adj3 wound*).mp. 2418
35 (diabet* adj3 amputat*).mp. 943
36 or/20-35 ALL CONDITIONS 1,341,638
37 systematic* review*.mp. 110,394
38 meta-analysis as topic/ 16,124
39 (meta-analytic* or meta-analysis or metanalysis
or metaanalysis or meta analysis or meta
synthesis or meta-synthesis or metasynthesis
or meta-regression or metaregression or meta
regression).mp.
135,296
40 (synthes* adj3 literature).mp. 2302
41 (synthes* adj3 evidence).mp. 6909
42 (integrative review or data synthesis).mp. 11,729
43 (research synthesis or narrative synthesis).mp. 1755
44 (systematic study or systematic studies).mp. 10,041
45 (systematic comparison* or systematic
overview*).mp.
2670
46 ((evidence based or comprehensive or critical or
quantitative or structured) adj review).mp.
27,447
47 (realist adj (review or synthesis)).mp. 287
48 or/37-47 ALL METHODS 251,135
49 review.pt. 2,316,960
50 (medline or pubmed or embase or cinahl or
psyc?lit or psyc?info).ab.
146,733
51 ((literature or database* or bibliographic or
electronic or computeri?ed or internet) adj3
search*).mp.
92,793
52 (electronic adj3 database*).mp. 19,642
53 included studies.ab. 14,433
54 (inclusion adj3 studies).ab. 11,371
55 ((inclusion or selection or predefined or
predetermined) adj criteria).ab.
84,815
56 (assess* adj3 (quality or validity)).ab. 60,800
57 (select* adj3 (study or studies)).ab. 53,516
58 (data adj3 extract*).ab. 45,707
59 extracted data.ab. 10,556
60 (data adj3 abstraction).ab. 1277
61 published intervention*.ab. 144
62 ((study or studies) adj2 evaluat*).ab. 149,931
63 (intervention* adj2 evaluat*).ab. 8850
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TABLE 42 MEDLINE (continued )
# Searches Results
64 (confidence interval* or heterogeneity or pooled
or pooling or odds ratio*).ab.
583,558
65 (Jadad or coding).ab. 153,954
66 or/50-65 ALL ABSTRACTS 1,141,840
67 49 and 66 COMBINE REVIEW.pt AND ABSTRACTS 186,735
68 review.ti. 365,140
69 66 and 68 COMBINE ABSTRACTS AND REVIEW TITLE 90,484
70 (review* adj4 (papers or trials or studies or
evidence or intervention* or evaluation*)).mp.
147,629
71 48 or 67 or 68 or 70 COMBINE METHODS, AND REVIEW.pt &
ABSTRACTS, AND ABSTRACT AND REVIEW
TITLE, AND REVIEW.TIABSTRACTS
435,212
72 letter.pt. 975,446
73 editorial.pt. 442,803
74 comment.pt. 693,044
75 or/72-74 ALL PUBLICATIONS 1,592,398
76 71 not 75 PUBLICATIONS REMOVED 424,748
78 exp animals/not humans/ 4,419,620
77 76 not 77 ANIMALS REMOVED 413,286
79 19 and 36 and 78 GRAND COMBINE 1545
TABLE 43 EMBASE
# Searches Results
1 exp Foot Orthosis/ 1783
2 exp Shoe/ 8340
3 exp health education/ 279,708
4 exp primary health care/ 137,391
5 emollient agent/ 4806
6 insole*.mp. 1769
7 footwear*.mp. 3499
8 educat*.mp. 1,130,926
9 specialist car*.mp. 2713
10 multi disciplinary team*.mp. 2710
11 multidisciplinary team*.mp. [mp = title, abstract,
heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device
trade name, keyword, floating subheading word]
22,086
12 routine podiatry car*.mp. 4
13 exp general practice/ 76,174
continued
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TABLE 43 EMBASE (continued )
# Searches Results
14 exp community care/ 110,817
15 off load*.mp. 614
16 offload*.mp. 800
17 emollient*.mp. 5569
18 shoe*.mp. 14,386
19 or/1-18 ALL INTERVENTIONS 1,460,708
20 exp Foot/ 47,405
21 exp Foot Disease/ 69,761
22 exp Diabetic Foot/ 11,959
23 exp Diabetic Neuropathy/ 20,680
24 exp Diabetes Mellitus/ 783,108
25 exp Diabetic Angiopathy/ 11,784
26 (diabet* adj3 complicat*).mp. 39,093
27 exp Podiatry/ 2293
28 exp Foot Ulcer/ 4598
29 exp Skin Ulcer/ 61,358
30 exp Ischemia/ 683,484
31 exp Bacterial Infection/ 815,279
32 (diabet* adj3 ulcer*).mp. 6114
33 (diabet* adj3 (foot or feet)).mp. 14,451
34 (diabet* adj3 wound*).mp. 3250
35 (diabet* adj3 amputat*).mp. 1231
36 or/20-35 ALL CONDITIONS 2,319,256
37 systematic* review*.mp. 198,683
38 meta analysis/ 128,965
39 (meta-analytic* or meta-analysis or metanalysis
or metaanalysis or meta analysis or meta
synthesis or meta-synthesis or metasynthesis
or meta-regression or metaregression or meta
regression).mp.
201,471
40 (synthes* adj3 literature).mp. 2631
41 (synthes* adj3 evidence).mp. 7723
42 (integrative review or data synthesis).mp. 14,150
43 (research synthesis or narrative synthesis).mp. 1823
44 (systematic study or systematic studies).mp. 10,732
45 (systematic comparison* or systematic
overview*).mp.
2845
46 ((evidence based or comprehensive or critical or
quantitative or structured) adj review).mp.
30,357
47 (realist adj (review or synthesis)).mp. 271
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TABLE 43 EMBASE (continued )
# Searches Results
48 or/37-47 ALL METHODS 363,489
49 review.pt. 2,272,717
50 (medline or pubmed or embase or cinahl or
psyc?lit or psyc?info).ab.
171,015
51 ((literature or database* or bibliographic or
electronic or computeri?ed or internet) adj3
search*).mp.
112,943
52 (electronic adj3 database*).mp. 25,563
53 included studies.ab. 17,536
54 (inclusion adj3 studies).ab. 13,486
55 ((inclusion or selection or predefined or
predetermined) adj criteria).ab.
125,186
56 (assess* adj3 (quality or validity)).ab. 76,902
57 (select* adj3 (study or studies)).ab. 67,123
58 (data adj3 extract*).ab. 58,865
59 extracted data.ab. 12,921
60 (data adj3 abstraction).ab. 1795
61 published intervention*.ab. 169
62 ((study or studies) adj2 evaluat*).ab. 202,130
63 (intervention* adj2 evaluat*).ab. 11,727
64 (confidence interval* or heterogeneity or pooled
or pooling or odds ratio*).ab.
698,437
65 (Jadad or coding).ab. 175,200
66 or/50-65 ALL ABSTRACTS 1,416,110
67 49 and 66 COMBINE REVIEW.pt AND ABSTRACTS 162,318
68 review.ti. 410,964
69 66 and 68 COMBINE ABSTRACTS AND REVIEW TITLE 105,269
70 (review* adj4 (papers or trials or studies or
evidence or intervention* or evaluation*)).mp.
172,793
71 48 or 67 or 69 or 70 COMBINE METHODS, AND REVIEW.pt &
ABSTRACTS, AND ABSTRACT AND REVIEW
TITLE, AND REVIEW.TIABSTRACTS
554,812
72 letter.pt. 978,666
73 editorial.pt. 538,173
74 or/72-73 ALL PUBLICATIONS 1,516,839
75 71 not 74 PUBLICATIONS REMOVED 540,237
76 exp animal/not human/ 4,795,342
77 75 not 76 ANIMALS REMOVED 527,970
78 19 and 36 and 77 GRAND COMBINE 4507
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Cochrane
Medical subject heading (MeSH) search:
l diabet* (56,868)
l foot ulcer* (1411)
l prevent* (176,372)
l #1 and #2 (1218)
l #4 and #3 (335).
Database of Abstracts of Reviews of Effects (DARE) search
Search in all Cochrane sites for ‘diabetic foot ulcer prevention’.
Health Technology Assessment database search
Search term: diabetic foot ulcer.
TABLE 44 PROSPERO international prospective register of SRs (status: ongoing) (URL: www.crd.york.ac.uk/PROSPERO/
#searchadvanced)
PROSPERO number Title Authors
CRD42017072816 Footwear and insole design features to prevent
foot ulceration in people with diabetes: a
systematic review protocol
Richard Collings, Jennifer Freeman, Jos Latour,
Sam Glasser and Joanne Paton
CRD42018105681 Effectiveness of offloading interventions to heal
foot ulcers and reduce mechanical pressure in
persons with diabetic foot ulcers: a systematic
review
Peter Lazzarini, Sicco Bus, David Armstrong,
Carlo Caravaggi, Vijay Vishwanathan,
Gustav Jarl and Catherine Gooday
CRD42018105073 Interventions to reduce modifiable risk factors
for foot ulcers in at-risk patients with diabetes:
a systematic review
Jaap van Netten, Sicco Bus,
Matilde Monteiro-Soares, Larry Lavery,
Anne Rasmussen, Anita Raspovic and
Isabel Sacco
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Overview flow diagram
List of excluded studies from the overview of systematic reviews
Records identified through database 
searching MEDLINE and EMBASE
(n = 6681)
Additional records identified through
other sources: HTA, DARE and Cochrane
(n = 735)
Full-text articles
excluded, with reasons
(n = 118)a
SRs from
electronic search
(n = 18)
Full-text articles assessed
for eligibility
(n = 136)
Records excluded
(n = 6886)
Records screened by title
and abstract
(n = 7022)
Duplicates removed
(n = 394)
Records after duplicates removed
(n = 7022)
SRs included
in narrative synthesis
(n = 20)
Full-text articles
found from
reference list
search
(n = 2)
RCTs retrieved from SR
after de-duplication
(n = 52)
Additional ongoing
SRs identified from
PROSPERO
(n = 3)a
FIGURE 51 Overview flow diagram. a, See Appendix 4.
TABLE 45 List of excluded studies [full reference details in References of excluded studies (overview)]
OVID
results
number Author (year) Reason for exclusion
1. 3775 Al-Saweer 2006 Not an empirical paper. Provides an easy-access overview for patients
2. 2598 Arad 2011 A review of Arad (2011) paper, which is included. This is not primary
research
3. 376 Arsanjani Shirazi 2016 Narrative review and not an actual SR
4. 1473 Attridge 2014 Assessed health-care advice and not prevention of DFUs
5. 486 Baptista 2016 Chronic care model developed to provide chronic disease patients with
self-care and tracking systems and not preventing DFUs
continued
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TABLE 45 List of excluded studies [full reference details in References of excluded studies (overview)] (continued )
OVID
results
number Author (year) Reason for exclusion
6. 860 Baradaran 2010 Treating and not preventing DFUs
7. 1982 Baptista 2013 Conference abstract meets our inclusion criteria, but we do not have
enough information for data extraction and quality assessment
8. 3890 Bazian 2005 Reanalysis of Valk (2015), not a SR
9. 424 Behforootan 2017 Overview of modelling techniques in the field of foot and footwear
biomechanics and to investigate their applicability in a clinical setting,
not prevention of DFUs
10. 3739 Behrenberg 2006 Patient knowledge and not preventing DFUs
11. 3649 Beran 2006 Diabetic care and not preventing DFUs
12. 4210 Bowering 2001 Treatment and not preventing DFUs
13. 4481 Braid 1992 Structured audit review and not a SR
14. 1429 Braun 2014 About new adjunctive management of DFUs and not preventing DFUs
15. 1666 Brownrigg 2013 Narrative review and not an SR
16. 1526 Buggy 2017 Management of the diabetic foot; not prevention of DFUs
17. 3345 Bus 2008 Clinical controlled trial is not an eligible study design for our SR
18. 21 Bus 2016 Literature review and not a SR
19. 120 Bus 2016 Integrated diabetes annual review and not a SR
20. 1756 Bus 2013 Pressure-time integral data analysed and reported next to peak pressure
data: outcome not relevant to overview
21. 1595 Caporale 2013 Prevalence and disease burden and not preventing DFUs
22. 4046 Cavanagh 2004 Narrative and not an SR
23. 2448 Cavanagh 2010 Narrative and not an SR
24. 1544 Cook 1997 The focus is on the diabetic foot and not preventing DFUs
25. 2832 Cooper 2009 General diabetes and not prevention of DFUs
26. 3217 Couch 2008 General diabetes and not prevention of DFUs
27. HTA Crawford 2015 Prediction not prevention
28. 186 Creamer 2016 General diabetes and not prevention of DFUs
29. 619 Crews 2016 The focus is on risk of physical activity and not preventing DFUs
30. 1039 de Oliveira 2015 The focus is on treating and not preventing DFUs
31. 4165 Echeverry 2003 Foot examination and not preventing DFUs
32. 1241 Eldor 2004 The focus is on a range of new treatments and not preventing DFUs
33. 104 Elraiyah 2016 The focus is on offloading and not preventing DFUs
34. 105 Elraiyah 2016b Does not look at prevention. Includes one RCT that mentions prevention;
incidental and therefore the SR is excluded
35. 1028 Eneroth 2008 Treatment and not prevention
36. 1069 Farid 2015 Treatment and not prevention
37. 3628 Farrow 2005 Rrheumatoid arthritis and not preventing DFUs
38. 413 Formosa 2016 The focus is on screening and not preventing DFUs
39. 297 Francis 2016 Protocol and not a SR
40. 1574 Gemechu 2013 Diabetic foot infection and not DFU prevention
41. 1402 Griffin 2000 General diabetes and not prevention of DFUs
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TABLE 45 List of excluded studies [full reference details in References of excluded studies (overview)] (continued )
OVID
results
number Author (year) Reason for exclusion
42. 285 Healy 201) Alteration of biomechanical factors associated with ulcer healing and not
preventing DFUs
43. 3285 Herber 2007 Examined QoL and not preventing DFUs
44. 2116 Heuch 2012 Protocol of Heuch (2016); not a SR
45. Hinchliffe 2016 Not prevention: SR of treatments for DFUs
46. 106 Hingorani 2016 Not a SR but a report of a clinical practice guideline based on five SRs
47. 3381 Hume 2008 Focused on lower limb injuries and not preventing DFUs
48. 928 Hunt 2009 Treatment of ulcers and not prevention
49. 226 Janisse 2015 Literature review and not a SR
50. 1534 Jarl 2016 Adherence to wearing therapeutic shoes and not preventing DFUs
51. 3401 Jeffcoate 2008 Foot management and not preventing DFUs
52. 1156 La Fontaine 2014 Narrative review and not an actual SR
53. 1832 Lavery 2013 Case–control study and not preventing DFUs
54. 2505 Lefebvre 2011 Not an intervention to prevent DFUs
55. 3260 Leung 2007 Literature review and not a SR
56. 473 Lewis 2013 Treatment and not preventing DFUs
57. 158 Lipsky 2016 Treatment and not preventing DFUs
58. 698 Ma 2016 Analysis microbiological profile and drug resistance of diabetic foot
infections; not DFU prevention
59. 4324 Margolis 2000 Estimating risk factors and not preventing DFUs
60. 160 Markakis 2016 Overview and not a SR
61. 237 Matricciani 2015 Psychosocial barriers to and enablers of foot self-care practices; not
prevention or a priori outcome
62. 2729 Mills 2010 Foot orthosis and gait, not prevention of DFUs
63. 944 Morey-Vargas 2015 Literature review and not a SR
64. 1646 Morona 2013 Adherence to wearing therapeutic shoes: not prevention or a priori outcome
65. 764 Moxey 2011 Quantify global variation in the incidence of LEA and not prevention of DFUs
66. 192 Naidoo 2015 Literature review and not a SR
67. 200 Navarro-Flores 2015 Meta-review. We checked the included relevant SRs and none meets our
eligibility criteria
68. HTA Nelson 2006 Treatment and not preventing DFUs
69. 1528 Noor 2017 Management and not preventing DFUs
70. 273 Nordheim 2014 Clinical, behavioural organisational outcomes of leg and foot ulcers and
not preventing DFUs
71. 4117 O’Brien 2003 Intervention study and not a SR
72. 1081 Oosterveld 2015 Peak pressure and not preventing DFUs
73. 1537 Otter 2015 Plantar pressure and not ulcer is the outcome
74. 424 Patry 2013 Pathogenesis of DFUs and not preventing DFUs
75. 1019 Perrin 2008 Behavioural outcome, not ulcer outcome
76. 1771 Pinilla 2013 Literature review and not a SR
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TABLE 45 List of excluded studies [full reference details in References of excluded studies (overview)] (continued )
OVID
results
number Author (year) Reason for exclusion
77. 3538 Pinzur 2007 Charcot’s arthropathy, not prevention of DFUs and not a SR
78. 4406 Pinzur 1997 Narrative and not an actual SR
79. 3734 Rakel 2006 Literature review and not a SR
80. 2041 Rawal 2012 General diabetic outcome and not preventing DFUs
81. 4026 Rheeder 2004 Management and not preventing DFUs
82. 1888 Rice 2013 Audit and not a SR
83. 1529 Rice 2014 Audit and not a SR
84. 4323 Rith-Najarian 2000 Management post amputation and not preventing DFUs
85. 665 Robineau 2016 Treatments for diabetic foot infections and not preventing DFUs
86. 204 Sanders Thompson 2015 General diabetic outcome and not preventing DFUs
87. 3147 Saunders 2009 General diabetic outcome and not preventing DFUs
88. 45 Schaper 2017 Summary guidance and not a SR
89. 2389 Schunk 2011 Evaluates diabetes care and not a SR
90. 1292 Seah 2014 Reducing diabetic complications and not preventing DFUs
91. 3987 Selwitz 2003 Risk of diabetes development and not preventing DFUs
92. 3580 Shank 2006 Diabetes foot management and not preventing DFUs
93. 3011 Sharma 2010 General diabetic outcome and not preventing DFUs
94. 58 Sherifali 2017 Developing coaching model and not preventing DFUs
95. 796 Shrivastava 2015 Guideline development and not a SR
96. 198 Shrivastava 2016 Diabetes management and not preventing DFUs
97. 1234 Singh 2005 Clinical review and not a SR
98. 2754 Spencer 2010 Explores causal factors of deteriorating metabolic control and not
preventing DFUs
99. 1088 Srulovici 2015 General diabetic outcome and not preventing DFUs
100. 3828 Stengel 2005 Looks at amputations but no ulcer outcome
101. 2719 Stolt 2010 Foot health care and not preventing DFUs
102. 3889 Stuart 2005 One-page commentary and not a SR
103. 3198 Tabrizi 2008 General diabetic outcome and not preventing DFUs
104. 299 Tang 2014 Risk of amputation and not preventing DFUs
105. 279 Telfer 2014 Finite element analysis-based computational simulations of diabetic foot and
not preventing DFUs
106. 212 Torsello 2015 Overview of 2012–14 comments on DFU treatment clinical trials and
meta-analyses; not a SR
107. 154 Uckay 2015 Diabetic foot infection and not DFU prevention
108. 3349 Unwin 2008 Narrative and not an actual SR
109. 346 Valencia 2017 Microvascular diabetes prevention and not preventing of DFUs
110. 1233 Valk 2002 Original manuscript published electronically in the Cochrane Library
(Valk GD, Kriegsman DMW, Assendelft WJJ. Patient education for
preventing diabetic foot ulceration. Oxford: Update Software Ltd; 2001).
This has since been updated by Dorresteijn et al.,51 which we have included
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Appendix 5 Chapter 5-related appendices
Search strategies
TABLE 46 The Cochrane Central Register of Controlled Trials
# Searches
1. MeSH descriptor: [Foot Orthoses] explode all trees
2. MeSH descriptor: [Shoes] explode all trees
3. MeSH descriptor: [Health Education] explode all trees
4. MeSH descriptor: [Primary Health Care] explode all trees
5. MeSH descriptor: [Emollients] explode all trees
6. insole*
7. footwear*
8. educat*
9. specialist car*
10. multi disciplinary team*
11. multidisciplinary team*
12. routine podiatry car*
13. MeSH descriptor: [General Practice] explode all trees
14. MeSH descriptor: [Community Health Services] explode all trees
15. off load*
16. offload*
17. emollient*
18. shoe*
19. {or #1-#18}
20. MeSH descriptor: [Foot] explode all trees
21. MeSH descriptor: [Foot Diseases] explode all trees
22. MeSH descriptor: [Diabetic Foot] explode all trees
23. MeSH descriptor: [Diabetic Neuropathies] explode all trees
24. MeSH descriptor: [Diabetes Mellitus] explode all trees
25. MeSH descriptor: [Diabetic Angiopathies] explode all trees
26. MeSH descriptor: [Diabetes Complications] explode all trees
27. MeSH descriptor: [Podiatry] explode all trees
28. MeSH descriptor: [Foot Ulcer] explode all trees
29. MeSH descriptor: [Skin Ulcer] explode all trees
30. MeSH descriptor: [Ischemia] explode all trees
31. MeSH descriptor: [Bacterial Infections] explode all trees
32. diabet* near/3 ulcer*
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TABLE 46 The Cochrane Central Register of Controlled Trials (continued )
# Searches
33. diabet* near/3 (foot or feet)
34. diabet* near/3 wound*
35. diabet* near/3 amputat*
36. {or #20-#35}
37. #19 and #36
TABLE 47 EMBASE
# Searches
1. exp Foot Orthosis/
2. exp Shoe/
3. exp health education/
4. exp primary health care/
5. emollient agent/
6. insole*.mp.
7. footwear*.mp.
8. educat*.mp.
9. specialist car*.mp.
10. multi disciplinary team*.mp.
11. multidisciplinary team*.mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
12. routine podiatry car*.mp.
13. exp general practice/
14. exp community care/
15. off load*.mp.
16. offload*.mp.
17. emollient*.mp.
18. shoe*.mp.
19. or/1-18
20. exp Foot/
21. exp Foot Disease/
22. exp Diabetic Foot/
23. exp Diabetic Neuropathy/
24. exp Diabetes Mellitus/
25. exp Diabetic Angiopathy/
26. (diabet* adj3 complicat*).mp.
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TABLE 47 EMBASE (continued )
# Searches
27. exp Podiatry/
28. exp Foot Ulcer/
29. exp Skin Ulcer/
30. exp Ischemia/
31. exp Bacterial Infection/
32. (diabet* adj3 ulcer*).mp.
33. (diabet* adj3 (foot or feet)).mp.
34. (diabet* adj3 wound*).mp.
35. (diabet* adj3 amputat*).mp.
36. or/20-35
37. systematic* review*.mp.
38. meta analysis/
39. (meta-analytic* or meta-analysis or metanalysis or metaanalysis or meta analysis or meta synthesis or
meta-synthesis or metasynthesis or meta-regression or metaregression or meta regression).mp.
40. (synthes* adj3 literature).mp.
41. (synthes* adj3 evidence).mp.
42. (integrative review or data synthesis).mp.
43. (research synthesis or narrative synthesis).mp.
44. (systematic study or systematic studies).mp.
45. (systematic comparison* or systematic overview*).mp.
46. ((evidence based or comprehensive or critical or quantitative or structured) adj review).mp.
47. (realist adj (review or synthesis)).mp.
48. or/37-47
49. review.pt.
50. (medline or pubmed or embase or cinahl or psyc?lit or psyc?info).ab.
51. ((literature or database* or bibliographic or electronic or computeri?ed or internet) adj3 search*).mp.
52. (electronic adj3 database*).mp.
53. included studies.ab.
54. (inclusion adj3 studies).ab.
55. ((inclusion or selection or predefined or predetermined) adj criteria).ab.
56. (assess* adj3 (quality or validity)).ab.
57. (select* adj3 (study or studies)).ab.
58. (data adj3 extract*).ab.
59. extracted data.ab.
60. (data adj3 abstraction).ab.
61. published intervention*.ab.
62. ((study or studies) adj2 evaluat*).ab.
63. (intervention* adj2 evaluat*).ab.
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TABLE 47 EMBASE (continued )
# Searches
64. (confidence interval* or heterogeneity or pooled or pooling or odds ratio*).ab.
65. (Jadad or coding).ab.
66. or/50-65
67. 49 and 66
68. review.ti.
69. 66 and 68
70. (review* adj4 (papers or trials or studies or evidence or intervention* or evaluation*)).mp.
71. 48 or 67 or 69 or 70
72. letter.pt.
73. editorial.pt.
74. or/72-73
75. 71 not 74
TABLE 48 MEDLINE
# Searches
1. exp Foot Orthoses/
2. exp Shoes/
3. exp health education/
4. exp primary health care/
5. exp Emollients/
6. insole*.mp.
7. footwear*.mp.
8. educat*.mp.
9. specialist car*.mp.
10. multi disciplinary team*.mp.
11. multidisciplinary team*.mp.
12. routine podiatry car*.mp.
13. exp general practice/
14. exp community health services/
15. off load*.mp.
16. offload*.mp.
17. emollient*.mp.
18. shoe*.mp.
19. or/1-18
20. exp Foot/
21. exp Foot Diseases/
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TABLE 48 MEDLINE (continued )
# Searches
22. exp Diabetic Foot/
23. exp Diabetic Neuropathies/
24. exp Diabetes Mellitus/
25. exp Diabetic Angiopathies/
26. exp Diabetes Complications/
27. exp Podiatry/
28. exp Foot Ulcer/
29. exp Skin Ulcer/
30. exp Ischemia/
31. exp Bacterial Infections/
32. (diabet* adj3 ulcer*).mp.
33. (diabet* adj3 (foot or feet)).mp.
34. (diabet* adj3 wound*).mp.
35. (diabet* adj3 amputat*).mp.
36. or/20-35
37. systematic* review*.mp.
38. meta-analysis as topic/
39. (meta-analytic* or meta-analysis or metanalysis or metaanalysis or meta analysis or meta synthesis or
meta-synthesis or metasynthesis or meta-regression or metaregression or meta regression).mp.
40. (synthes* adj3 literature).mp.
41. (synthes* adj3 evidence).mp.
42. (integrative review or data synthesis).mp.
43. (research synthesis or narrative synthesis).mp.
44. (systematic study or systematic studies).mp.
45. (systematic comparison* or systematic overview*).mp.
46. ((evidence based or comprehensive or critical or quantitative or structured) adj review).mp.
47. (realist adj (review or synthesis)).mp.
48. or/37-47
49. review.pt.
50. (medline or pubmed or embase or cinahl or psyc?lit or psyc?info).ab.
51. ((literature or database* or bibliographic or electronic or computeri?ed or internet) adj3 search*).mp.
52. (electronic adj3 database*).mp.
53. included studies.ab.
54. (inclusion adj3 studies).ab.
55. ((inclusion or selection or predefined or predetermined) adj criteria).ab.
56. (assess* adj3 (quality or validity)).ab.
57. (select* adj3 (study or studies)).ab.
58. (data adj3 extract*).ab.
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Search was carried out on 21 February 2019.
TABLE 48 MEDLINE (continued )
# Searches
59. extracted data.ab.
60. (data adj3 abstraction).ab.
61. published intervention*.ab.
62. ((study or studies) adj2 evaluat*).ab.
63. (intervention* adj2 evaluat*).ab.
64. (confidence interval* or heterogeneity or pooled or pooling or odds ratio*).ab.
65. (Jadad or coding).ab.
66. or/50-65
67. 49 and 66
68. review.ti.
69. 66 and 68
70. (review* adj4 (papers or trials or studies or evidence or intervention* or evaluation*)).mp.
71. 48 or 67 or 69 or 70
72. letter.pt.
73. editorial.pt.
74. comment.pt.
75. or/72-74
76. 71 not 75
77. exp animals/not humans/
78. 76 not 77
79. 19 and 36 and 78
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TABLE 49 ClinicalTrials.gov search results
Number Title Status
Study
results Conditions Interventions Locations
1 Patients with diabetic neuropathy
who receive physiotherapy
treatment will have a decrease in
diabetic foot ulcers
Not yet
recruiting
No results
available
DFU, diabetic neuropathy
peripheral
Other: physiotherapy protocol
2 Foot intervention study utilizing
commercially available infrared
thermometers with individuals
with diabetes
Recruiting No results
available
Diabetic foot
Device: education and
thermometer group
Other: education only group Memorial University, St John’s, NL, Canada
3 Preventing diabetic foot ulcers
through cleaner feet
Enrolling by
invitation
No results
available
DFU Drug: chlorhexidine Baltimore Veterans Affairs Medical Center
Veterans Affairs Maryland Health Care
System, Baltimore, MD, USA
4 Diabetic foot ulcer recurrence:
pilot study
Recruiting No results
available
Diabetic foot, ulcer foot Other: no interventions Indiana University Health Methodist
Hospital, Indianapolis, IN, USA
5 Abnormal plantar pressure in
patients with diabetes
Completed No results
available
Diabetes complications Other: retrospective observational
study with no intervention
Department and Division of Medical
Rehabilitation, Wroclaw, Lower Silesia,
Poland
6 Reliability of a diabetic foot ulcer
risk stratification and referral
algorithm
Completed No results
available
Foot ulcer, diabetic St Joseph’s Healthcare Primary Care
Diabetes Support Program, St Joseph’s
Healthcare Family Medical and Dental
Centre, London, ON, Canada
7 Predictors of skin temperature,
plantar pressure and ulceration in
diabetic foot patients
Enrolling by
invitation
No results
available
Diabetic foot, diabetes
8 Offloading interventions for diabetic
foot problems in upper Egypt
Not yet
recruiting
No results
available
DFU Device: cast shoe
Device: forefoot offloading shoe
9 Pressure and diabetic foot Recruiting No results
available
Diabetes and risk
of DFUs
Other: measure of cutaneous
microcirculation
Service d’endocrinologie, Centre Hospitalier
Lyon Sud, Pierre-Bénite, France
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TABLE 49 ClinicalTrials.gov search results (continued )
Number Title Status
Study
results Conditions Interventions Locations
10 Foot assessment in people with
diabetes: a quantitative diagnostic
approach
Recruiting No results
available
Diabetes, diabetic foot,
diabetes complications,
diabetes; neuropathic
(manifestation)
Diagnostic test: observation Staffordshire University, Stoke-on-Trent,
Staffordshire, UK
11 Novel offloading for diabetic foot
ulcers with pulseflow: a prospective
study
Recruiting No results
available
DFU, offloading Device: offloading boot: pulse flow Baylor College of Medicine, Houston,
TX, USA
12 Prevention of amputation in diabetic
foot ulcers using amniotic tissue
Active, not
recruiting
No results
available
DFU Boise Veterans Affairs Medical Center,
Boise, ID, USA
13 Pressure-sensing insoles in the
neuropathic ulcer treatment pathway
Recruiting No results
available
Diabetes, diabetes
complications,
neuropathy, peripheral
neuropathy, DFU
Device: SurroSense Rx™ System
(Orpyx Medical Technologies Inc.,
Calgary, AB, Canada)
Zivot Limb Preservation Centre – Peter
Lougheed Centre, Calgary, AB, Canada
14 Diabetic Foot Ulcer Prevention
System (DFUPS) – part 2
Unknown
status
No results
available
Diabetic foot Device: DFUPS King’s College Hospital, London, UK
The Pennine Acute Hospitals NHS Trust,
Manchester, UK
The Newcastle upon Tyne Hospitals,
Newcastle upon Tyne, UK
15 Implementation of foot thermometry
and sms and voice messaging to
prevent diabetic foot ulcer
Completed No results
available
Diabetic foot Behavioural: SMS and voice
messaging device: thermometry
Hospital Cayetano Heredia, Lima, Peru
Hospital Nacional Arzobispo Loayza,
Lima, Peru
16 Diabetic foot ulcer prevention
system
Completed No results
available
Diabetic foot Device: DFUPS King’s College Hospital, London, UK
The Pennine Acute Hospitals NHS Trust,
Manchester, UK
The Newcastle upon Tyne Hospitals,
Newcastle upon Tyne, UK
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Number Title Status
Study
results Conditions Interventions Locations
17 Randomized, prospective evaluation
of the toad brace in plantar ulcer
off-loading and healing
Unknown
status
No results
available
Diabetic foot, pedal ulcers Device: optimal medical therapy
Debridement + toad brace
Other: optimal medical therapy –
debridement
University Hospitals Cleveland Medical
Center, Cleveland, OH, USA
18 Off-loading shoe to improve healing
and prevention of recurrence of
neuropathic diabetic plantar
foot ulcers
Completed No results
available
Diabetes mellitus,
diabetic neuropathic
foot ulcer
Device: Sanidiab
Device: Barouk
Groupe hospitalier Pitié-Salpêtrière, Paris,
France
19 Prevention of secondary foot ulcers
in patients with diabetes using
systematic measuring of skin
temperature
Completed No results
available
Foot ulcer, diabetic Device: Temp Touch (Diabetica
Solutions Inc., San Antonio,
TX, USA)
Other: Inspection
Oslo University Hospital Ulleval, Oslo,
Norway
20 Developing a diabetic foot ulcer
protocol
Unknown
status
No results
available
DFU Other: type of footwear
Other: collagen dressing with and
without silver
Harris County Hospital District Community
Health, Houston, TX, USA
21 A comparison of insoles used to
prevent neuropathic diabetic
foot ulceration
Completed No results
available
Diabetes, neuropathic
foot
Device: insole Liskeard Community Hospital, Liskeard, UK
Mount Gould Local Care Centre,
Plymouth, UK
22 Shear and pressure reducing insoles
for the diabetic foot
Completed No results
available
Diabetes, ulceration,
amputation, foot
deformity, neuropathy
Device: pressure-reducing insole
Device: GlideSoft®
Kevin R Higgins, Doctor of Podiatric
Medicine, San Antonio, TX, USA
23 Evaluating the effects of foot
orthotics on plantar pressures in
people with diabetes
Completed No results
available
Diabetes Other: no intervention Texas Diabetes Institute, San Antonio,
TX, USA
South Texas Veterans Healthcare System,
San Antonio, TX, USA
24 FDG-PET imaging in complicated
diabetic foot
Active, not
recruiting
No results
available
Diabetic foot disease Procedure: FDG-PET imaging Hospital of the University of Pennsylvania,
PA, USA
FDG-PET, fluorodeoxyglucose-positron emission tomography; SMS, short message service.
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Systematic review: flow diagram
MEDLINE: 4487
EMBASE: 2399
CENTRAL: 3602
Title and abstract excluded,
with reasons
(n = 10,421)
Records screened by
title and abstract
(n = 10,488)
Full-text articles excluded,
with reasons
(n = 33)a
Full-text articles assessed
for eligibility
(n = 67)
Full texts meeting
inclusion criteria
(n = 34)
Reports excluded because
no full text available
(n = 15)
Full texts meeting
inclusion criteria
(n = 19)
Full texts meeting inclusion 
criteria from SRs
(n = 5)
Additional ongoing trials identif ied
from ClinicalTrials.gov unpublished
end-point data
(n = 24)a
RCTs included in quantitative
synthesis 24 full texts
reporting 22 trials
FIGURE 52 Systematic review flow diagram. a, See Appendix 6.
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List of randomised controlled trials: full text unavailable
l Higgins KR, Lavery LA, Athanasiou KA, Lanctot DR, Costantinidis GP, Agrawal CM, et al. Personal
communication with Arad Y.
l Huang P. Effect of diabetes education on prevention of diabetic foot. Chinese journal of multiple organ
diseases in the elderly 2010;33:362.
l Lifeng F, Zheng L, Ju-ming L, Zheng Y. Strengthening the long-term effect of educational intervention
on prevention of diabetic foot. Chin J Mul Organ Dis 2006;5:24–9.
l Soulier SM. The use of running shoes in the prevention of plantar diabetic ulcers. J Am Podiatr Med
Assoc 1986;76:395–400.
l Tyrell W, Philips C, Gibby O, Price P. An Investigation into the Therapeutic Effectivness and Cost-
Effectiveness of Othortic Therapy Provided for Those Attending the Diabetic Foot Clinicat Richmond House
Diabetes Centre, Royal Gwent Hospital, Newport. Report prepared for the Wales Office of Research
and Development for Health and Social Care 1998.
l Van Putten M, Leffers P, Schaper NC. Podiatric Insoles Cause Foot Ulcers in Diabetic Patients.
46th Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden,
20–24 September 2010.
l Veitenhansl M, Stegner K, Hierl FX, Dieterle C, Feldmeier H, Gutt B, et al. Special pre-manufactured
footwear with insoles can prevent ulceration in diabetic patients with diabetic foot syndrome by
pressure reduction. A prospective randomised study. Diabetologia 2004;47:A1–A464.
l Veitenhansl M, Hierl FX, Landgraf R. Pressure reduction through various premanufactured shoe
models with insoles in diabetic foot syndrome to prevent ulceration: a prospective randomised
study. Diabetologia 2003;46:A4–A5.
l Veitenhansl M, Stegner K, Hierl EX, Dieterle C, Feldmeier H, Gutt B. Special pre-manufactured footwear
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TABLE 50 List of RCTs: full text unavailable
1. Higgins – unpublished
2. Huang 2010 – sent request for full text to no avail
3. Fan 2006 – sent request for full text to no avail
4. Souellier 1986 – not available at The British Library
5. Tyrell 1998 – not available at The British Library
6. Van Putten 2010 – conference abstracts only
7. Veitenhansl 2001 – conference abstracts only
8. Veitenhansl 2003a – not available at The British Library
9. Veitenhansl 2003b – not available at The British Library
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11. Xiaomin 2010 – sent request for full text to no avail
12. Xue-hua 2010 – sent request for full text to no avail
13. Zhengguang 2008 – sent request for full text to no avail
14. Zhenghua 2011 – Dorresteijn excluded because no full text
DOI: 10.3310/hta24620 Health Technology Assessment 2020 Vol. 24 No. 62
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
183
l Xiaomin L, Jianning W. The significance of individualized educational intervention in preventing
diabetic foot. J Med Sci 2010;20:212–13.
l Xue-hua H. Effect of diabetes education on prevention of diabetic foot. Chin For Health Dig
2010;33:362.
l Zhengguang L, Xiaokui L, Yan L, Hulin C, Yucheng Y, Yuxiong C, Shiwei Z. Evaluation of preventive
effect of preventive health education on senile diabetic foot ulcer. Chin J Pract Intern Med
2008;28:68–9.
l Zhenghua X, Dingyu C, Qiling Y, Qian Z, Jin X, Chunling H, et al. Individualised Diabetic Education
Can Contribute to Decrease the Incidence of Diabetic Foot and Avoid Amputation: Results of a 9-year
Prospective Study. 47th Annual Meeting of the European Association for the Study of Diabetes,
Lisbon, Portugal, 12–16 September 2011.
List of excluded studies, with reasons
TABLE 51 List of excluded RCTs
First author and year Reason for exclusion
1. Barth 1991150 Not all participants ulcer free at baseline
2. Bloomgarden 198783 Not all participants ulcer free at baseline
3. Borges 2004151 No DFU outcome
4. Borges 2008152 No DFU outcome
5. Colagiuri 1995153 No DFU outcome
6. Corbett 2003154 No DFU outcome
7. Deakin 2006155 No DFU outcome
8. Donaghue 1996 No DFU outcome
9. Donohoe 2000156 No DFU outcome
10. Frank 2003157 No DFU outcome
11. Frank 2005158 No DFU outcome
12. Huang 2009159 Not all participants ulcer free at baseline
13. Jeffcoate 2007 Not all participants ulcer free at baseline
14. Kruger 1992160 No DFU outcome
15. Malone 1989 Not all participants ulcer free at baseline
16. Mazzuca 1986161 No DFU outcome
17. McMurray 2002162 No DFU outcome
18. Mueller 1989163 Treatment study
19. Mueller 2003164 Not all participants ulcer free at baseline
20. Piaggesi 1998165 Treatment study
21. Pieber 1995166 Not a RCT
22. Reiber 1997 Not a RCT
23. Reichard 1993167 Purpose of RCT was not to evaluate intervention to prevent DFUs
24. Rettig 1986168 No DFU outcome
25. Rönnemaa 199781 No DFU outcome
26. Spraul 2015 Not a RCT
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TABLE 51 List of excluded RCTs (continued )
First author and year Reason for exclusion
27. Tazi 2008 Not a RCT
28. Viswanathan 2004 Not a RCT
29. Waxman 2003107 Not diabetic patients
30. Weintraub 2003169 Treatment study
31. Westphal 2011 Not all participants ulcer free at baseline
32. Wooldridge 1994170 No DFU outcome
33. Wooldridge 1996171 No DFU outcome
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Data extraction and quality assessment: systematic review of randomised
controlled trials
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Appendix 6 Chapter 6 health economics-
related appendices
Literature review of cost–utility analyse
Aim
To undertake a review of published cost–utility analyses of the prevention of DFUs.
Population
Studies including patients with a diagnosis of diabetes mellitus who were at risk of DFU.
Intervention
Any intervention aimed at preventing DFUs.
Comparator
Any comparator.
Criterion for inclusion of studies
Any study that included both costs and a measure of health utility relating to an intervention aimed at
preventing DFUs.
Search strategy
Our search strategy involved the combination of terms: (1) diabetic patients, (2) with foot/plantar ulcers/
lesions and (3) cost-effectiveness/utility models. We searched MEDLINE, EMBASE, Cumulative Index to
Nursing and Allied Health Literature (CINAHL) and the Cochrane Economic Evaluation Database. Only
studies in the English language were included owing to resource constraints. The databases were searched
from inception to January 2018. No start date was chosen as we were not concerned with whether or not
the treatments involved were still clinically relevant; rather, we were interested in understanding the
different modelling approaches used, for which there was no specific timespan of interest.
Results
Our search returned 11 relevant papers to be reviewed. Four other relevant papers were identified
by ‘hand-searching’ the references of the 11 papers identified. Of the 15 papers identified in our
review, five were cost–utility analyses of the prevention of DFUs. The remaining papers were either
concerned with the cost–utility of treatments for patients who had already experienced DFUs or
related to the cost burden of DFUs.
Table 52 provides details of the economic study characteristics. Figure 53 is the PRISMA flow diagram
of the literature selection process.
Survival analysis of Scottish Care Information – Diabetes Collaboration data
Table 53 provides our rationale about the extrapolation of ulceration, amputation and death event data
from SCI-Diabetes.
Kaplan–Meier plots for a selection of the key transitions required for the model are in Figures 54–58.
DOI: 10.3310/hta24620 Health Technology Assessment 2020 Vol. 24 No. 62
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
191
TABLE 52 Economic study characteristics
Study (first
author and year) Type of analysis Intervention
Measure of
effectiveness
Evidence for
effectiveness Costs Utilities Results (ICERs)
Eastman 1997121 Cost–utility, using
Monte Carlo
simulation
Glycaemic control (average
HbA1c level of 7.2%
maintained for life)
Reduction in
LEAs
Based on US community
and population data on
incidence of NIDDM
complications
Javitt et al.;173 Brechner
et al.;174 and the DCCT
Study Group.175
Reported in US dollars
Eckman et al.176 US$16,003 per QALY
gained
Tennvall 2000172 Cost–utility, using
a Markov model
Education, specialised
footwear, multidisciplinary
foot care team
Reduction in
DFUs
Reduced by 25%, based
on Malone et al.82 and
McCabe et al.84
Apelqvist et al.;177
Apelqvist et al.;178 and
Tennvall.172 Reported
in euros
UK Prospective
Diabetes Study
Group;179 and
Tennvall et al.172
Varied across risk
groups, but all < €6000
per QALY gained
Ortegon 2004123 Cost–utility, using
a Markov model
Glycaemic control,
specialised foot care,
education, regular
inspection, identification of
risk, multidisciplinary team
Reduction in
LEAs
Reduction of between
49% and 85%, based on
Larsson et al.180
Redekop et al.132
Reported in US dollars
Redekop et al.132 <US$25,000 per
QALY gained
Rauner 2005124 Cost–utility, using
a Markov model
Specialised footwear,
patient education,
chiropody, and regular
checks by general
practitioners and/or in
hospital
Reduction in
DFUs
Reduction of between
25% and 50%, based
on Malone et al.82 and
Boulton et al.181
Costs were obtained
from literature review
and clinical expert
(references not given).
Reported in euros
Tennvall et al.172 Varied across risk
groups. Risk 1, not
cost-effective; risk 2,
cost-effective; risks 3
and 4, cost-effective
and cost saving
Barshes 2017125 Cost–utility, using
a Markov model
Primary prevention
(would care, digital
substraction angiography,
revascularisation)
Reduction in
DFUs
N/A Barshes et al.182
Reported in US dollars
Barshes et al.126 Cost and effectiveness
estimates required for
cost saving
DCCT, Diabetes, Control and Complications Trial; N/A, not applicable; NIDDM, non-insulin-dependent diabetes mellitus.
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FIGURE 53 Flow diagram of search process.
TABLE 53 Parametric model selection and diagnostics
Transition(s)
Parametric
model choice
Diagnostic
tests used Reasons
Transitions 1–3: time to death
conditional on CPR state (Figure 54)
Log-logistic AIC/BIC, KM
plot, log-CM plot
Lowest AIC/BIC; does not appear contradicted
by KM or log-CM plots
Transition 4: time from ulceration
to amputation
Gompertz AIC/BIC, KM
plot, parametric
model plot
Lowest AIC/BIC; does not appear contradicted
by KM plot; visually fits well to Gompertz
model
Transition 5: time from ulceration
to death
Weibull AIC/BIC, KM
plot, parametric
model plot
Lowest AIC/BIC; does not appear contradicted
by KM plot; visually fits well to Weibull model
Transition 6: time from amputation
to death
Log-normal AIC/BIC, KM
plot, parametric
model plot
Lowest AIC/BIC; does not appear contradicted
by KM plot; visually fits well to log-normal
model
Transitions 7: time from low to
moderate risk (Figure 55)
Gompertz AIC/BIC, KM
plot, parametric
model plot
Gompertz has lowest AIC/BIC; does not
appear contradicted by KM plot; visually fits
very well to log-normal model
Transitions 8: time from low to
high risk
N/A 0 and 2 failures, respectively; do not think we
can fit model
Transitions 9: time from moderate
to high risk (Figure 56)
Gompertz AIC/BIC, KM
plot, parametric
model plot
Lowest AIC/BIC, does not appear contradicted
by KM plot; visually fits well to Gompertz model
Transitions 10–12: time to
ulceration conditional on CPR state
(Figure 57)
Log-logistic AIC/BIC, KM
plot, log-CM plot
Lowest AIC/BIC; does not appear contradicted
by KM or log-CM plot. Hazard appears to
increase initially and then decease (hence
require flexibility)
Transitions 13–15: time to
amputation conditional on CPR
state (Figure 58)
Gompertz AIC/BIC, KM
plot, log-CM plot
Lowest AIC/BIC; does not appear contradicted
by KM or log-CM plots
CM, Cox model; KM, Kaplan–Meier; N/A, not applicable.
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FIGURE 54 Kaplan–Meier survival estimates. Time to death, stratified by risk status (CPR) (transitions 1–3).
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FIGURE 55 Kaplan–Meier survival estimates. Time to change from low to moderate risk (transition 7).
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FIGURE 56 Kaplan–Meier survival estimates. Time to change from moderate to high risk (transition 9).
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Scottish Care Information – Diabetes Collaboration missing data
and assumptions
Table 54 presents the name, number of observations and proportion of missing data for each variable
in the SCI-Diabetes data set, which we received from the Health Informatics Centre at the University
of Dundee via the University of Edinburgh, where the data were cleaned. The fact that there is more
than one observation per patient influences the interpretation of the proportion of missing data.
Our discussions with clinicians who were involved in entering data into SCI-Diabetes suggest that
some clinicians may input patient information only when a risk is present, for example highlighting
active ulcer or amputation when it occurs, and not input this as negative at visits prior to that time.
For example, in the case of variables such as active ulcer or amputation, a patient may have 10 visits and
be negative for both conditions at the first nine and then develop one or the other (or both) by the final
visit. This would result in nine missing observations and one observation recorded. Table 55 lists the
variables that were created by the University of Glasgow (the SCI-Diabetes NHS Fife data dictionary).
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FIGURE 57 Kaplan–Meier survival estimates. Time to ulceration, stratified by risk status (CPR) (transitions 10–12).
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FIGURE 58 Kaplan–Meier survival estimates. Time to amputation, stratified by risk status (CPR) (transitions 13–15).
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TABLE 54 List of variables provided by the Health Informatics Centre (University of Dundee, Dundee, UK)
Variable name Description Observationsa (n) Missing (%)
PROCHI (MISUMI Europa
GmbH, Frankfurt am
Main, Germany)
Patient ID 231,846 N/A
Date Date of visit 231,846 0
DoDeath Date of death 57,289 0
Death Binary variable for death 57,289 0
PeripheralPulsesLeft Peripheral pulses absent, left foot 197,195 15
PeripheralPulsesRight Peripheral pulses absent, left foot 197,543 15
MonofilamentLeftSites Insensitive to monofilament, left foot 145,084 37
MonofilamentRightSites Insensitive to monofilament, right foot 145,088 37
PreviousUlcerLeft Previous ulcer, left foot 94,675 59
PreviousUlcerRight Previous ulcer, right foot 94,661 59
ActiveUlcerLeft Ulcer, left foot 96,406 58
ActiveUlcerRight Ulcer, right foot 96,454 58
UoE_LHS_amput Amputation, left foot 38,121 84
UoE_RHS_amput Amputation, right foot 38,192 84
N/A, not applicable.
a There are 26,086 unique patients in the data set. There are multiple rows per patient because patients attended
multiple foot screening visits.
TABLE 55 Variables created by the University of Glasgow
Variable name Description Observations (n)
Positive
(at risk) (n)
Pulses 1, Pulses absent in either foot; 0, both present 231,914 5255
Monofilament sensitivity 1, Absent for either foot; 0, both present 231,914 24,600
History 1, Previous ulcer on either foot; 0, no history for
either foot
231,914 3536
Active ulcer 1, Active ulcer on either foot, 0, no active ulcer on
either foot
231,914 3131
Amputation 1, Amputation of either foot (or leg); 0, no amputation
of either foot (leg)
231,914 1316
CPR low-risk status Negative for history AND also negative for at least
one of monofilaments or pulses
26,086 25,003a
CPR moderate-risk status Positive for history but negative for both
monofilaments and pulses OR negative for history but
positive for both monofilaments and pulses
26,086 7,13a
CPR high-risk status Positive for history and also positive for at least one
of monofilaments and pulses
26,086 370a
Survival timeb Variable for time from time 0 to event of interest N/A N/A
Event/censoringb Event/censoring variables, which take the value 1 if
the event of interest occurs and 0 otherwise
N/A N/A
N/A, not applicable.
a At first visit.
b See Table 24.
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Assumptions regarding missing data
Owing to the type of missing data, and the lack of other clinical data relating to the patient from which
to predict the missing data, imputation methods were not deemed to be appropriate. The following are
the assumptions made with regard to missing data.
l Dates: owing to a lack of death records prior to 2005, we removed patients with any dates before
1 January 2005.
l CPR data: when no data existed for a patient predictor, we assumed that the patient did not have
this risk factor (i.e. if pulses = ’missing’ then pulses = 0 = present). Once a patient is recorded as
having a risk factor, then they will have the risk factor for all subsequent visits (i.e. if pulses = 1,
then pulses always = 1).
l Ulceration data: when no data existed for ulceration, we assume that the patient did not have an
ulcer. Patients who were recorded as having an ‘active ulcer’ on their first visit were recoded as
having a previous ulcer.
l Amputation data: patients who were recorded as having an amputation on their first visit were
recoded as having a previous amputation.
l Patients with only one visit recorded, if this visit was recorded as ‘death’, were removed from the
data set. As no other information is available for these patients, they cannot be included in the
survival analysis.
Cost data
The costs of both ulceration and amputation were obtained from the literature.131 The cost of ulceration
was based on the cost of an ‘episode’, that is the mean cost of a single ulceration, weighted by duration of
ulceration and the proportion of ulcer treatments that are carried out as an inpatient (10%) or outpatient
procedure (90%) (proportions based on expert clinical opinion).
The cost of amputation was similarly estimated as the mean cost of an amputation, including acute and
ongoing costs, weighted by the proportion that were major (33.3%) or minor (66.6%) amputations.143
Footwear and insole costs were based on the advice of clinical experts involved in the treatment of
patients at risk of DFUs. Off-the-shelf footwear was estimated at £80 per pair, with a cost of £20 for
insoles. Cost estimates were obtained from the surgical appliances manager of NHS Fife, who is in
charge of purchasing and negotiating with external providers.
Digital infrared thermometry costs are highly uncertain. We obtained the device cost from a clinical
expert who was involved in a clinical trial of digital thermometry among DFU patients in the UK.89
The cost was estimated at £10, plus a cost of 15 minutes’ face-to-face time with a diabetic foot
clinician for advice on usage.
The cost of a complex intervention was based on the advice of clinical experts involved in the treatment
of patients at risk of DFUs. We included the cost of footwear and insoles, foot screening with face-to-face
education with (30-minute) consultation, consultation with complex intervention team (30 minutes) and
a consultation with an Agenda for Change band 8 practitioner, representing vascular surgeons and/or
diabetologists (15 minutes). These consultations are assumed to take place quarterly; hence, each
consultation cost is multiplied by 4 to give the annual cost.
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